| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Becton, Dickinson and Company$151.94
+1.09 (+0.72%)
B 60Pipeline Score MedTech · Commercial
Market Cap
39.80 B
EPS
3.95
P/E Ratio
36.62 $
Value Trade
234.21 M
SEC Financials
Q1 2026Dilution Risk
Revenue
4.71 B
R&D Expenses
249.00 M
Total Assets
50.83 B
Total Liabilities
50.83 B
Equity
24.13 B
D/E Ratio
12,345
1.93 %
Week
-6.17 %
1 Month
-18.79 %
3 Month
-1.09 %
6 Month
-21.62 %
5 Year
4,913.02 %
All Time
Cash Data
Cash Position
1.01 B
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.05 M
52 Week Range
127.54 - 187.35
% held by Insiders
0.22 %
% held by Institutions
99.55 %
Enterprise Value
56.06 B
Total Shares
284.63 M
Short %
3.96 %
Float Shares
283.77 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
B60
Pipeline Score $5.2B
Pipeline ValueValuation Signal
6
Drugs Scored0.4x
rNPV / MCap Top 88%
Mid Cap (rank 110 of 911)
Percentile RankBecton, Dickinson and Company holds a solid B-grade pipeline (60/100), with $6.1B risk-adjusted pipeline value, led by Regular insulin in Diabetes Mellitus, Type 1 (Phase 2), across $101B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Regular insulin Small molecule | Diabetes Mellitus, Type 1 | Phase 2 | NCT00553488 | 23% | $4.7B | COMPLETED | 30 | - | - | Jan 1, 2008 | - | Aug 22, 2008 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
— | peripheral intravenous catheters (PIVCs) | — | 2021-02-02 | PIVC failure rate standard: 47.5%; PIVC failure rate BD solution: 34.8%; median time to failure standard: 30.0 hours; median time to failure BD solution: 50.4 hours; catheter colonization standard: 16.9%; catheter colonization BD solution: 0.9%; local infection standard: 1.2%; local infection BD solution: 0% Read More | First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust ... Read More | |
— | peripheral intravenous catheters (PIVCs) | — | 2021-02-02 | PIVC failure rate standard: 47.5%; PIVC failure rate BD solution: 34.8%; median time to failure standard: 30.0 hours; median time to failure BD solution: 50.4 hours; catheter colonization standard: 16.9%; catheter colonization BD solution: 0.9%; local infection standard: 1.2%; local infection BD solution: 0% Read More | First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust ... Read More | |
— | peripheral intravenous catheters (PIVCs) | — | 2021-02-02 | PIVC failure rate standard: 47.5%; PIVC failure rate BD solution: 34.8%; median time to failure standard: 30.0 hours; median time to failure BD solution: 50.4 hours; catheter colonization standard: 16.9%; catheter colonization BD solution: 0.9%; local infection standard: 1.2%; local infection BD solution: 0% Read More | First-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust ... Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BDX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
BDX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-12-18 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BDX▲ +0.7%today
BD to Announce Financial Results for its Third Quarter of Fiscal 2026
BD (Becton, Dickinson and Company) will announce its financial results for Q3 of fiscal 2026 on August 6, 2026. The announcement will be accompanied by an audio webcast at 8 a.m. ET, where management will discuss the results and provide updates on operations and strategy. A news release and presentation materials will be available prior to the call.
Read more →BDXBD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System
BD's CentroVena One™ Insertion System has been awarded an Innovative Technology contract by Vizient, acknowledging its potential to improve central line insertion. The system's all-in-one design simplifies the procedure, enhancing safety and efficiency. This recognition reflects the growing demand for innovative solutions in healthcare delivery.
Read more →BDXBD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
BD has launched the Elyra™ Thulium Fiber Laser System, designed to improve efficiency and workflow in urology for kidney stone management. The system features advanced Thulium Fiber Laser technology, offering quieter operation and a smaller footprint. Positive initial feedback from clinical cases highlights its user-friendly design and safety features.
Read more →BDXPeter Menziuso Named EVP and President, BD Interventional
BD (Becton, Dickinson and Company) has appointed Peter Menziuso as executive vice president and president of BD Interventional, effective June 1. Menziuso, who has over 30 years of experience in global healthcare, previously led a $5 billion business at Johnson & Johnson Vision. His leadership is expected to enhance BD Interventional's growth and performance.
Read more →BDX▲ +5.9%on this news
BD Reports Second Quarter Fiscal 2026 Financial Results
BD (Becton, Dickinson and Company) reported strong financial results for the second quarter of fiscal 2026, with revenue, margins, and earnings per share surpassing expectations. The company has raised its full-year adjusted EPS guidance and reaffirmed revenue growth expectations, attributing this success to broad-based execution and strong performance from growth platforms. The results reflect the company's ongoing commitment to its New BD strategy post-spin-off of its Biosciences and Diagnostic Solutions business.
Read more →BDX▲ +5.9%on this newsshared move
BD Appoints Vitor Roque Chief Financial Officer
BD has appointed Vitor Roque as Chief Financial Officer, effective May 7, 2026. Roque, who has been serving as interim CFO since December 2025, has over 25 years of experience at BD. His leadership is expected to enhance financial performance and support the company's growth strategy. Roque emphasizes the importance of disciplined financial management in driving BD's future success.
Read more →BDX▲ +5.9%on this newsshared move
Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Shawn Bevec, SVP, Investor Relations - investor.relations bd.com Media Matt Marcus, VP, Public Relations - matt.marcus bd.com BD Reports Second Quarter
BD (Becton, Dickinson and Company) announced its fiscal 2026 second quarter financial results, revealing a revenue growth of 5.2% totaling $4.7 billion. The adjusted diluted EPS increased to $2.90, although the reported diluted EPS showed a loss of $(0.13). The company plans to execute strategies focused on innovation, partnerships, and growth, including launching new medical products and a strategic alliance for medication management. Additionally, BD reaffirmed its revenue growth expectations and raised adjusted EPS guidance for the year, despite facing some challenges in international markets and recent business restructuring.
Read more →BDX▲ +5.9%on this newsshared move
BD Appoints Vitor Roque Chief Financial Officer FRANKLIN LAKES, N.J. (
BD (Becton, Dickinson and Company) has appointed Vitor Roque as its Chief Financial Officer, effectively immediately. Roque, who has been serving as the interim CFO since December 2025, has over 25 years of experience within the company, holding various significant roles. His appointment follows a comprehensive search process, and he is expected to continue driving the company’s growth and financial strategy. BD aims to leverage Roque's deep understanding of its operations and market dynamics to enhance performance and shareholder value.
Read more →BDXBD and Wellstar Advance Patient Care and Safety with Medication Management Powered by AI
BD has partnered with Wellstar Health System to enhance medication management through the integration of BD Pyxis™ Pro and BD Alaris™ platforms. This collaboration aims to improve safety and quality in medication delivery by providing clinicians with better accuracy and real-time insights. The use of AI technology will streamline workflows and empower healthcare professionals to focus on patient care.
Read more →BDXBD Achieves Excellence in Employee Well‑Being, Earning Top Industry Recognition
BD has been honored for its innovative approach to employee well-being, receiving multiple recognitions including the 2026 'Best Employers Award: Excellence in Health & Well-being.' The company emphasizes a holistic approach to health, addressing emotional, physical, social, and financial needs. This commitment supports BD's corporate sustainability goals and enhances workforce performance.
Read more →BDXBD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology
BD has launched the CentroVena One™ Insertion System, a groundbreaking device aimed at simplifying central line placement and enhancing patient safety. This innovative system consolidates multiple components into one platform, reducing procedural steps and insertion time significantly. The device has received FDA clearance and is being piloted by UNC Health Blue Ridge, marking BD's entry into the acute CVC market.
Read more →BDXBD Board Declares Dividend
BD (Becton, Dickinson and Company) has announced a quarterly dividend of $1.05 per share, payable on June 30, 2026. This dividend is part of an indicated annual rate of $4.20 per share. BD is a prominent player in the medical technology sector, focusing on innovation and improving healthcare outcomes.
Read more →BDXBD to Present at Bank of America Securities Health Care Conference
BD (Becton, Dickinson and Company) will present at the Bank of America Securities Health Care Conference on May 12, 2026. The presentation is scheduled for 11:40 am Eastern Time and will be accessible via a live webcast on the BD investor relations website. A replay will be available after the event.
Read more →BDXBD Earns Industry Top Honors for Transparency, Resiliency and Partnership
BD (Becton, Dickinson and Company) has been honored by the Healthcare Industry Resilience Collaborative with its inaugural Member Choice Awards in three categories: Transparency, Resiliency, and Partnership. This recognition is based on real-world customer experiences and highlights BD's commitment to enhancing supply chain transparency and continuity of patient care. BD has consistently demonstrated its dedication to collaboration and high-quality service in the healthcare sector.
Read more →BDXBD introduce un'innovazione TIPS di nuova generazione per migliorare il trattamento dell'ipertensione portale in tutta l'Unione Europea BD (Becton, Dickinson and Company) (NYSE: BDX), azienda leader a livello mondiale nel settore della tecnologia medicale, ha annunciato oggi la...
BD (Becton, Dickinson and Company) has announced the CE marking request for its Liverty™ TIPS Stent Graft, aimed at improving treatment for portal hypertension across the European Union. This innovative device, designed for patients with cirrhosis and related complications, is a significant advancement in interventional therapies for complex liver diseases. Clinical safety and effectiveness data from the pivotal ARCH study will be presented at the upcoming Society of Interventional Radiology (SIR) annual conference. The device's adjustable diameter allows for tailored therapy, potentially enhancing long-term outcomes for patients suffering from severe complications of portal hypertension.
Read more →BDXFor Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
A recent study published in the Journal of Clinical Medicine found that the BD PureWick® Urine Collection System significantly improves sleep and comfort for women managing nighttime urinary incontinence. The study involved 165 women and highlighted the system's ease of use and non-invasive design. Key findings included improved quality of life and a low incidence of skin irritation.
Read more →BDXBD to Announce Financial Results for its Second Quarter of Fiscal 2026
BD (Becton, Dickinson and Company) will announce its financial results for Q2 of fiscal 2026 on May 7, 2026. The announcement will include an audio webcast discussing the results and updates on operations and strategy. A news release and presentation materials will be available prior to the call.
Read more →BDXRick Byrd to Retire from BD
Rick Byrd, executive vice president at BD, has announced his retirement after nearly 25 years with the company. He has held several leadership roles, most recently overseeing the Interventional Segment. Byrd's tenure included significant contributions to BD's growth and innovation, particularly in Vascular Access Management. He will remain in his position until June, with a successor to be named soon.
Read more →BDXBD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
BD has received CE Marking for its Liverty™ TIPS Stent Graft, aimed at improving treatment for portal hypertension in patients with cirrhosis. This next-generation device features an adjustable diameter and is designed to enhance individualized patient management. The safety and effectiveness data from the ARCH clinical trial will be presented at the upcoming SIR Annual Scientific Meeting.
Read more →BDXBD stellt die nächste Generation der TIPS-Technologie vor, um die Behandlung der portalen Hypertonie in der gesamten Europäischen Union voranzubringen BD (Becton, Dickinson and Company) (NYSE: BDX), ein weltweit führendes Medizintechnikunternehmen, gab heute bekannt, dass es die CE-Kennzeichnung für ...
BD (Becton, Dickinson and Company) has announced the CE marking for its Liverty TIPS Stent Graft, designed to enhance treatment for portal hypertension across the European Union. This next-generation device aims to improve care for patients with advanced liver disease, notably offering an adjustable diameter feature. Data from the clinical ARCH study, which evaluates the stent's safety and effectiveness, will be presented at the Society of Interventional Radiology conference in April 2026. The stent represents a significant advancement in managing complications associated with portal hypertension.
Read more →BDXBD ofrece la tecnología TIPS para impulsar la atención de la hipertensión portal en toda la Unión Europea BD (Becton, Dickinson and Company) (NYSE: BDX), empresa líder mundial en tecnología médica, anunció hoy la solicitud de la marca CE para el stent de...
BD (Becton, Dickinson and Company) has announced the submission for CE marking of their innovative Liverty™ TIPS stent, aimed at treating portal hypertension across the European Union. This next-generation device is tailored for patients with advanced liver disease, incorporating features such as an adjustable diameter and dual-layer ePTFE encapsulation. Clinical data from the pivotal ARCH trial will be presented at an upcoming medical conference, highlighting the stent's safety and efficacy. In the U.S., the stent remains investigational, limited to research purposes only.
Read more →BDXBD propose une innovation TIPS de nouvelle génération pour faire progresser les soins de l'hypertension portale dans l'Union européenne BD (Becton, Dickinson and Company) (NYSE : BDX), l'une des principales sociétés mondiales de technologie médicale, a annoncé aujourd'hui la demande...
BD (Becton, Dickinson and Company) announced the CE marking request for its Liverty™ TIPS device designed to improve treatment options for portal hypertension across the European Union. This next-generation device aims to enhance the safety and adaptability of therapeutic approaches for patients with advanced liver disease. Preliminary data from the pivotal ARCH clinical trial, which evaluates the device's safety and efficacy, will be presented at the Society of Interventional Radiology's annual scientific meeting in April 2026. The introduction of this innovative device into the market is expected to be a significant advancement in interventional therapies for liver disease.
Read more →BDXWhen Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the HemoSphere Stream™...
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™ Module, which provides continuous, noninvasive arterial waveform data directly to compatible patient monitors. This new device aims to enhance patient monitoring by delivering real-time blood pressure insights, promoting more informed clinical decisions. The technology is designed for ease of use in clinical settings without occupying significant space, and is expected to improve safety in surgical environments. The initiative supports the Anesthesia Patient Safety Foundation's recommendations for continuous hemodynamic monitoring.
Read more →BDXQuand chaque battement compte, BD aide les professionnels de santé à éliminer les zones d'ombre grâce à une surveillance continue et non invasive de la pression artérielle. BD (Becton, Dickinson and Company) (NYSE : BDX), l'une des principales entreprises mondiales de technologie médicale, a annoncé aujourd'hui le...
BD (Becton, Dickinson and Company) a annoncé le lancement de son module HemoSphere Stream™, offrant une surveillance continue non invasive de la pression artérielle. Ce dispositif permet aux professionnels de santé d'accéder à des données en temps réel, améliorant ainsi la gestion des soins pour un plus grand nombre de patients. Le module est conçu pour être compatible avec des moniteurs multiparamétriques existants et vise à réduire les complications postopératoires en détectant rapidement les variations hémodynamiques.
Read more →BDXCuando cada latido cuenta, BD ayuda a los médicos a eliminar los puntos ciegos BD (Becton, Dickinson and Company) (NYSE: BDX), empresa líder mundial en tecnología médica, anunció hoy el lanzamiento del módulo HemoSphere Stream™, ...
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™, a module offering continuous and non-invasive arterial pressure monitoring. This device integrates with compatible multiparametric monitors, enabling real-time data collection for more patients, which addresses gaps in intermittent readings. The product is positioned to improve patient outcomes during and after surgery by providing essential hemodynamic information, thereby enhancing clinical decision-making. BD aims to transform patient care through this innovative technology, which is designed for ease of use in clinical environments.
Read more →BDXWenn jeder Herzschlag zählt, hilft BD Ärzten dabei, blinde Flecken zu beseitigen - dank kontinuierlicher, nicht-invasiver Blutdruckmessung BD (Becton, Dickinson and Company) (NYSE: BDX), ein weltweit führendes Medizintechnikunternehmen, gab heute die Markteinführung des HemoSphere...
BD (Becton, Dickinson and Company) has launched the HemoSphere Stream™ module, which allows for continuous non-invasive blood pressure monitoring. This innovation facilitates real-time access to arterial waveform data for healthcare professionals, improving patient monitoring and care outcomes. The system is designed to help detect hemodynamic changes that occur between intermittent measurements typically done in surgical settings. Endorsed by experts, this module aims to enhance patient safety during and after surgical procedures.
Read more →BDXNon-GAAP Financial Measures Included in the Financial Tables The unaudited financial information included herein contains certain financial measures that differ from those presented in accordance with generally accepted
Becton Dickinson and Company (BDX) has included unaudited non-GAAP financial measures in its financial reports, emphasizing adjustments related to regulatory costs and other operational expenses. The management asserts that these measures provide clearer insights into the company's performance year-over-year, despite the potential for misleading interpretations due to the exclusions. Key adjustments are made to reflect compliance with new EU Medical Device Regulations. Adjustments are provided in the attached financial tables for clarity.
Read more →BDXBD Launches AI-Enabled Medication Dispensing System to the European MarketUSA - EnglishUSA - English
BD has launched the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe, enhancing medication management through AI and automation. This system aims to improve efficiency, medication availability, and patient care in healthcare settings. The rollout will support multiple languages and leverage AWS for data management.
Read more →BDXBD lanza al mercado europeo un sistema de dispensación de medicamentos con inteligencia artificial
BD has launched its BD® Pyxis™ Pro medication dispensing solution in Europe, integrating advanced automation and AI to enhance medication management. This system aims to improve efficiency and patient care by providing reliable access to medications. Additionally, BD will extend its BD® Incada™ Analytics platform to European hospitals, leveraging cloud technology for better inventory management.
Read more →BDXBD bringt ein KI-gestütztes Medikamentenausgabesystem auf den europäischen Markt
BD has launched its next-generation BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe. This system integrates advanced automation with AI insights to enhance medication management and efficiency in healthcare settings. The solutions aim to ensure reliable access to medications and improve patient care while adapting to evolving healthcare needs.
Read more →BDXBD lance un système de distribution de médicaments basé sur l'IA sur le marché européen
BD has launched its BD® Pyxis™ Pro medication distribution system and BD® Incada™ connected care platform in Europe. This advanced system integrates AI to enhance medication management, reduce interruptions, and improve efficiency in healthcare settings. The solution aims to provide secure and traceable medication storage, adapting to the evolving needs of patient populations.
Read more →BDXBD Launches AI-Enabled Medication Dispensing System to the European Market
BD has launched the BD® Pyxis™ Pro Dispensing Solution and BD® Incada™ Connected Care Platform in Europe, enhancing medication management through advanced automation and AI. This system aims to improve efficiency and medication availability in healthcare settings. The rollout will support 15 languages and leverage AWS for digital sovereignty compliance.
Read more →BDXBD avanza en el tratamiento de la arteria ilíaca en toda la Unión Europea BD (Becton, Dickinson and Company) (NYSE: BDX), empresa líder mundial en tecnología médica, anunció hoy la obtención de la marca CE para el stent...
BD (Becton, Dickinson and Company) has received CE mark approval for its Revello™ covered vascular stent, aimed at treating atherosclerotic lesions in the common and external iliac arteries. This approval comes at a critical time as peripheral artery disease significantly affects the aging population in the EU. The Revello™ stent features a thin PTFE coating and a triaxial release system for precise placement, promising to raise the standard for iliac artery revascularization. The stent is currently being evaluated in a multicenter clinical trial, AGILITY, which assesses its performance in patients with peripheral artery disease.
Read more →BDXBD treibt die Behandlung der Iliakalarterien in der gesamten Europäischen Union voranUSA - DeutschUSA - EnglishUSA - Français
BD has received CE marking for its Revello™ Vascular Covered Stent, aimed at treating atherosclerotic lesions in the iliac arteries. This innovative stent combines the flexibility of a self-expanding nitinol stent with tailored radial strength, addressing the growing issue of peripheral artery disease in the aging EU population. The device was showcased at the LINC Congress 2026, where its potential impact was discussed.
Read more →BDXBD fait progresser le traitement de l'artère iliaque dans l'Union européenneUSA - FrançaisUSA - EnglishUSA - Deutsch
BD has received CE marking for its Revello™ covered vascular stent, designed for treating atherosclerotic lesions in common and external iliac arteries. This advancement addresses the substantial disability burden from peripheral artery disease in the aging EU population. The stent combines flexibility with radial strength and features a tri-axial delivery system for precise deployment.
Read more →BDXBD Advances Iliac Artery Treatment Across the European Union
BD has received CE Marking for its Revello™ Vascular Covered Stent, aimed at treating atherosclerotic lesions in the iliac arteries. This stent is designed to enhance the standard of care for patients with peripheral artery disease (PAD) in the EU. The device features a tri-axial delivery system for accurate placement and is expected to improve treatment outcomes for complex iliac artery conditions.
Read more →BDXBD Pioneers New Standard in Surgical Safety with FDA-Cleared Surgiphor™ 1000mL for Wound Irrigation
BD has received FDA 510(k) clearance for its Surgiphor™ 1000mL, the first 1000 mL antimicrobial irrigation system. This innovation aims to enhance surgical safety and efficiency by providing a ready-to-use solution that simplifies complex procedures. The system is designed to fit into existing powered irrigation workflows, allowing for better patient care and operational efficiency.
Read more →BDXBecton, Dickinson and Company Announces Pricing of the Tender Offers and Amounts Accepted for Purchase
Becton, Dickinson and Company (BD) has announced the pricing of its tender offers to purchase up to $2 billion in senior notes. The offers include various series of senior notes with specific acceptance priorities. The company will accept tenders up to the aggregate offer cap and has set an early settlement date for accepted securities. Investors are encouraged to review the offer to purchase for complete details.
Read more →BDXBecton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap and Aggregate Offer Cap
Becton, Dickinson and Company (BDX) announced early tender results for its debt securities, increasing the Aggregate Offer Cap from $1.6 billion to $2 billion. The tender offers are aimed at purchasing various senior notes and debentures, with the early settlement date set for February 27, 2026. The company has confirmed that all conditions for the tender offers were satisfied by the early tender date.
Read more →BDXBD to Present at Barclays 28th Annual Global Healthcare Conference
BD (Becton, Dickinson and Company) will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026. The live presentation will be accessible via the BD investor relations website, with a replay available afterward. BD emphasizes its role in advancing healthcare through innovative technologies and solutions.
Read more →BDXBD Expands Testing Capabilities to Help Clinicians Improve Diagnostic Accuracy and Efficiency
BD has launched the Vacutainer® Urine Complete Cup Kit, which enhances urine testing capabilities by allowing multiple tests from a single specimen. This innovative kit aims to preserve sample integrity, improve workflow efficiency, and reduce contamination risks. It is designed to support better patient care by minimizing the need for repeat collections and exposure risks for healthcare workers.
Read more →BDXLanesha Minnix Named General Counsel for BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Lanesha Minnix has been named...
BD (Becton, Dickinson and Company) has announced the appointment of Lanesha Minnix as executive vice president and general counsel, effective March 16. Minnix brings extensive experience from her previous role at Walgreens Boots Alliance, where she played a pivotal role in a $24 billion transaction. She is set to lead BD's Law Group and Public Affairs, reporting directly to CEO Tom Polen and contributing to the Executive Leadership Team. This move is aimed at enhancing BD's governance and growth strategies in a dynamic healthcare landscape.
Read more →BDX▲ +5.2%on this news
Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
Becton, Dickinson and Company (BD) has initiated tender offers to purchase up to $1.6 billion of its outstanding debt securities. The offers are set to expire on March 11, 2026, with an early tender date of February 24, 2026. Investors are encouraged to review the Offer to Purchase for detailed terms and conditions.
Read more →BDXBD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
BD has successfully completed the spin-off of its Biosciences & Diagnostic Solutions business, merging it with Waters Corporation. Shareholders will receive shares of Waters stock and cash, valuing the transaction at $18.8 billion. The move is part of BD's strategy to focus on MedTech, positioning the company for future growth. Additionally, Claire M. Fraser has joined the Waters Board after stepping down from BD's Board.
Read more →BDXBD Reports First Quarter Fiscal 2026 Financial Results
BD (Becton, Dickinson and Company) reported a strong first quarter for fiscal 2026, exceeding expectations due to effective execution and growth across key markets. The company is set to complete the merger of its Biosciences and Diagnostic Solutions business with Waters Corporation, marking a significant strategic milestone. BD's outlook for the fiscal year remains positive, with expectations for long-term revenue and earnings growth.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Shawn Bevec, SVP, Investor Relations - investor.relations bd.com Media Matt Marcus, VP, Public Relations - matt.marcus bd.com BD Reports First Quarter F
BD (Becton, Dickinson and Company) reported its first quarter fiscal 2026 financial results with revenues reaching $5.3 billion, a 1.6% increase from the previous year. The company noted a growth in New BD revenues and affirmed its revenue growth guidance for the fiscal year. Significant milestones include the anticipated completion of merging its Biosciences and Diagnostic Solutions business with Waters Corporation. However, there was a notable decline in adjusted diluted EPS and a decrease in revenue from BD Life Sciences.
Read more →BDXNon-GAAP Financial Measures Included in the Financial Tables These revenue schedules include adjusted revenues and revenue growth rates on a currency-neutral, adjusted and organic basis. These non-GAAP financial measures
Becton Dickinson and Company (BDX) has published its financial tables including non-GAAP revenue measures, highlighting revenue growth on a currency-neutral basis. Management believes that these measures enhance understanding of the company's performance and help analyze underlying trends. BD reported a substantial increase in total revenues for the fiscal year 2024 compared to the previous year, although reliance on non-GAAP results is acknowledged as limited due to potential material impacts from excluded items. Investors are encouraged to review complete consolidated financial statements for comprehensive insights.
Read more →BDXBD and Envetec Demonstrate Closed-Loop Recycling Solution for Laboratory Plastics in Health Care
BD and Envetec have completed a feasibility study demonstrating the recycling of polystyrene Petri dishes into new manufacturing feedstock. This pilot study suggests that various high-quality polymers can be reused in the healthcare supply chain after disinfection. The initiative aims to reduce environmental impact and promote sustainability in medical device manufacturing.
Read more →BDXBD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $250 Million Repurchase to Date in FY26
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.05 per share, payable on March 31, 2026. The company also authorized an additional repurchase of up to 10 million shares, following a successful $250 million repurchase in fiscal 2026. These actions reflect BD's commitment to returning value to shareholders.
Read more →BDXBD Announces Record Date for the Spin-Off of its Biosciences & Diagnostic Solutions Business
BD has set February 5, 2026, as the record date for the spin-off of its Biosciences & Diagnostic Solutions business, which will merge with Waters Corporation on February 9, 2026. Shareholders will receive Waters common stock representing 39.2% of the combined entity. The transaction is expected to provide BD with $4 billion in cash and is subject to customary closing conditions.
Read more →BDXBD to Announce Financial Results for its First Quarter of Fiscal 2026
BD (Becton, Dickinson and Company) will host an audio webcast on February 9, 2026, to discuss its financial results for the first quarter of fiscal 2026, which ended on December 31, 2025. The company will also provide updates on its operations and strategy. A news release and presentation materials will be available prior to the call.
Read more →BDXBD Helps Scientists Advance Immunology and Cancer Research with AI-Powered Insights and Automation
BD has launched the BD Research Cloud 7.0, featuring the BD Horizon Panel Maker, an AI-powered tool designed to enhance panel design for immunology and cancer research. This tool automates panel recommendations, improving the quality and usability of scientific results. The new version aims to streamline workflows and support collaboration among researchers.
Read more →BDXBD and Ypsomed Expand Partnership to Address Rapidly Growing Biologics Market
BD and Ypsomed are expanding their partnership to develop a new 5.5mL version of the BD Neopak XtraFlow Glass Prefillable Syringe, compatible with Ypsomed's YpsoMate 5.5 autoinjector. This innovation aims to address the growing demand for large-volume self-injection systems in the biologics market. The syringe features advanced technologies to improve injection efficiency and patient experience.
Read more →BDXBD Receives FDA 510(k) Clearance for EnCor EnCompass™ Breast Biopsy and Tissue Removal System
BD has received FDA 510(k) clearance for its EnCor EnCompass™ Breast Biopsy and Tissue Removal System, set to launch in early 2026. This innovative system aims to enhance breast disease diagnosis by providing flexibility across various imaging modalities. BD emphasizes its commitment to improving breast health through advanced technology and patient-centered solutions.
Read more →BDXBD Names Shawn Bevec as Senior Vice President of Investor Relations
BD has appointed Shawn Bevec as the new senior vice president of investor relations, effective January 20, 2026. Bevec will oversee communication of the company's strategic progress to investors and will report to the interim CFO, Vitor Roque. His background includes significant roles in investor relations and equity research, which will support BD's growth initiatives.
Read more →BDXBD Announces $110 Million to Support U.S. Pharmaceutical Supply Chain for Biologic Drugs
BD announced a $110 million investment to expand its production of prefillable syringes in Columbus, Nebraska. This initiative aims to enhance the U.S. pharmaceutical supply chain for biologics and GLP-1 drug delivery, creating around 120 new jobs. The investment reflects BD's commitment to American manufacturing and supports the growing demand for advanced injectable solutions.
Read more →BDXBD To Host Virtual 2026 Annual Meeting of Shareholders
BD (Becton, Dickinson and Company) will host its virtual 2026 Annual Meeting of Shareholders on January 27, 2026. Shareholders as of December 8, 2025, can participate and vote, while guests can listen in. A replay will be available for one year on the BD website. The meeting highlights BD's commitment to health care innovation.
Read more →BDXBD Marks Milestone with First Phasix™ Hernia Prevention Case in Greece and Over 85% Enrollment in U.S. PREVENT Trial
BD (Becton, Dickinson and Company) has achieved a significant milestone with the first Phasix™ Mesh laparotomy reinforcement case in Greece, following its expanded indication for prophylactic use in Europe. Concurrently, the PREVENT trial has treated over 85% of its target population, aiming to provide clinical evidence for the use of bioabsorbable mesh in preventing incisional hernias. This advancement reflects BD's commitment to improving patient outcomes and reducing healthcare costs associated with hernia repairs.
Read more →BDXBD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the...
BD (Becton, Dickinson and Company) has announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania. This partnership aims to advance immune-mediated therapies by developing a high-parameter flow cytometry panel for investigating cellular responses in whole blood. The collaboration includes a planned study involving 1,000 patients, demonstrating a significant commitment to deepening understanding of the human immune system. The initiative reflects a strong partnership between industry and academia to enhance medical research and improve patient outcomes.
Read more →BDXBD Expands BD MAX™ System Menu with New IVDR-Certified VIASURE Assays in Partnership with Certest Biotec
BD has announced the expansion of its BD MAX™ System with two new IVDR-certified VIASURE assays developed in partnership with Certest Biotec. This addition enhances the system's diagnostic capabilities for respiratory and sexually transmitted infections in Europe. The BD MAX™ System offers a fully automated molecular platform that processes up to 24 samples per run, providing timely results to support clinical decision-making.
Read more →BDXBecton Dickinson, Bio-Rad, and Thermo Fisher Propel Safety and Automation in Blood Collection Tubes—New Market Report Highlights $7Billion Opportunity
A new market report highlights the growth of the global blood collection tubes market, estimating an increase from $4.18 billion in 2024 to $4.46 billion in 2025, with a projected value of $7.23 billion by 2032. The report emphasizes innovations in safety, compliance, and operational efficiency driven by rising diagnostic demands. Key advancements include automated systems and improved materials, meeting the diverse needs of end users across various healthcare settings. The report outlines strategic insights for stakeholders aiming to capitalize on this expanding market.
Read more →BDXBD and ChemoGLO™ Collaborate to Expand Hazardous Drug Contamination Testing for Health Care Facilities and Laboratories
BD and ChemoGLO™ have announced a strategic collaboration to enhance hazardous drug contamination testing in healthcare settings. This partnership combines BD's rapid HD Check System with ChemoGLO™'s advanced LC-MS/MS analysis, providing timely and comprehensive results. The collaboration aims to improve safety for healthcare workers by enabling better monitoring of contamination risks.
Read more →BDXBD Launches New Cell Analyzer Configurations to Bring Cutting-Edge Capabilities to Labs of All Sizes
BD has launched new configurations of its FACSDiscover A8 Cell Analyzers, enhancing accessibility for labs of all sizes. These analyzers feature advanced spectral and real-time imaging technologies, allowing for detailed analysis of cellular characteristics. The new models complement existing offerings and provide flexible financing options, making cutting-edge technology available to a broader range of researchers.
Read more →BDXBD Surgiphor™ Surgical Wound Irrigation System Expands to Europe to Help Hospitals Improve Patient Safety
BD (Becton, Dickinson and Company) has launched the BD Surgiphor™ Surgical Wound Irrigation System in Europe, marking a significant advancement in surgical care. This system is the first to receive CE approval and is designed to reduce the risk of surgical site infections by flushing out debris and microorganisms. The launch reflects BD's commitment to improving patient safety and operational efficiency in hospitals.
Read more →BDXBD Appoints Robert Huffines and Jacqueline Wright to Board of Directors
BD has announced the appointments of Robert Huffines and Jacqueline Wright to its board of directors, effective December 1, 2025. Both appointees bring extensive experience in healthcare, technology, and finance, which will support BD's strategy as it evolves into a pure-play innovative medical technology company. Their leadership is expected to unlock value for shareholders and improve patient care globally.
Read more →BDXBD Onclarity™ HPV Assay for BD COR™ and BD Viper™ LT Systems Receive WHO Prequalification
BD (Becton, Dickinson and Company) announced that its Onclarity™ HPV Assay has received WHO prequalification, enhancing cervical cancer screening in low- and middle-income countries. The assay detects 14 high-risk HPV types and allows for self-collection, improving access to diagnostics. This development supports better patient management and aligns with WHO's goal to eliminate cervical cancer as a public health issue.
Read more →BDXDuncan Regional Hospital Becomes First in U.S. to Implement BD Alaris™ EMR Infusion Interoperability with MEDITECH
Duncan Regional Hospital has become the first hospital in the U.S. to implement BD Alaris EMR interoperability with MEDITECH, enhancing patient safety and workflow efficiency. This integration allows for seamless connection between infusion pumps and electronic health records, reducing manual errors and improving documentation. BD aims to expand this technology to a broader range of healthcare organizations.
Read more →BDXBD Expands PureWick™ Portfolio with First-of-its-Kind Portable Solution to Confidently Manage Urinary Incontinence On the Go
BD has launched the PureWick™ Portable Collection System, a battery-powered device designed for wheelchair users to manage urinary incontinence discreetly. This innovative solution builds on the success of the PureWick™ Urine Collection System, which is widely used in hospitals. The new system aims to enhance mobility and confidence for individuals facing urinary incontinence.
Read more →BDXBD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results
BD (Becton, Dickinson and Company) reported strong financial results for its fiscal 2025, with revenues reaching $5.89 billion, an 8.3% increase from the previous year. The company achieved 3.9% organic growth, driven by its Medical segment's performance. BD is on track to complete its merger with Waters Corporation by early 2026, aiming to enhance its market position. However, the company faces challenges related to regulatory compliance and rising operational costs.
Read more →BDXBD Board Increases Dividend for 54th Consecutive Year
BD (Becton, Dickinson and Company) has announced a quarterly dividend increase of 1.0% to $1.05 per share, marking the 54th consecutive year of dividend growth. This decision underscores the company's confidence in its long-term prospects, even amidst ongoing transactions. The annual dividend rate for fiscal year 2026 is set at $4.20 per share.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Adam Reiffe, VP, Investor Relations - 201-847-6927 Media Fallon Mcloughlin, Director, Public Relations - 201-258-0361 BD Reports Fourth Quarter and Full
BD (Becton, Dickinson and Company) reported its fourth quarter and full year financial results for fiscal 2025, showcasing an 8.3% revenue increase to $5.9 billion in Q4. The company noted strong growth in adjusted diluted EPS, which rose by 9.6% for the fiscal year, while GAAP EPS experienced a slight drop. BD introduced various innovations, including AI-enabled medication management solutions, and is on track to complete significant business combinations by early 2026. Despite strong overall performance, the company faced some challenges, including a reduction in GAAP EPS and operating margin.
Read more →BDXBD Achieves Milestone in AGILITY Study of Revello™ Vascular Covered Stent for Treatment of Peripheral Artery Disease
BD has announced the full enrollment of the iliac artery patient cohort in its AGILITY study, which evaluates the Revello™ Vascular Covered Stent for treating peripheral artery disease (PAD). This milestone was presented at the VIVA 2025 conference by Dr. Sean Lyden. The study aims to enhance treatment options for patients with PAD through innovative stent technology.
Read more →BDXBD Receives FDA 510(k) Clearance and CE-IVDR Certification for High-Throughput Enteric Bacterial Panels on BD COR™ System
BD has announced the receipt of FDA 510(k) clearance and CE-IVDR certification for its Enteric Bacterial Panels on the BD COR™ System. These panels utilize advanced PCR technology to streamline testing for gastrointestinal bacterial pathogens from a single stool sample. This innovation aims to improve diagnostic speed and accuracy, addressing the urgent need for effective GI infection management.
Read more →BDXBD Simplifies At-Home HPV Testing to Broaden Access to Cervical Cancer Screening Outside United States
BD has introduced a new self-collection solution for HPV testing aimed at expanding access to cervical cancer screening outside the United States. This IVDR-certified technology allows for simple, non-invasive sample collection and automates lab processing using advanced robotics. The initiative is expected to improve laboratory efficiency and encourage participation in screening programs.
Read more →BDXBD Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings
BD (Becton, Dickinson and Company) has launched the BD Incada™ Connected Care Platform, a scalable, AI-enabled solution designed to unify device data across healthcare settings. This platform, along with the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, aims to enhance connectivity and provide actionable insights for care teams. The solutions leverage advanced AI technologies and cloud infrastructure to improve medication management and operational efficiency.
Read more →BDXBD Looks Ahead to the Next Era of Manufacturing Excellence in Broken Bow, NE and Celebrates 65 Years of Innovation in the Region
BD (Becton, Dickinson and Company) celebrates 65 years of manufacturing at its Broken Bow, Nebraska facility, which is the largest producer of BD Vacutainer® tubes. The company has invested over $50 million since 2020 to modernize operations and plans to create 50 new jobs at its Columbus facility. BD continues to support local communities through scholarships and educational partnerships.
Read more →BDXBD Announces CFO Transition Plan
BD (Becton, Dickinson and Company) announced a CFO transition plan with Chris DelOrefice set to leave the company on December 5, 2025. Vitor Roque will serve as interim CFO during this transition. The company also provided preliminary revenue results for fiscal 2025, highlighting strong growth in certain segments despite challenges in others.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Adam Reiffe, VP, Investor Relations - 201-847-6927 Media Fallon Mcloughlin, Director, Public Relations - 201-258-0361 BD Announces CFO Transition Plan P
BD (Becton, Dickinson and Company) has announced a transition plan for its Chief Financial Officer (CFO), Chris DelOrefice, who will leave the company on December 5, 2025, to pursue new opportunities. Vitor Roque will serve as the interim CFO while the company searches for a permanent successor. Alongside this announcement, BD provided preliminary revenue results indicating an estimated increase in revenue for both the fourth quarter and the full fiscal year 2025. Despite challenges in certain sectors, the company reported strong growth in various areas and aims to continue executing its strategic objectives.
Read more →BDXBD Reaches Major Milestone for Rotarex™ Catheter System with First Patient Enrolled in XTRACT™ Registry to Advance Real-World Evidence in Peripheral Artery Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in...
BD (Becton, Dickinson and Company) has successfully enrolled the first patient in the XTRACT™ Registry, a pivotal study evaluating the Rotarex™ Catheter System for treating peripheral artery disease (PAD). This registry aims to collect real-world performance data, expected to include up to 600 patients across 100 clinical sites in the U.S. The Rotarex™ device employs innovative mechanisms of action to enhance treatment efficacy. This milestone is seen as a major step towards improving clinical outcomes for PAD patients.
Read more →BDXBD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2025 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...
Becton, Dickinson and Company (BD) has announced that it will host an audio webcast on November 6, 2025, to discuss its financial results for the fourth quarter and full year of fiscal 2025. This follows the close of the fiscal year on September 30, 2025. The webcast will provide updates on the company's operations and strategy, along with summary financial information. Investors can access the webcast on BD's investor relations website, with a replay available shortly after the event.
Read more →BDXBD and Opentrons Collaborate to Accelerate Single-Cell Multiomics Discoveries with Robotic Automation BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Opentrons Labworks, Inc., recognized worldwide for...
BD and Opentrons Labworks have announced a multi-year collaboration to integrate robotic automation with BD's single-cell multiomics instruments. This partnership aims to automate key steps in drug development and disease research, enhancing speed and reproducibility. The integration includes the BD Rhapsody System and the Opentrons Flex platform, offering hands-free workflows for scientists. Early access opportunities for labs are anticipated soon, as both companies prepare to showcase their collaboration at the upcoming ASHG Annual Meeting in Boston.
Read more →BDXBD Celebrates 55 Years of Manufacturing Excellence and Impact in Sumter, S.C. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today will commemorate 55 years of manufacturing...
BD (Becton, Dickinson and Company) is commemorating its 55th anniversary of manufacturing at its Sumter facility in South Carolina. The site has expanded significantly since its inception, now employing about 900 individuals and producing critical medical products. BD has committed over $90 million in investments to improve operations and plans further investment in the coming years. The anniversary celebration includes acknowledgment of long-serving employees and a donation to local health initiatives, emphasizing BD's focus on community and innovation.
Read more →BDXBD and Henry Ford Health Sign Pharmacy Automation Partnership to Revolutionize Medication Storage and Prescription Delivery BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a pharmacy automation partnership with...
BD (Becton, Dickinson and Company) has announced a new pharmacy automation partnership with Henry Ford Health, focusing on the development of advanced robotics for medication storage and delivery. The collaboration will deploy the BD Rowa™ Vmax system at Henry Ford Health's pharmacies, allowing patients to retrieve prescriptions around the clock. This initiative aims to enhance patient-centered care by freeing up healthcare staff to focus on high-impact tasks. The two organizations are committed to advancing healthcare innovation and clinical outcomes through this partnership.
Read more →BDXBD Marks 1,000th BD Rhapsody System, Driving Scientific Breakthroughs via Single-Cell Multiomics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the placement of the 1,000th BD Rhapsody™...
BD (Becton, Dickinson and Company) has announced the significant milestone of placing its 1,000th BD Rhapsody System at Addenbrooke's Hospital, University of Cambridge. This flagship instrument specializes in single-cell multiomics analysis, providing deeper insights into cellular behavior and aiding in disease research. The system has been integral to over 700 published studies since its introduction and continues to evolve with flexible sample processing capabilities. The rapid adoption of this technology underscores its importance in addressing critical scientific needs.
Read more →BDXBD Expands Peripheral Artery Disease Awareness Efforts with 'Love Your Limbs' Community Screening Initiative In recognition of Peripheral Artery Disease (PAD) Awareness Month, BD (Becton, Dickinson and Company) (NYSE: BDX) is shining a spotlight on a serious ...
BD (Becton, Dickinson and Company) has launched the 'Love Your Limbs' Community Screening Initiative as part of its effort to raise awareness for Peripheral Artery Disease (PAD) during PAD Awareness Month. The initiative aims to address the underdiagnosis and undertreatment of PAD, which affects millions globally, by offering free ankle-brachial index screenings. BD's partnership with healthcare providers and community organizations will help facilitate early detection and intervention, ultimately reducing preventable amputations and improving patient care. Additionally, the company is employing data-driven strategies to identify high-need communities for targeted outreach.
Read more →BDXBD to Present at Wells Fargo 2025 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo...
BD (Becton, Dickinson and Company) has announced its presentation at the Wells Fargo 2025 Healthcare Conference scheduled for September 3, 2025. The presentation can be accessed via a live webcast on the company's investor relations website. BD, known for its global presence and commitment to improving health care, emphasizes its role in advancing medical discovery and diagnostics. This conference offers an opportunity for BD to showcase its innovative technologies and solutions that enhance health care delivery.
Read more →BDX▲ +8.9%on this news
Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Third Quarter Fiscal
Becton, Dickinson and Company (BD) reported financial results for the third quarter of fiscal 2025, revealing a 10.4% rise in revenue to $5.5 billion and significant growth in earnings per share. The company raised its full-year adjusted EPS guidance, reflecting optimism about its performance. Notably, BD is set to combine its Biosciences and Diagnostic Solutions business with Waters Corporation, which is expected to strengthen its position in the life sciences sector. Furthermore, investments in production capabilities and the introduction of new medical products highlight BD's proactive approach to market demands.
Read more →BDX▲ +8.9%on this news
BD Reports Third Quarter Fiscal 2025 Financial Results Revenue of $5.5 billion increased 10.4% as reported, 8.5% adjusted FXN and 3.0% organic GAAP and adjusted diluted EPS grew to $2.00 and $3.68,...
BD (Becton, Dickinson and Company) reported strong financial results for Q3 of fiscal 2025, with revenues reaching $5.5 billion, a 10.4% increase from the previous year. The company achieved significant growth in earnings, raising adjusted EPS guidance to reflect this positive trend. Additionally, BD announced a planned merger with Waters Corporation to enhance its position in life sciences and diagnostics. The company aims to accelerate growth and maximize shareholder value through this strategic move.
Read more →BDXBD Businesses Become First in MedTech to Achieve HIRC's Diamond Badge Across All Supply Chain Resiliency Categories BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Urology and Critical Care (UCC) ...
BD (Becton, Dickinson and Company) announced that its Urology and Critical Care and Surgery business units are the first in the MedTech industry to achieve a diamond-level rating in all seven domains of the Healthcare Industry Resilience Collaborative's Resiliency Badging program. This achievement underscores BD's dedication to a resilient supply chain and operational excellence. The recognition followed a comprehensive audit assessing supply chain practices across various resilience domains. BD's ongoing investments aim to enhance safety stock and improve order management, ultimately benefiting healthcare providers and patients alike.
Read more →BDXBD to Invest $35 Million in Nebraska Facility to Expand Prefilled Flush Syringe Manufacturing to Support U.S. Health Care BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest more than $35 million...
BD (Becton, Dickinson and Company) announced a significant investment exceeding $35 million to expand its prefilled flush syringe manufacturing at its Columbus, Nebraska facility. This initiative will create around 50 new jobs and aims to enhance the production capacity of BD PosiFlush syringes to meet rising demand in U.S. hospitals. The facility's expansion is part of a larger strategy to reinforce the U.S. health care system's resilience, following previous investments totaling over $80 million in recent years. BD's ongoing commitment to U.S. manufacturing is evident as it aims to ensure a consistent supply of essential medical devices.
Read more →BDXBD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening Self-Collected At Home BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted an application to the U....
BD has submitted a new application to the FDA for an at-home HPV test that enables women to self-collect samples comfortably. The test uses advanced technology to report a wider array of high-risk HPV strains compared to existing tests. This initiative aims to make cervical cancer screening more accessible, with a focus on empowering women. A recent survey reveals significant interest among women for more convenient and less invasive testing options.
Read more →BDXBD Receives FDA 510(k) Clearance for Rapid Point-of-Care COVID-19 Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug...
BD (Becton, Dickinson and Company) has announced its receipt of FDA 510(k) clearance for the BD Veritor System for SARS-CoV-2, a rapid COVID-19 antigen test. This test allows for results to be delivered in approximately 15 minutes, aimed at improving point-of-care testing in various settings. The new clearance will replace the previous Emergency Use Authorization version starting in early fall 2025. The BD Veritor System leverages digital technology for enhanced accuracy and ease of use in detecting COVID-19 antigens.
Read more →BDXBD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product ...
BD (Becton, Dickinson and Company) has announced its first pharma-sponsored clinical trial utilizing the BD Libertas™ Wearable Injector for the subcutaneous delivery of biologics. This trial follows favorable outcomes from over 50 prior studies and highlights the company's commitment to enhancing drug delivery solutions. The BD Libertas™ system is designed for patient-friendly self-administration, potentially transforming the administration of complex biologics. The market for biologics is anticipated to grow significantly, making this development strategically important for BD's pharmaceutical partnerships.
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has...
BD (Becton, Dickinson and Company) has announced a quarterly dividend of $1.04 per common share, payable on September 30, 2025, to shareholders on record as of September 8, 2025. This dividend declaration signals the company's solid financial health and commitment to its investors. The indicated annual dividend rate is set at $4.16 per share. BD continues to be a prominent player in the global medical technology landscape, focusing on enhancing healthcare processes and outcomes.
Read more →BDXWaters and BD s Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing Strong strategic fit that increases presence in multiple hi
Waters Corporation and Becton, Dickinson and Company announced a definitive agreement to combine BD's Biosciences & Diagnostic Solutions business with Waters, forming a robust leader in life sciences and diagnostics. This transaction, valued at approximately $17.5 billion, aims to create significant shareholder value and enhance their presence in high-growth markets. The combination is structured as a tax-efficient Reverse Morris Trust and is expected to close by the end of the first quarter of 2026, subject to regulatory approvals. Udit Batra will lead the new entity, which will retain the Waters name and listing on the NYSE.
Read more →BDXBD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, effective July 2, Bilal Muhsin has ...
Becton, Dickinson and Company (BD) has appointed Bilal Muhsin as executive vice president and president of its newly created Future Connected Care segment, effective July 2. Muhsin will lead the development and execution of BD's connected care strategy, focusing on advanced analytics, AI solutions, and smart devices to enhance patient care. His appointment is part of BD's broader New BD strategy aimed at leveraging cutting-edge technology to drive growth and improve healthcare outcomes. With a strong background in medical engineering and over 50 patents, Muhsin's leadership is expected to have a significant impact on the company's innovation initiatives.
Read more →BDXBD to Initiate Real-World Patient Data Registry for the Rotarex™ Atherectomy System in Treatment of Peripheral Artery Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to initiate a patient data...
BD (Becton, Dickinson and Company) announced plans to initiate the XTRACT patient data registry for its Rotarex™ Atherectomy System, aimed at evaluating real-world patient outcomes for those suffering from peripheral artery disease (PAD). The registry, set to enroll up to 600 patients across 100 sites in the U.S., will comprehensively assess clinical performance post-procedure. The data will thus contribute to better optimizing treatment strategies in collaboration with leading clinicians. The initiative reflects BD's dedication to enhancing patient care through innovative technology and research.
Read more →BDXBD to Present at Goldman Sachs 46th Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman...
Becton, Dickinson and Company (BD) will present at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025. This event reflects BD's ongoing engagement in advancing healthcare discussions and investor interest. A live webcast of the presentation will be available on BD's investor relations website, and a replay will be accessible afterward. BD continues to position itself as a leader in medical technology and innovation.
Read more →BDXCancer Patients Face Elevated Risk of Carrying Antimicrobial Resistant 'Superbugs' First-of-their-kind studies published in The Lancet Oncology1 and Cancer Medicine2 provide new data showing that cancer patients in both hospital and ...
Recent studies published in The Lancet Oncology and Cancer Medicine have found that cancer patients are at a significantly higher risk of antimicrobial resistant (AMR) infections compared to non-cancer patients. This highlights the vulnerability of cancer patients to 'superbugs', which could jeopardize the effectiveness of critical treatments such as CAR T-cell therapy. Experts emphasize the urgent need for improved infection prevention measures and antibiotic stewardship to combat this rising threat within oncology.
Read more →BDXBD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the global commercial launch of the world's...
BD (Becton, Dickinson and Company) has launched the BD FACSDiscover™ A8 Cell Analyzer, the world's first cell analyzer featuring advanced spectral and real-time imaging technologies. This new device allows researchers to analyze up to 50 characteristics of single cells, providing deeper insights and enhancing workflows in various scientific applications. In addition to the analyzer, new software innovations were introduced to simplify laboratory processes. The cell analyzer is expected to significantly benefit translational research, particularly in immuno-oncology.
Read more →BDXBD to Announce Financial Results for its Third Quarter of Fiscal 2025 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...
Becton, Dickinson and Company (BD) has announced plans to host an audio webcast on August 7, 2025, to discuss its financial results for the third quarter of fiscal year 2025. The financial period concludes on June 30, 2025. Attendees will receive updates on the company’s operations and strategy, alongside summary financial information, which will be made available prior to the call. BD continues to play a significant role in advancing health care through its innovative technology and services.
Read more →BDX▼ -18.1%on this news
Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Second Quarter Fisca
BD (Becton, Dickinson and Company) reported second-quarter fiscal 2025 results showing a revenue increase of 4.5% to $5.3 billion. The company announced a $2.5 billion investment in U.S. manufacturing capacity. Challenges include a 42.2% decline in GAAP diluted EPS and the impact of tariffs on their financial outlook. Notably, BD's Medication Management Solutions received awards for excellence in safety and technology innovation.
Read more →BDX▼ -18.1%on this news
BD Reports Second Quarter Fiscal 2025 Financial Results BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second...
BD (Becton, Dickinson and Company) reported its fiscal 2025 second quarter financial results, revealing a 4.5% increase in total revenues compared to the previous year. The organic revenue growth was relatively modest at 0.9%, attributed to a challenging operating environment and specific declines in certain segments. Although adjusted diluted earnings per share showed an increase, the overall diluted earnings per share saw a significant decline. Management remains optimistic about the company's future growth trajectory, leveraging its strengths to navigate the current macroeconomic challenges.
Read more →BDXBD to Present at Bank of America Securities Health Care Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of...
Becton, Dickinson and Company (NYSE: BDX) announced its participation in the upcoming Bank of America Securities Health Care Conference set for May 13, 2025. They will provide a presentation that can be accessed via a live webcast on their investor relations website. Following the event, a replay will be available for those who wish to view it later. BD is recognized for its substantial impact in developing medical technology aimed at improving healthcare delivery and patient outcomes.
Read more →BDXBD Launches Industry-First Bioabsorbable Mesh Designed for Umbilical Hernia Repair BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and...
BD (Becton, Dickinson and Company) has announced the launch of the Phasix ST Umbilical Hernia Patch, the first fully bioabsorbable hernia repair patch designed specifically for umbilical hernias. The patch received 510(k) clearance from the FDA and is expected to provide surgeons with a reliable alternative to permanent mesh. Made from a biologically-derived material, it utilizes technology that allows for deployment through standard surgical techniques. The introduction of this product reflects BD's commitment to innovative solutions that address the preferences of both patients and healthcare providers.
Read more →BDXBD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring...
BD (Becton, Dickinson and Company) has launched the HemoSphere Alta™ platform, a cutting-edge hemodynamic monitoring solution that utilizes artificial intelligence to assist clinicians in managing blood pressure and blood flow during critical situations. This innovative platform features the Cerebral Autoregulation Index, providing personalized insights into patients' blood pressure needs. Additionally, the incorporation of the Hypotension Prediction Index software enhances the ability to predict low blood pressure events, potentially reducing risks during procedures. The platform is designed to improve user experience with a customizable interface and advanced interaction features.
Read more →BDXBD to Announce Financial Results for its Second Quarter of Fiscal 2025 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...
BD (Becton, Dickinson and Company) has announced that it will host an audio webcast on May 1, 2025, to discuss its financial results for the second quarter of fiscal year 2025 and provide operational updates. The call will cover results from the period ending March 31, 2025. Prior to the webcast, BD will release summary financial information along with presentation materials on its investor relations website. This approach underlines BD's commitment to transparency with its investors and stakeholders.
Read more →BDXBD Named One of America's Most Innovative Companies by Fortune BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most ...
BD (Becton, Dickinson and Company) has been recognized on Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25%. This recognition highlights BD's achievements in developing innovative healthcare products and fostering a culture of continuous improvement. CEO Tom Polen underlined the responsibility to innovate, given the company's vast impact on patient care globally. The list is based on a survey of over 40,000 U.S. employees and 2,500 industry experts, showcasing the company's strengths in advancing healthcare technology.
Read more →BDXBD Names Gregory J. Hayes to Board of Directors BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to...
BD (Becton, Dickinson and Company) has appointed Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, with over 30 years of executive experience, is expected to contribute to BD's transformation as the company prepares for the separation of its Diagnostic Solutions and Biosciences business. This appointment aligns with BD's commitment to strong corporate governance and ongoing board refreshment. Hayes' expertise in portfolio optimization and operational efficiency is viewed as crucial for BD's future success.
Read more →BDXBD Announces Milestone in Clinical Trial for Use of Bioabsorbable GalaFLEX LITE™ Scaffold in Breast Implant Revision Surgery BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the first patient treated in an...
BD (Becton, Dickinson and Company) has announced the treatment of its first patient in a clinical trial for the GalaFLEX LITE™ Scaffold, aimed at reducing capsular contracture recurrence in breast revision surgeries. This Investigational Device Exemption (IDE) study is crucial for obtaining Premarket Approval (PMA) from the FDA. With an enrollment goal of at least 250 patients across 40 sites, the trial seeks to provide evidence of the safety and efficacy of GalaFLEX LITE™ in surgical procedures. BD highlights its commitment to addressing significant medical challenges in implant-based surgeries through innovative solutions.
Read more →BDXBD to Present at Investor Healthcare Conferences BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following...
Becton, Dickinson and Company (BDX) announced its participation in multiple healthcare conferences, including the Citi's 2025 Unplugged Medtech and Life Sciences Access Day and the Barclays 27th Annual Global Healthcare Conference. These events provide BD an opportunity to present its innovations in medical technology and engage with investors. The company emphasizes its commitment to improving healthcare delivery and advancing diagnostics and therapeutics. Live webcasts of the presentations will be available on BD's investor relations website.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports First Quarter Fiscal
Becton, Dickinson and Company (BD) reported strong first quarter results for fiscal 2025, with revenues reaching $5.2 billion, up by 9.8% from the previous year. The company also achieved an increase in earnings per share, with adjusted diluted EPS growing by 28.0%. BD is optimistic about its future, raising its adjusted diluted EPS guidance for the full fiscal year 2025. Key highlights include significant revenue contributions from multiple business units and strategic share repurchases.
Read more →BDXBD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market...
BD has announced its decision to separate its Biosciences and Diagnostic Solutions business from the rest of the company to enhance strategic focus and drive growth. The separation aims to create a new entity, New BD, which is expected to concentrate on medical technology with an approximate revenue of $17.8 billion in fiscal 2024. The company anticipates that the separated business will thrive as a pure-play leader in life sciences while maintaining strong recurring revenue and enabling further investments in R&D. The operational separation is expected to be completed by fiscal 2026, subject to various approvals and conditions.
Read more →BDXBD Reports First Quarter Fiscal 2025 Financial Results BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 first...
BD (Becton, Dickinson and Company) reported strong financial performance for the first quarter of fiscal 2025, with revenue reaching $5.168 billion, marking a 9.8% increase from the previous year. The adjusted diluted earnings per share grew by 28.0% to $3.43, driven by improved operational efficiencies. The company continues to implement its BD 2025 strategy, which includes separating its Biosciences and Diagnostic Solutions segments, aiming to enhance growth and innovation. The updated fiscal guidance reflects confidence in sustained performance throughout the year.
Read more →BDXBD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25 The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has...
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $1.04 per share, set to be paid on March 31, 2025. Additionally, the company has completed $750 million in stock repurchases in FY25 and approved the purchase of up to 10 million more shares. These actions reflect BD's efforts to enhance shareholder value while supporting its ongoing growth in the medical technology sector.
Read more →BDXBD and Biosero Collaborate to Enable Robotic Integration with Flow Cytometers Used in Drug Discovery and Development BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Biosero, a developer of laboratory automation...
BD (Becton, Dickinson and Company) has announced a collaboration with Biosero to enable robotic integration with their flow cytometry instruments to improve drug discovery and development. The partnership aims to automate traditionally manual processes in laboratories, allowing for the analysis of multiple multiwell plates without human intervention. As a result, biopharmaceutical and contract research organizations can enhance their productivity and efficiency in high-throughput drug screening. New software compatible with BD instruments will be released for research use in 2025, marking a significant advancement in laboratory automation.
Read more →BDXCarilion Clinic First in Virginia to Offer Needle-free In-patient Blood Draws, Redefining Patient Standard of Care Carilion Clinic, a not-for-profit health care organization serving more than 1 million people in Virginia, in partnership with BD, (Becton, Dickinson ...
Carilion Clinic has partnered with BD to become the first health system in Virginia to offer needle-free blood draws using the PIVO™ Pro Needle-free Blood Collection Device. This technology aims to enhance patient care by reducing the frequency of needlesticks, thereby decreasing pain and anxiety for patients. The implementation is part of Carilion's commitment to patient-centered care and aims to streamline clinical workflows. As the technology is rolled out across more hospitals, it promises to improve overall patient satisfaction and outcomes.
Read more →BDXBD to Announce Financial Results for its First Quarter of Fiscal 2025 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio...
Becton, Dickinson and Company (BD) has announced plans to host an audio webcast on February 6, 2025, at 8 a.m. ET, to discuss its financial results for the first quarter of fiscal year 2025, which concluded on December 31, 2024. The company will provide updates regarding its operations and strategy during the session. Prior to the call, relevant financial information will be made available through a press release and presentation materials on its investor relations website.
Read more →BDXBD Boosts U.S. Manufacturing of Critical Medical Devices BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional investments in its U.S....
BD (Becton, Dickinson and Company) has announced over $10 million in investments to expand its U.S. manufacturing capabilities for critical medical devices, including syringes and IV catheters. This expansion involves new production lines in Connecticut and Nebraska, enhancing production capacity by over 40% for safety-engineered injection devices and 50% for conventional syringes. Additionally, BD plans further investments of over $30 million in 2025 to bolster IV line manufacturing in Utah. These efforts aim to improve the resilience of the nation's healthcare supply chain.
Read more →BDXNew ASCCP Guidelines Include More Precise Method of Cervical Cancer Screening BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the BD Onclarity™ HPV Assay has...
BD (Becton, Dickinson and Company) announced that its BD Onclarity™ HPV Assay has been included in the ASCCP Enduring Risk-Based Management Guidelines. This assay provides a more detailed identification of high-risk HPV types, which enhances cervical cancer screening and management. The new guidelines suggest that the assay's extended genotyping enables tailored patient care and reduces unnecessary procedures for lower-risk individuals. Additionally, self-collection for screening is promoted, making it more accessible for various patients.
Read more →BDXBD Names Pamela Spikner as Chief Accounting Officer and Controller BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Pamela Spikner has been named...
BD (Becton, Dickinson and Company) has appointed Pamela Spikner as its new senior vice president, chief accounting officer, and controller, effective January 20. Spikner brings over 25 years of experience in corporate finance, having previously served as chief accounting officer at R1 RCM, Inc. In her new role, she will oversee BD's accounting policy and financial reporting, reporting directly to the CFO. Her appointment reflects the company's commitment to strengthening its finance team with proven leadership.
Read more →BDXNew Survey Finds Women Are Skipping Their OB/GYN Exams, Increasing Risks for Cervical Cancer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new survey, revealing...
BD (Becton, Dickinson and Company) released a new survey showing that 72% of women in the U.S. have delayed gynecology visits, primarily due to fear and scheduling challenges. Despite awareness of cervical cancer prevention through regular screenings, many women desire more comfortable and less invasive testing options. The company advocates for self-collection strategies, emphasizing that innovative solutions such as the FDA-approved BD Onclarity™ HPV Assay can significantly improve cervical cancer screening processes. Additionally, guidelines promoting self-collection are gaining traction among health organizations.
Read more →BDXBD To Host Virtual 2025 Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host its virtual 2025...
BD (Becton, Dickinson and Company) announced that it will host its virtual 2025 Annual Meeting of Shareholders on January 28, 2025, at 1:00 p.m. ET. Shareholders as of December 9, 2024, will have the opportunity to attend, vote, and ask questions during the meeting, with guests permitted to listen only. A replay of the meeting will be available on BD's website for one year after the event. BD is recognized as a leading global medical technology company, dedicated to improving health outcomes through innovative technologies and solutions.
Read more →BDXBD and Babson Diagnostics Launch Innovative Fingertip Blood Testing to Health Care Organizations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Babson Diagnostics, a science-first health care...
BD (Becton, Dickinson and Company) and Babson Diagnostics have expanded their partnership to offer innovative fingertip blood testing technologies for U.S. healthcare systems. The integration of BD's MiniDraw Capillary Blood Collection System with Babson's BetterWay technologies allows for blood tests using only six drops of blood collected from a finger, making procedures less invasive. This collaboration aims to increase efficiency in healthcare settings and improve patient outcomes by addressing service gaps and enhancing access to testing.
Read more →BDXBD Resolves Previously Disclosed SEC Investigation BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement: BD has reached an...
BD (Becton, Dickinson and Company) has resolved an SEC investigation regarding prior disclosures and reporting tied to the BD Alaris System. The company agreed to pay $175 million to settle the issues without requiring financial restatements and without impacting its fiscal 2025 guidance. BD maintains that the Alaris System is safe and effective, having undergone clearance updates from the FDA. Improvements have also been made to BD's operational and governance processes in light of this matter.
Read more →BDXFirst of Its Kind HPV Self-Collection Study Launched to Improve Cervical Cancer Screening in Underserved Communities A first of its kind Human Papillomavirus (HPV) self-collection screening pilot program aimed at improving cervical cancer screening in underserved...
A pioneering HPV self-collection screening pilot program has launched in Texas, aimed at enhancing cervical cancer screening in underserved communities. The initiative utilizes the FDA-approved BD Onclarity™ HPV Assay for self-testing, eliminating the need for invasive procedures. Conducted at Su Clinica in collaboration with MD Anderson Cancer Center, the study will assess the program's effectiveness and identify challenges in health care accessibility. Supported by a $2.5 million grant from CPRIT, the program emphasizes health equity and aims to develop strategies that can be adapted across other underserved regions.
Read more →BDXBD to Present at the 7th Annual Evercore ISI HealthCONx Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 7th Annual...
Becton, Dickinson and Company (BD) announced its participation in the 7th Annual Evercore ISI HealthCONx Conference, scheduled for December 3, 2024. The presentation will be accessible via a live webcast on the company's investor relations website. BD, a major player in global medical technology, focuses on improving medical discovery and care delivery, reflecting its commitment to innovation and health care advancement.
Read more →BDX▼ -5.4%on this news
BD Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results Strong Growth and Margin Execution Drives Performance in Quarter Q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and...
BD (Becton, Dickinson and Company) reported its fiscal 2024 fourth quarter and full year results, showing a revenue increase to $5.4 billion, which is a 6.9% rise compared to the previous year. The company's diluted earnings per share from continuing operations increased significantly by 173.6%. BD's growth strategy focuses on leveraging advancements in technology and its recent acquisition of the Critical Care product group from Edwards Lifesciences. However, the company anticipates challenges with a potential revenue decrease in the Chinese market and variabilities in the Bioscience and Pharma sectors affecting future growth.
Read more →BDX▼ -5.4%on this news
BD Board Increases Dividend for 53rd Consecutive Year The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $1.04 per common share, an increase of...
Becton, Dickinson and Company (BD) has declared a quarterly dividend of $1.04 per common share, marking a 9.5% increase from the previous quarter. This is the company's 53rd consecutive year of dividend increases, affirming its position in the S&P 500 Dividend Aristocrats Index. The new annual dividend rate for fiscal year 2025 is set at $4.16 per share. CEO Tom Polen stated that this increase reflects BD's confidence in its long-term outlook and commitment to value creation and shareholder returns.
Read more →BDX▼ -5.4%on this news
Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Adam Reiffe, Sr. Director, Investor Relations - 201-847-6927 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Fourth Quarter and F
Becton, Dickinson and Company (BD) reported strong financial results for its fourth quarter and full fiscal year 2024, with substantial revenue growth and a significant increase in earnings per share. The company's revenue reached $5.4 billion in Q4, a 6.9% increase year-over-year. BD anticipates continued growth in fiscal year 2025, providing guidance of 8.9% to 9.4% growth in GAAP revenue and an adjusted diluted EPS range of $14.25 to $14.60. The report highlights BD's strategic focus on higher-growth areas and significant advancements in its product offerings, including new AI and automation technologies.
Read more →BDXBD Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched the new BD® Intraosseous Vascular Access...
BD (Becton, Dickinson and Company) has launched the innovative BD® Intraosseous Vascular Access System which facilitates rapid access to the circulatory system in emergency scenarios. This system is designed for both adult and pediatric patients, allowing healthcare providers to insert it when traditional intravenous access is difficult. Unique features include integrated needle safety and a rechargeable battery that ensures extended operational efficiency. BD aims to enhance patient outcomes and support healthcare teams with this advancement in medical technology.
Read more →BDXBD Named Among the 100 Best Corporate Citizens of 2024 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named as one of the 100 Best ...
BD (Becton, Dickinson and Company) has been named one of the 100 Best Corporate Citizens of 2024, securing the second position in the health care equipment sector for the second consecutive year. This recognition is based on extensive evaluations of environmental, social, and governance responsibilities among large U.S. corporations. BD's efforts in corporate sustainability and commitment to transparency have played a significant role in this achievement, further affirming its position as a leader in medical technology.
Read more →BDXBD Announces New Robotics Solution to Automate, Standardize Single-Cell Research BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial launch of the first in a...
BD (Becton, Dickinson and Company) has launched a new family of high-throughput, robotics-compatible reagent kits designed to automate single-cell research. The BD OMICS-One XT WTA Assay works alongside Hamilton's Microlab NGS STAR automated liquid handling platform, streamlining labor-intensive processes in genetic sequencing. This innovation aims to enhance consistency and efficiency in laboratory workflows, significantly reducing manual errors and time investment. BD's solutions are available globally, integrating seamlessly into existing laboratory operations.
Read more →BDXBD to Announce its Fiscal 2024 Fourth Quarter and Full Year Financial Results BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
BD (Becton, Dickinson and Company) has announced its plans to report the financial results for its fiscal 2024 fourth quarter and full year on November 7, 2024. A news release detailing summary financial information will be available at 6:30 a.m. ET. Additionally, the management will host an audio webcast at 8 a.m. ET to discuss these results along with updates on the company's operations and strategic directions.
Read more →BDXBD Reaches Agreement to Resolve Vast Majority of Hernia Litigation BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has reached an agreement to resolve...
BD (Becton, Dickinson and Company) announced reaching an agreement to resolve most of its hernia litigation, affecting both Rhode Island consolidated cases and federal multidistrict litigation in Ohio. The terms of the settlement, which remain confidential, will be paid out over multiple years and were factored into the company's cash flow planning. Importantly, the settlement includes no admission of liability, and BD will continue to defend against unresolved cases. This agreement is expected to eliminate uncertainty for stakeholders regarding settled cases.
Read more →BDXNew Data Reveals BD's Artificial Intelligence Software Highly Effective in Detecting Indicators of Controlled Substance Diversion BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data that highlights how its...
BD (Becton, Dickinson and Company) announced new data revealing the effectiveness of its AI software in detecting controlled substance diversion in healthcare settings. A study at Ochsner Health showed that implementation of the BD HealthSight Diversion Management software led to a 55% increase in detected discrepancies and improved resolution efficiency. The advancements in tracking and analyzing drug diversion incidents indicate a significant opportunity for health systems to combat this critical issue in the operating room.
Read more →BDXBD Expands Capacity for Advanced Prefillable Syringes and Enhances Injection Experience for the Next Generation of Biologics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial release of the BD Neopak™...
BD (Becton, Dickinson and Company) has announced the commercial release of the BD Neopak™ XtraFlow™ Glass Prefillable Syringe and significant capacity expansion at its manufacturing site in Le Pont-de-Claix, France. The new syringe design improves usability for biologic drugs, allowing for higher viscosity delivery with reduced injection force and time. This innovation meets the rising demand in the biologics market, supporting over 30 approved drugs across various indications. The expansion at the manufacturing site is expected to increase production capacity substantially, promoting efficient supply for pharmaceutical partners globally.
Read more →BDXBD Completes Acquisition of Critical Care from Edwards Lifesciences Expands BD's portfolio of smart connected care solutions with leading monitoring technologies, including advanced AI-enabled clinical decision tools...
BD (Becton, Dickinson and Company) has completed the acquisition of the Critical Care product group from Edwards Lifesciences, which will be rebranded as BD Advanced Patient Monitoring. This strategic move is expected to enhance BD's portfolio of smart connected care solutions, particularly with the addition of AI-enabled technologies. Katie Szyman, formerly a corporate vice president at Edwards, will lead the new business unit. The acquisition is not anticipated to significantly impact BD's fiscal year 2024 guidance.
Read more →BDXBD Celebrates 75 years of U.S. Manufacturing Excellence in Nebraska BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today celebrated the 75th anniversary of its...
BD (Becton, Dickinson and Company) celebrated its 75th anniversary of manufacturing in Columbus, Nebraska, emphasizing the importance of domestic production of critical medical devices. The event recognized the contributions of its 2,100 employees and local officials, while highlighting significant investments made in the facility. Over the past 75 years, BD has played a vital role in healthcare by producing billions of medical supplies and has increased syringe production by 50% in response to recent demand. The company's historical commitment reflects its resilience in supporting national health needs.
Read more →BDXBD Names Michael Feld as President of Life Sciences Segment BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michael Feld has been named...
BD (Becton, Dickinson and Company) has appointed Michael Feld as the new executive vice president and president of its Life Sciences segment, effective August 20, 2024. Feld, who previously held several prominent positions at Veralto and Danaher, is expected to bring his expertise to advance BD's operations within the Life Sciences division. His appointment comes after the retirement of former president Dave Hickey. The company intends to leverage Feld's background to enhance its efforts in innovative solutions for diagnosis and treatment in healthcare.
Read more →BDXBD to Present at Wells Fargo 2024 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo...
BD (Becton, Dickinson and Company) will present at the Wells Fargo 2024 Healthcare Conference on September 4, 2024. The presentation will be accessible via a live webcast from the BD investor relations website, with a replay available afterward. BD is a leading global medical technology firm focused on improving healthcare through innovative solutions.
Read more →BDXBD Reports Third Quarter Fiscal 2024 Financial Results Strong Margin Execution Drives Performance in Quarter Revenue of $5.0 billion as reported, adjusted revenue of $5.1 billion, driven by strong organic ...
BD (Becton, Dickinson and Company) reported its third-quarter fiscal 2024 financial results, showcasing a 2.3% increase in revenues amounting to $5.0 billion. The growth was attributed to strong performances in various segments, particularly in medical and life sciences. The company also demonstrated improved margin execution and cash flows, allowing for an upward revision of its adjusted earnings per share guidance for the fiscal year. Despite these positives, the report highlighted a minor decline in international revenues and legal matters affecting prior year earnings.
Read more →BDXBD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Quest Diagnostics (NYSE: DGX), a leader in...
BD (Becton, Dickinson and Company) and Quest Diagnostics have entered into a global collaboration to develop and commercialize flow cytometry-based companion diagnostics for cancer and other diseases. This partnership seeks to combine BD's flow cytometry innovation with Quest's expertise in biomarker and assay development. The goal is to create an end-to-end solution for the pharmaceutical industry that can significantly improve patient outcomes and reduce healthcare costs. The collaboration aims to leverage advanced technologies and integrated solutions to advance personalized health care.
Read more →BDXBD Statement on Supplier Issue Impacting BD BACTEC™ Blood Culture Vials BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to a U.S....
BD (Becton, Dickinson and Company) announced a supplier issue affecting the availability of blood culture vials, prompting a letter from the U.S. FDA to healthcare providers. The company is implementing measures such as air shipments and modified manufacturing schedules to address the situation while collaborating closely with the FDA. Although the supply disruption is not expected to result in significant financial impact, BD is manually allocating vials to prioritize clinical needs until normal supply levels can be restored.
Read more →BDXBD Surpasses Scope 1 and 2 Reduction Milestones for FY 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has surpassed its Scope 1 and 2...
Becton, Dickinson and Company (BD) announced that it exceeded its Scope 1 and 2 greenhouse gas emissions reduction targets for FY 2023 by 5 percentage points. The company achieved an 18% reduction from a FY 2019 baseline, surpassing its annual goal of 13%. BD has also doubled the number of sites using renewable energy sources and has received approval for its emissions reduction targets from the Science Based Target initiative. The company aims to reach net-zero GHG emissions across its value chain by FY 2050.
Read more →BDXBD to Announce Financial Results for its Third Quarter of Fiscal 2024 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
Becton, Dickinson and Company (BD) has announced the scheduled release of its financial results for the third quarter of fiscal year 2024, which will occur on August 1, 2024. The company's results will encompass summary financial information for the quarter ending June 30, 2024. Following the release, BD management will hold an audio webcast to detail the financial outcomes and update on their operations and strategy. Additional materials will be accessible on their investor relations website.
Read more →BDXNew BD Research Tool Helps Scientists Study Cells that are Often Key Culprits in the Development of Cancer and Infectious Diseases BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell...
BD (Becton, Dickinson and Company) has launched the BD Rhapsody™ Single Cell ATAC-Seq Assay, designed to enhance the study of cellular functions and disease mechanisms. This tool allows researchers to analyze the epigenome at a single-cell level, providing insights into how environmental factors affect DNA and cellular behavior. The technology aims to support advancements in cancer and infectious disease research by facilitating a deeper understanding of disease progression and therapy development.
Read more →BDXBD Announces Dates for Third Quarter and Fourth Quarter Fiscal 2024 Earnings Webcasts BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to...
BD (Becton, Dickinson and Company) announced the scheduled dates for webcasts to discuss its third and fourth quarter fiscal 2024 earnings. These webcasts will provide detailed financial information and insights ahead of each quarter's results. As a prominent global medical technology company, BD plays a critical role in medical advancements and healthcare delivery.
Read more →BDXBD to Acquire Edwards Lifesciences' Critical Care Product Group for $4.2 Billion to Expand Smart Connected Care Solutions and Become an Advanced Monitoring Technology Leader Combination unlocks new future value-creation opportunities and is expected to be immediately accretive to BD revenue growth, adjusted gross margin,...
BD (Becton, Dickinson and Company) has announced its acquisition of Edwards Lifesciences’ Critical Care product group for $4.2 billion. This acquisition aims to enhance BD's portfolio of smart connected care solutions and is expected to provide immediate benefits such as revenue growth and margin improvement. Critical Care is a leader in advanced patient monitoring, with a strong financial profile. The transaction is subject to regulatory approvals and is expected to close by the end of the calendar year.
Read more →BDXWomen in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA)...
Becton, Dickinson and Company (BD) has received FDA approval for self-collected vaginal specimens for HPV testing, enabling women to participate in cervical cancer screening in non-traditional settings like retail pharmacies and mobile clinics. This development aims to alleviate barriers to screening, which disproportionately affect underserved populations. The new self-collection method is shown to significantly increase participation, particularly among women who have never been screened. BD's Onclarity™ HPV Assay is notable for providing individualized strain information, enhancing the precision of cervical cancer risk assessments.
Read more →BDXBD Reports Second Quarter Fiscal 2024 Financial Results Margin Execution Drives Better Performance in Quarter and Higher Guidance for Fiscal 2024 Q2 revenue of $5.0 billion increased 4.6% as reported, 4.7% ...
Becton, Dickinson and Company (BD) reported its second quarter financial results for fiscal 2024, ending March 31, with revenues reaching $5.0 billion, marking a 4.6% increase from the previous year. The company noted strong operating margins and cash flow, attributing this performance to their ongoing strategic initiatives and diverse product portfolio. BD has raised its earnings guidance for the remainder of fiscal 2024, indicating confidence in continued growth. Specific revenue growth was observed across its medical, life sciences, and interventional segments.
Read more →BDXBD to Present at Bank of America Securities Health Care Conference 2024 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of...
Becton, Dickinson and Company (NYSE: BDX) will present at the Bank of America Securities Health Care Conference 2024 on May 14, 2024. The presentation will be accessible via a live webcast, with a replay available afterward. BD, known for its role in improving medical technology and healthcare services, aims to advance various aspects of medical discovery and patient care. The event marks another opportunity for BD to showcase its contributions to global health.
Read more →BDXBD Named a Best Employer for Excellence in Employee Well-Being BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will receive the Business Group...
BD (Becton, Dickinson and Company) has been named a recipient of the 'Best Employers: Excellence in Health & Well-being Award' by the Business Group on Health, recognizing its commitment to advancing employee well-being. The company also received accolades for its efforts in global health and equity. BD focuses on a holistic well-being strategy that prioritizes various facets of employee health and is working towards its 2030+ goals for a healthy workforce. These recognitions reflect BD's dedication to fostering a culture of inclusion and safety within the company.
Read more →BDXBD Increases Access to Cutting-Edge Image-Enabled, Spectral Cell Sorters BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global commercial release of new...
BD (Becton, Dickinson and Company) announced the global release of its new FACSDiscover™ S8 Cell Sorters, designed to enhance research in cell biology, cancer research, and immunology. Featuring advanced BD CellView™ Image Technology and BD SpectralFX™ Technology, these cell sorters offer greater options and flexibility for scientists. They enable real-time imaging and isolation of cells based on visual characteristics, improving the quality of biological outputs and expediting research insights. These innovations will be showcased at upcoming conferences, including the AACR Annual Meeting.
Read more →BDXBD to Announce Financial Results for its Second Quarter of Fiscal 2024 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
BD (Becton, Dickinson and Company) is scheduled to announce its financial results for the second quarter of fiscal year 2024 on May 2, 2024. The announcement will include a news release and related presentation materials summarizing financial information from the quarter ending March 31, 2024. Following the announcement, BD management will host an audio webcast to discuss the results and provide updates on the company's operations and strategy.
Read more →BDXNew Survey Reveals Patients Receive Too Many Needlesticks BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new survey conducted by ...
BD (Becton, Dickinson and Company) announced survey results indicating that many patients experience excessive needlestick attempts during hospital procedures, with over half of patients unaware of expected limits on such attempts. The findings highlight concerns among nurses, who believe repeated needlestick practices negatively impact patient care and experience. Additionally, while awareness of innovative solutions to reduce needle sticks is low among patients, interest in these alternatives is high. BD aims to improve this situation with its 'One-Stick Hospital Stay' vision, proposing a new standard in patient care.
Read more →BDXBD Named Among Fortune's Most Innovative Companies BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Fortune's 2024 list of America's Most ...
BD (Becton, Dickinson and Company) has been recognized on Fortune's 2024 list of America's Most Innovative Companies. This accolade is a result of a survey conducted among over 35,000 employees and 8,000 industry experts, emphasizing BD's dedication to innovation in healthcare technology. Tom Polen, the CEO, highlighted the company's commitment to delivering enhanced healthcare solutions for patients. BD's innovation strategy is focused on improving medical discovery, diagnostics, and overall care delivery.
Read more →BDXBD Increases Domestic Production to Support U.S. Health Care Need for Syringes BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the March ...
Becton, Dickinson and Company (BD) is enhancing domestic syringe production to address increased healthcare needs, as highlighted in a recent FDA safety communication. The company assures that their syringes are unaffected by the current FDA evaluations. BD has already boosted syringe manufacturing at its facilities in Nebraska and Connecticut, demonstrating its commitment to patient care continuity. With a long-standing reputation for quality medical products, BD continues to play a vital role in healthcare delivery, including support during the COVID-19 pandemic.
Read more →BDXBD and Health Care Consortium in Denmark Find Success in Medical Waste Recycling Study BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and a consortium of health care institutions in Denmark...
BD (Becton, Dickinson and Company) has partnered with several health care institutions in Denmark to develop an innovative recycling method for used blood collection tubes. The feasibility study demonstrates that these biohazardous tubes can be effectively cleaned and recycled into new products, significantly reducing their environmental impact. With PET plastic being highly suitable for recycling, this initiative could divert 33 tonnes of plastic waste from incineration each year. The collaborative effort supports Denmark's larger Climate Action Strategy to reduce greenhouse gas emissions by 70% by 2030.
Read more →BDXNew Study Highlights Benefits of Medication Management Automation in Long-Term Care Facilities BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new data from a research study...
BD (Becton, Dickinson and Company) has announced promising results from a study on the implementation of automated dispensing cabinets (ADCs) in long-term care facilities. The research highlights significant improvements in clinical workflows and operational efficiency, noting a 71% reduction in medication retrieval times and a 96% drop in unscheduled medication delivery costs. Additionally, pharmacy labor was notably reduced, and a majority of nurses reported a preference for using the ADC system over manual methods. These results underscore the potential benefits of automation in enhancing patient care within challenging healthcare settings.
Read more →BDXBD Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the enrollment of the first patient in...
Becton, Dickinson and Company (BD) has commenced the AGILITY study, enrolling its first patient to assess the safety and effectiveness of a new Vascular Covered Stent for treating Peripheral Arterial Disease (PAD). This multi-center clinical trial will involve 315 patients across various regions, including the U.S., Europe, Australia, and New Zealand. The investigation aims to address significant unmet needs in PAD treatment, showcasing a potentially differentiated technology to improve patient care. Results from this study may offer new solutions for interventionalists managing PAD.
Read more →BDXDave Hickey Announces Intent to Retire from BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Dave Hickey has informed the...
Dave Hickey, executive vice president and president of the Life Sciences segment at BD (Becton, Dickinson and Company), has announced his retirement effective July 1, 2024. Hickey has been instrumental in guiding BD through key developments, especially during the COVID-19 pandemic, where he oversaw the rapid launch of diagnostic tests. The company plans to appoint a successor before his retirement date. Hickey expressed pride in his time at BD and the accomplishments of his teams in advancing medical technology and diagnostics.
Read more →BDXBD Partners with Camtech Health to Increase Access to Cervical Cancer Screening in Singapore BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic partnership with Camtech...
BD has partnered with Camtech Health to introduce Singapore's first at-home self-collection option for cervical cancer screening. This initiative aims to improve screening rates in the country, where less than half of eligible women are tested. The program utilizes the Camtech Health HPV test alongside the BD Onclarity HPV Assay, which can accurately detect various high-risk HPV strains. With the support of this partnership, women can now collect samples privately, potentially increasing participation and contributing to the WHO's cervical cancer elimination goals.
Read more →BDXBD to Present Next Installment of BD Innovates Series: Spotlight on Peripheral Vascular Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next...
Becton, Dickinson and Company (BD) announced it will present the next installment of its BD Innovates series, focusing on solutions for Peripheral Vascular Disease. This event is scheduled for February 26, 2024, and will showcase BD's products and innovations within its Peripheral Intervention business unit. The presentation can be accessed via a live webcast, with a replay available after the event concludes. This initiative aligns with BD's 2025 Strategy aimed at advancing healthcare solutions.
Read more →BDXBD Reports First Quarter Fiscal 2024 Financial Results BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal...
BD (Becton, Dickinson and Company) reported its first-quarter fiscal 2024 financial results, showcasing a 2.6% increase in revenues compared to the previous year. The company raised its fiscal 2024 guidance, attributing the improved performance to effective margin execution and strong cash flow. Despite positive revenue trends in its core segments, the company noted a significant drop in reported diluted earnings per share and a decline in revenue for the BD Life Sciences segment. BD continues to focus on innovation and operational excellence to drive future growth.
Read more →BDXBD, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence...
BD (Becton, Dickinson and Company) has partnered with Techcyte to develop an AI-based digital cervical cytology system aimed at improving the efficiency and accuracy of Pap testing for cervical cancer and precancerous lesions. The new system allows for whole-slide imaging that can be evaluated remotely, addressing critical shortages in laboratory technicians. The technology will be CE-marked for clinical use in Europe, with plans for FDA approval in the U.S. The collaboration seeks to enhance cancer screening and significantly reduce potential human error in diagnostic processes.
Read more →BDXBD Helps Advance Health Equity for Women in Kenya through Critical Cancer Screening BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with the Kenyan...
BD (Becton, Dickinson and Company) has announced a collaboration with the Kenyan Government and the National Cancer Institute to improve access to cervical cancer diagnostics for women in Kenya. The initiative aims to align with the Ministry of Health's Cancer Control Strategy, which emphasizes early detection and care linkage for various cancers. Pilot programs will be conducted in Nairobi County before potentially expanding nationwide. Through this partnership, BD aims to address the high burden of cervical and breast cancers disproportionately affecting women in the region.
Read more →BDXBD, Hamilton Collaborate to Standardize Single-Cell Multiomics Experiments Using Robotics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced a collaboration agreement with Hamilton, a...
BD (Becton, Dickinson and Company) has announced a collaboration with Hamilton to automate single-cell multiomics experiments using robotics. This partnership will lead to the development of automated applications and compatible reagent kits, enhancing standardization and reducing human error in high-throughput studies. The BD Rhapsody™ Single-Cell Analysis Library Preparation Reagent Kits will work with Hamilton's Microlab® NGS STAR™ robotic platform to streamline the library preparation process for genetic sequencing. The new products are set to be released in phases starting in 2024.
Read more →BDXNew Survey by The Harris Poll Highlights Gaps in Cervical Cancer Screening Access BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a Harris Poll survey of...
BD (Becton, Dickinson and Company) announced the findings of a Harris Poll survey that highlights gaps in cervical cancer screening access in the U.S., U.K., and Sweden. The survey indicates a significant delay in gynecological visits due to various factors, such as discomfort and embarrassment, with U.S. women particularly affected by issues of access and equity. Many women are interested in self-collection for screening, indicating a potential avenue to improve accessibility. However, the survey also reveals substantial confusion over screening guidelines and knowledge about cervical cancer and HPV testing options.
Read more →BDXBD Announces Webcast of Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will host a live webcast of its...
BD (Becton, Dickinson and Company) has announced the hosting of a live webcast for its Annual Meeting of Shareholders on January 23, 2024. This event will be available on BD's investor relations website, allowing shareholders and interested parties to access important company updates. The webcast reflects BD's commitment to engaging with its shareholders and fostering transparency. Following the live event, a replay will also be made available on the same website.
Read more →BDXBD to Announce Financial Results for its First Quarter of Fiscal 2024 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
Becton, Dickinson and Company (BD) has announced that it will disclose its financial results for the first quarter of fiscal year 2024 on February 1, 2024. The results will cover the financial performance for the quarter ending December 31, 2023. An audio webcast is scheduled for the same day where BD management will discuss the results and their operational strategies. The financial information will be available on BD's investor relations website following the release.
Read more →BDXBD to Present at the 42nd Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 42nd Annual...
BD (Becton, Dickinson and Company) announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference scheduled for January 9, 2024. The live presentation will be accessible through BD's investor relations website, along with a replay afterwards. As a leading global medical technology company, BD focuses on enhancing health care solutions, improving clinical processes, and advancing diagnostics.
Read more →BDXBD Signs World Economic Forum's Zero Health Gaps Pledge BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it signed the World Economic Forum's...
BD (Becton, Dickinson and Company) has signed the World Economic Forum's Zero Health Gaps Pledge, reaffirming its commitment to improving health equity globally. The pledge outlines ten commitments aimed at enhancing access to healthcare for vulnerable populations. Additionally, BD has a strong history of supporting health initiatives, such as providing essential diagnostic tools and working in under-resourced communities. The company's initiatives extend to various countries, including Kenya and Colombia, focusing on expanding essential healthcare services.
Read more →BDXBD Receives FDA 510(k) Clearance for Potentially Transformative Fingertip Blood Collection Device BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearances from...
BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for its BD MiniDraw™ Capillary Blood Collection System, which enables lab-quality blood testing via less invasive fingertip collection. This innovative device aims to improve patient convenience by allowing blood collection in various settings, including retail pharmacies. The device focuses on commonly ordered tests and is expected to broaden access to blood testing while enhancing the overall patient experience. BD is committed to expanding the tests offered through this system and improving health equity in diagnostic testing.
Read more →BDXBD to Present Next Installment of BD Innovates Series: Spotlight on Pharmaceutical Systems BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present the next...
Becton, Dickinson and Company (BD) announced the upcoming installment of its BD Innovates series, focusing on its Pharmaceutical Systems business. Scheduled for December 11, 2023, this presentation aligns with BD's 2025 Strategy aimed at promoting innovation and product development. The event will be streamed live, and a replay will be accessible afterward, underscoring the company's emphasis on stakeholder engagement and transparency.
Read more →BDXFDA Safety Communication Does Not Impact BD Syringes BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the U.S....
BD (Becton, Dickinson and Company) reassured that the recent FDA Safety Communication does not pertain to its syringes. The company's products are primarily manufactured in the U.S., ensuring compliance and quality. BD expressed its readiness to enhance production capacity to support healthcare providers affected by the FDA notice. Emphasizing its long-standing commitment to healthcare, BD has consistently supplied critical medical products throughout its history.
Read more →BDXBD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, advanced ultrasound system...
BD (Becton, Dickinson and Company) has launched the SiteRite™ 9 Ultrasound System, an advanced tool aimed at improving clinician efficiency in the placement of vascular access devices. The system features a user-friendly 15.6-inch touch screen and enhanced image quality, supporting successful first attempts at IV insertion. Notable elements include the Cue™ Needle Tracking System and the Sherlock 3CG+™ Tip Confirmation System, ensuring precision in catheter placement. The product received 510(k) clearance and is now available commercially in the U.S.
Read more →BDXBD Names Dr. Ronald Silverman as Chief Medical Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Ronald (Ron) Silverman, MD, FACS,...
BD (Becton, Dickinson and Company) has appointed Dr. Ronald Silverman as the new Chief Medical Officer, effective December 4, 2023. Dr. Silverman, with nearly three decades of experience in medical affairs, replaces Dr. William Sigmund, who is retiring. He will lead the Medical Affairs organization, focusing on improving BD's innovative solutions. Known for his work at 3M Health Care and academic positions at prominent universities, Silverman aims to enhance patient outcomes through effective and personalized healthcare solutions.
Read more →BDXBD to Present at the 6th Annual Evercore ISI HealthCONx Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 6th Annual...
Becton, Dickinson and Company (BD) has announced its participation in the 6th Annual Evercore ISI HealthCONx Conference, scheduled for November 28, 2023. The presentation will be accessible via a live webcast, with a replay available post-event. BD is recognized as a leading global medical technology company, emphasizing its dedication to improving healthcare through innovative technologies and solutions.
Read more →BDX▼ -9.3%on this newsshared move
BD Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results Execution of BD 2025 Strategy Driving Durable, Broad-Based Growth Q4 revenue of $5.1 billion increased 6.8% as reported and 5.9% on a...
BD (Becton, Dickinson and Company) announced its fourth quarter and full-year financial results for fiscal 2023, with Q4 revenue reaching $5.1 billion, demonstrating a 6.8% increase compared to the previous year. The significant rise in adjusted diluted earnings per share suggests robust operational strength, although reported earnings saw a notable decrease of 42.4%. The company's strategy, BD2025, continues to drive performance across its medical technology segments, particularly in higher-growth markets. However, the company anticipates ongoing challenges due to expected declines in COVID-related testing revenues.
Read more →BDX▼ -9.3%on this newsshared move
BD Board Increases Dividend for 52nd Consecutive Year The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.95 per common share, an increase of...
Becton, Dickinson and Company (BDX) has declared a quarterly dividend of $0.95 per share, marking a 4.4% increase from the previous quarter. This increase represents the 52nd consecutive year of dividend raises, affirming BD's status as a member of the S&P 500 Dividend Aristocrats Index. The decision reflects the company's confidence in its long-term growth strategy and commitment to shareholder value. The dividend is set to be paid on December 29, 2023, to shareholders on record as of December 8, 2023.
Read more →BDXBD Advances One-Stick Hospital Stay Vision with Launch of Next-Generation Needle-Free Blood Draw Technology BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched new needle-free blood draw technology...
BD (Becton, Dickinson and Company) has launched the PIVO™ Pro Needle-free Blood Collection Device, which is the first technology compatible with integrated catheters. This new device aims to enhance patient care by allowing clinicians to draw high-quality blood samples without additional needlesticks. Clearances from the FDA affirm its safety and efficacy. The innovation supports BD's objective of reducing unnecessary pain during hospital stays and improving overall healthcare delivery.
Read more →BDXBD Named Among the 100 Best Corporate Citizens of 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named to the 100 Best...
BD (Becton, Dickinson and Company) has been recognized as one of the 100 Best Corporate Citizens of 2023, ranking second in the healthcare equipment and services sector. The recognition is awarded based on a comprehensive evaluation of environmental, social, and governance (ESG) transparency and performance among large U.S. companies. BD has emphasized its commitment to minimizing its environmental impact and promoting health equity globally. This accolade highlights the company's ongoing efforts to integrate ESG principles into its business strategy and operations.
Read more →BDXBD Names Greg Rodetis as Senior Vice President of Investor Relations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Greg Rodetis, currently BD senior vice...
BD (Becton, Dickinson and Company) announced the appointment of Greg Rodetis as Senior Vice President of Investor Relations, effective immediately. Rodetis will maintain his role as company treasurer while also managing investor communications and strategies aimed at enhancing shareholder value. His experience includes roles at Terex, PepsiCo, and GE, equipping him well for this expanded responsibility. BD emphasizes its mission to improve healthcare delivery through innovative solutions and strong partnerships globally.
Read more →BDXBD, Casella Complete Industry-First Pilot Recycling 40,000 Pounds of Used Medical Devices BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Casella Waste Systems, Inc. (Nasdaq: CWST)...
BD (Becton, Dickinson and Company) and Casella Waste Systems, Inc. have completed an industry-first pilot recycling program that successfully recycled 40,000 pounds of used medical devices, primarily syringes and needles. This pilot aims to tackle the substantial plastic waste challenge within the healthcare sector and explores the technical feasibility of mechanical and advanced recycling methods. Following this successful phase, the initiative will expand regionally to include more facilities and additional medical materials for recycling. Both companies emphasize the importance of collaborative efforts to enhance sustainability in healthcare waste management.
Read more →BDXBD to Announce Fiscal 2023 Fourth Quarter and Full Year Financial Results BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report its fiscal 2023...
Becton, Dickinson and Company (BDX) announced that it will report its fiscal 2023 fourth quarter and full year financial results on November 9, 2023. The company will issue a news release detailing the financial information and host an audio webcast at 8 a.m. ET that same day to discuss the results and provide updates on operations and strategy. BD emphasizes its commitment to transparency and investor relations through this announcement.
Read more →BDXBD Ranks in Top 10 for Transparency, Awarded Best Code of Conduct in 2023 U.S. Transparency Awards BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been ranked in the top 10 for...
BD (Becton, Dickinson and Company) has achieved significant recognition by ranking in the top 10 for overall transparency and receiving the Best Code of Conduct award in the 2023 U.S. Transparency Awards. This acknowledgment by Labrador emphasizes the company's ethical standards and commitment to transparency amid growing stakeholder scrutiny. BD's user-friendly approach to transparency and accessibility of its policies were highlighted as key differentiators in the industry. The accolades reflect BD's ongoing dedication to enhancing trust with its stakeholders and improving healthcare outcomes.
Read more →BDXBD Reports Third Quarter Fiscal 2023 Financial Results Continues Strong Performance and Progress Toward Achieving BD 2025 Strategy; Advances Innovation Pipeline and Receives Clearance for Updated BD...
BD (Becton, Dickinson and Company) announced its third quarter fiscal 2023 financial results, showcasing a strong performance with a 5.1% revenue increase year-over-year. Notably, the company received 510(k) clearance for the updated BD Alaris™ Infusion System as part of its BD 2025 strategy. However, challenges in the BD Life Sciences segment were highlighted with a drop in diagnostic testing revenue. Overall, the company raised its full-year revenue growth guidance despite currency headwinds.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Third Quarter
BD (Becton, Dickinson and Company) announced its third quarter fiscal 2023 results, reporting a revenue growth of 5.1% to $4.9 billion. The company achieved FDA clearance for its updated BD Alaris Infusion System, marking a significant milestone in its innovation pipeline. Additionally, BD raised its full-year base organic revenue growth guidance, reflecting strong operational performance across its business segments, although specific challenges related to previous COVID testing modalities were noted.
Read more →BDXBD Receives 510(k) Clearance for COVID-19, Influenza A/B, RSV Molecular Combination Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA)...
BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for its Respiratory Viral Panel (RVP) for the BD MAX™ System. This molecular diagnostic test can detect COVID-19, influenza A/B, and RSV from a single sample within approximately two hours. The test streamlines the diagnostic process by eliminating the need for multiple individual tests and aims to improve patient management during peak respiratory illness seasons. The BD MAX™ System is designed for automation and efficiency, addressing current laboratory staffing challenges.
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, payable on...
BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.91 per common share, which will be payable on September 29, 2023. The company has set an indicated annual dividend rate of $3.64 per share. BD is recognized as a leading global medical technology firm, focusing on improving healthcare delivery and advancing medical discoveries through innovative solutions.
Read more →BDX▲ +5.7%on this newsshared move
BD Names Joanne Waldstreicher to Board of Directors BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Dr. Joanne...
BD (Becton, Dickinson and Company) has appointed Dr. Joanne Waldstreicher to its board of directors, bringing over 30 years of experience in clinical and strategic leadership. Her expertise aligns with BD's goals to enhance innovation, quality, and safety in medical technology. Waldstreicher's prior roles include positions on various boards and advisory panels, which are expected to further strengthen BD's strategic initiatives in healthcare.
Read more →BDX▲ +5.7%on this newsshared move
BD CEO Tom Polen Addresses FDA 510(k) Clearance of BD Alaris™ Infusion System BD (Becton, Dickinson and Company) (NYSE: BDX) Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug...
BD (Becton, Dickinson and Company) has obtained FDA 510(k) clearance for its updated Alaris™ Infusion System. This milestone enables the company to return to full commercial operations with a focus on providing an innovative solution for delivering medications and fluids to patients. The updated system includes cybersecurity improvements as well as enhancements in hardware and software to streamline care processes for clinicians. BD is prepared for a smooth rollout, having bolstered its manufacturing capacity and service teams during the approval process.
Read more →BDXBD Receives FDA 510(k) Clearance for Updated BD Alaris™ Infusion System BD Alaris™ Infusion System is the only modular and most comprehensive infusion system on the U.S. market that includes large volume pumps, syringe...
BD has announced the receipt of FDA 510(k) clearance for the updated BD Alaris™ Infusion System, which includes enhanced hardware and software features aimed at improving patient care. The system's improvements focus on cybersecurity, interoperability with electronic medical records, and integrating multiple infusion capabilities into a single module. Although the company does not anticipate significant revenue from this product for the remainder of FY23, it remains optimistic about meeting its future financial targets. BD plans to work closely with customers to ensure smooth remediation or replacement of existing devices in the field.
Read more →BDXBD Issues FY 2022 ESG Report, Highlights Notable Progress in Energy and Waste Reduction, Health Care Access and Diversity BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its Fiscal Year 2022 Environmental, Social...
BD (Becton, Dickinson and Company) has released its Fiscal Year 2022 Environmental, Social and Governance (ESG) Report, which highlights significant strides in sustainability and health equity. The company has achieved a 10% reduction in greenhouse gas emissions and expanded its use of renewable energy across locations. It aims to create measurable change over the next decade, focusing on improving community health and advancing access to healthcare. The report underscores BD's commitment to aligning its operations with its 2030+ ESG goals.
Read more →BDXBD Recognized as a Best Place to Work for Disability Inclusion BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its recognition as a Best Place to Work...
BD (Becton, Dickinson and Company) has been recognized as a Best Place to Work for Disability Inclusion for the fifth consecutive year, scoring highly on the Disability Equality Index. This recognition highlights the company's commitment to creating employment opportunities for individuals with disabilities and its ongoing efforts in diversity and inclusion initiatives. BD's Associate Resource Group, Limitless, has been instrumental in launching programs like a paid internship for individuals with autism, contributing to a culture that values diverse abilities. Additionally, BD's achievements align with its broader environmental, social, and governance goals.
Read more →BDXBD to Announce Financial Results for its Third Quarter of Fiscal 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
Becton, Dickinson and Company (NYSE: BDX) announced that it will release its financial results for the third quarter of fiscal 2023 on August 3, 2023. The announcement includes plans for a webcast discussion at 8 a.m. ET to provide insights into the company's operations and strategic direction. The results will reflect the fiscal period ending June 30, 2023, and corresponding materials will be accessible through its investor relations website.
Read more →BDXBD to Sell Surgical Instrumentation Platform to STERIS BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has signed a definitive...
BD (Becton, Dickinson and Company) has signed a definitive agreement to divest its Surgical Instrumentation platform to STERIS for $540 million. This move aligns with BD's 2025 strategy to simplify its product portfolio and focus on higher-growth markets. The transaction will include branded products and three manufacturing facilities, with the sale expected to close within BD's fiscal year 2023. Approximately 360 employees working on this platform will transition to STERIS upon completion of the sale. The divestiture is projected to support BD's financial growth and operational efficiency.
Read more →BDXBD Launches New Robotic System to Automate Clinical Flow Cytometry BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a new...
BD (Becton, Dickinson and Company) has announced the worldwide launch of the BD FACSDuet™ Premium Sample Preparation System, a robotic solution designed to automate sample preparation for clinical diagnostics using flow cytometry. This new system aims to improve standardization and reproducibility in cellular diagnostics while minimizing manual intervention. It integrates seamlessly with the BD FACSLyric™ Clinical Flow Cytometry System, allowing for a more streamlined workflow. The BD FACSDuet™ Premium System is now available for order through local sales representatives.
Read more →BDXBD Advances Prefilled Flush Syringe with Integrated 'Scrub-the-Hub' Innovation BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced expanded customer availability of an...
BD (Becton, Dickinson and Company) has announced the expanded availability of its BD PosiFlush™ SafeScrub, a prefilled flush syringe with an integrated disinfection unit. This new product aims to enhance compliance with infection prevention guidelines and streamline nursing workflows, particularly in the context of increasing catheter-related bloodstream infections. The design allows for easier adherence to the 'scrub the hub' process, potentially improving patient safety and care outcomes. BD's innovation aligns with their vision to reduce complications associated with intravenous therapy.
Read more →BDXBD Launches World's First Spectral Cell Sorter with High-Speed Cell Imaging BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the worldwide commercial launch of a...
BD (Becton, Dickinson and Company) has launched the BD FACSDiscover™ S8 Cell Sorter, which combines spectral flow cytometry with real-time imaging technology. This innovative cell sorting instrument allows researchers to obtain detailed images of individual cells and sort them at high speeds based on visual characteristics. The new technologies, BD CellView™ and BD SpectralFX™, expand the capabilities for high-parameter experiments, making significant contributions to fields like drug discovery and immuno-oncology. The product will be featured at CYTO 2023 and is now available for global order.
Read more →BDXBD Gains 510(k) Clearance of Artificial Intelligence Software for MRSA Diagnostics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced 510(k) clearance from the U.S. Food and...
Becton, Dickinson and Company (BD) has received 510(k) clearance from the FDA for its BD Kiestra MRSA imaging application, which employs artificial intelligence to automate the process of inspecting Petri dishes for bacterial growth. This new technology aims to improve laboratory efficiency and workflow by allowing technicians to focus on more complex analyses. The application organizes specimens and assists in reducing the labor-intensive nature of microbiological tests, which is particularly crucial given the ongoing labor challenges in healthcare laboratories. The clearance positions BD to enhance diagnostics for MRSA, a significant concern in hospital settings.
Read more →BDXHealth Care Collaboration in Denmark Aims to Reduce Medical Waste A new health care sector collaboration in Denmark will evaluate the feasibility of recycling used blood collection tubes to reduce medical waste as...
A new health care collaboration in Denmark aims to evaluate the feasibility of recycling used blood collection tubes to reduce medical waste. The initiative, involving BD and several health organizations, is part of Denmark's sustainability goals and Climate Action Strategy. The pilot program will investigate the challenges and requirements for recycling the plastic tubes, which are currently treated as biohazardous waste. Key focuses of the initiative will be on safety and hygiene, as well as the quality of recycled materials. The project is set to play a role in promoting a circular economy within the health care sector.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Second Quarte
BD (Becton, Dickinson and Company) announced its second-quarter fiscal 2023 financial results, showcasing a revenue increase of 1.5% to $4.8 billion. The company raised its full-year revenue guidance, signaling confidence in growth driven by strategic investments and innovations. Notable recent developments include FDA approvals for new diagnostic assays and the launch of advanced medical technologies. However, overall performance was affected by a decline in COVID-only diagnostic testing revenues.
Read more →BDXBD Reports Second Quarter Fiscal 2023 Financial Results BD 2025 Strategic Investments Driving Growth and Advancing Innovation; Company Raises Mid-point of Revenue and Adjusted EPS Guidance Ranges Revenue...
BD (Becton, Dickinson and Company) reported its second quarter fiscal 2023 results, showing a revenue increase of 1.5% year-over-year. The company raised its mid-point revenue and adjusted EPS guidance, reflecting confidence in its strategic investments and innovation pipeline. However, the BD Life Sciences segment experienced a decline in revenues, notably due to reduced COVID testing. Overall, the company remains focused on capitalizing on growth opportunities and enhancing healthcare technologies.
Read more →BDXBD Recognized by DiversityInc as a Top U.S. Company for Diversity in 2023 List BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named a Noteworthy...
BD (Becton, Dickinson and Company) has been recognized as a Noteworthy Company in DiversityInc's annual ranking for 2023, highlighting its commitment to diversity and inclusion. The company's efforts span leadership accountability, workplace practices, and philanthropic engagement. Additionally, BD is included in the 2023 Bloomberg Gender-Equality Index, underlining its progress towards environmental, social, and governance goals. With 77,000 employees worldwide, BD continues to focus on improving health outcomes and delivering innovative medical technology.
Read more →BDXBD to Present at Bank of America Securities 2023 Health Care Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Bank of...
Becton, Dickinson and Company (BD) announced its participation in the Bank of America Securities 2023 Health Care Conference scheduled for May 9, 2023. The presentation will be accessible through a live webcast on BD's investor relations website, with a replay available afterwards. BD, a significant player in the medical technology sector, highlights its efforts to improve healthcare through innovation and collaboration with healthcare providers and researchers.
Read more →BDXBD Recognized by Forbes as a Best Employer for Diversity in 2023 List BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Forbes as ...
BD (Becton, Dickinson and Company) has been recognized by Forbes as a top employer for diversity, highlighting positive employee perceptions and progress in their ESG strategy. This accolade reflects BD's commitment to fostering an inclusive workplace and achieving its 2030+ goals aimed at promoting a healthy workforce and community well-being. The recognition is based on survey responses from approximately 45,000 employees, indicating strong employee sentiment about the company's efforts in inclusion and diversity.
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, payable on June ...
BD (Becton, Dickinson and Company) has declared a quarterly dividend of $0.91 per common share, payable on June 30, 2023, to shareholders on record as of June 9, 2023. The annual dividend rate is set at $3.64 per share. This action signifies BD's ongoing commitment to providing returns to its investors amidst its operations as a global leader in medical technology.
Read more →BDXNew Harris Poll Finds Women Want More Education on Sexually Transmitted Infections Testing and Treatment BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released findings from a survey conducted online...
BD (Becton, Dickinson and Company) has released findings from a Harris Poll survey revealing that U.S. women feel less knowledgeable about sexually transmitted infections (STIs) than about other vaginal diseases. The survey indicates that 82% of women who have seen a healthcare provider believe more education on STIs is necessary. It also highlights disparities in diagnosis and treatment, particularly among women of color, and emphasizes the need for enhanced education and access to effective testing and treatment options. The findings are particularly timely, aligning with STI Awareness Month initiatives.
Read more →BDXBD Introduces Advanced Ultrasound Technology to Help Drive First-Stick Success for IV Insertions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new, easy-to-use advanced ultrasound...
BD has launched the BD Prevue™ II System, an advanced ultrasound device designed to improve IV placement success rates. This system features real-time needle depth markers and the BD Cue™ Needle Tracking System, aiming to reduce the frequency of needlesticks and enhance patient comfort during vascular access procedures. BD envisions a 'One-Stick Hospital Stay' where first-stick success is prioritized, benefiting both clinicians and patients. The new technology is targeted at tackling the challenges of difficult IV access, particularly for patients with chronic conditions.
Read more →BDXBD to Announce Financial Results for its Second Quarter of Fiscal 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
Becton, Dickinson and Company (BD) has announced it will report its financial results for the second quarter of fiscal year 2023 on May 4, 2023. The results will be disseminated through a news release at 6:30 a.m. ET, followed by an audio webcast at 8 a.m. ET for further discussion. This announcement highlights BD's ongoing engagement with investors and stakeholders regarding its operational strategies and financial performance.
Read more →BDXMichelle Quinn Named General Counsel for BD FRANKLIN LAKES, N.J., April 3, 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that ...
Becton, Dickinson and Company (BD) has appointed Michelle Quinn as their new executive vice president and general counsel, effective April 1, 2023. Quinn, who joined BD in 2019, has previously held positions including acting general counsel and senior vice president. She has a diverse background in healthcare legal roles, having worked with Sandoz Inc. and Catalent Pharma Solutions. BD's CEO emphasized Quinn's alignment with the company's core values and her vital role in advancing business strategies and governance.
Read more →BDXBD Receives FDA 510(k) Clearance for First-of-Its-Kind High-Throughput Diagnostic Test for Infectious Vaginitis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance...
BD (Becton, Dickinson and Company) has received FDA 510(k) clearance for its BD Vaginal Panel on the BD COR™ System, a diagnostic test that detects common causes of vaginitis with a single swab. This test simplifies the diagnostic process and can help reduce misdiagnosis and the need for repeat visits for treatment. The high-throughput system addresses the significant need for effective diagnosis in women's health, allowing laboratories to efficiently process multiple samples.
Read more →BDXBD to Present at Barclays Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Barclays...
Becton, Dickinson and Company (BD) announced its participation in the Barclays Global Healthcare Conference scheduled for March 15, 2023. BD will present at 9:00 am Eastern Time, with a live webcast available on its investor relations website. This appearance reflects BD's ongoing commitment to engage with the investment community and highlight its advancements in medical technology and healthcare solutions.
Read more →BDXBD to Present at Cowen 43rd Annual Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Cowen 43rd...
BD (Becton, Dickinson and Company), a leading global medical technology company, announced its participation in the Cowen 43rd Annual Healthcare Conference scheduled for March 6, 2023. The presentation will be webcast live, with a replay available on the investor relations website. The company emphasizes its commitment to enhancing medical discovery and care delivery through innovative technologies and solutions.
Read more →BDXBD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA)...
BD (Becton, Dickinson and Company) has received FDA approval for its Onclarity HPV Assay, which is now authorized for use alongside the ThinPrep Pap Test. This assay is particularly notable as it can individually identify high-risk HPV31, improving cervical cancer risk assessment compared to other tests that pool results. The approval represents a significant advance in diagnostic solutions for women's health, increasing access to more tailored screening methods. Additionally, it comes backed by a robust real-world evidence study, underscoring its clinical validation in routine clinical practice.
Read more →BDXBD Named as One of America's Best Large Employers BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the company has been named to America's...
BD (Becton, Dickinson and Company) has been recognized on Forbes' America's Best Large Employers List for 2023, showcasing the company's strong employee culture. This recognition stems from a survey of 45,000 Americans, with BD ranking among the top 500 large employers based on employee recommendations. CEO Tom Polen emphasizes that this accolade is a reflection of BD's commitment to fostering a workplace where associates feel valued and can grow. The company continues to focus on advancing health through its innovative technologies and solutions.
Read more →BDXBD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received Emergency Use...
BD (Becton, Dickinson and Company) has received Emergency Use Authorization from the FDA for a new molecular diagnostic combination test that detects SARS-CoV-2, Influenza A + B, and RSV. This test can provide results in as little as two hours using a single nasal swab sample. By enabling quick differentiation between these viruses, the test aims to improve treatment plans during respiratory virus seasons, enhancing clinical decision-making and patient care.
Read more →BDXBD Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new instrument for single-cell...
BD (Becton, Dickinson and Company) has unveiled its BD Rhapsody™ HT Xpress System, a new instrument designed for high-throughput single-cell multiomics analysis. This system allows researchers to isolate and analyze more samples efficiently, optimizing the research process across various fields, including immunology and cancer research. The BD Rhapsody™ HT Xpress System will be featured at the AGBT General Meeting, along with additional tools such as the Mouse TCR/BCR Multiomic Assay. These innovations are expected to enrich scientific exploration and expedite discovery.
Read more →BDXBD Reports First Quarter Fiscal 2023 Financial Results BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal...
BD (Becton, Dickinson and Company) announced its first quarter fiscal 2023 financial results, showing a revenue decrease of 2.8% to $4,586 million compared to the previous year. The company's performance highlighted the successful execution of its BD 2025 strategy, but the results included a decline in revenues from its international segments. Despite these challenges, BD raised its guidance for the full fiscal year in terms of revenue and adjusted EPS, indicating a positive outlook for future performance.
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports First Quarter
BD (Becton, Dickinson and Company) reported its first quarter fiscal 2023 results, highlighting a revenue of $4.6 billion, which represents a 2.8% decline as reported but a 1.7% increase on a currency-neutral basis. The company raised its full-year guidance for revenue and adjusted EPS, showing optimism despite challenges like decreased COVID-related revenues and international sales. Notably, the core business showed a modest growth, emphasizing strong innovation and execution under the BD 2025 strategy. The firm also made strides in its ESG initiatives, receiving recognition for its commitment to diversity and cybersecurity.
Read more →BDXBD Named to Bloomberg Gender-Equality Index for 4th Consecutive Year BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to the 2023...
BD (Becton, Dickinson and Company) has been named to the 2023 Bloomberg Gender-Equality Index for the fourth straight year, reflecting its commitment to workplace equality. The company has made notable progress in improving female leadership and enhancing its talent pipeline. Through various inclusive policies and employee-led resource groups, BD fosters an environment promoting personal and professional growth for women within the organization. This recognition aligns with BD's broader environmental, social, and governance goals aimed at achieving significant milestones by 2030.
Read more →BDXBD Publishes 2022 Cybersecurity Annual Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its third annual cybersecurity report to...
BD (Becton, Dickinson and Company) has published its third annual cybersecurity report, highlighting its commitment to tackling cybersecurity challenges in healthcare. The report emphasizes the importance of transparency and collaboration in protecting patient safety and privacy. Chief Information Security Officer Rob Suárez stated that robust cybersecurity measures are essential for maintaining trust with patients. The report reflects BD's efforts to advance its cybersecurity maturity and inform stakeholders about ongoing cyber risks.
Read more →BDXBD Introduces Fully Automated Robotic Track System for Microbiology Labs BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a new, robotic track system for the BD...
BD (Becton, Dickinson and Company) has launched its 3rd Generation BD Kiestra™ Total Lab Automation System, designed for microbiology labs. The robotic track system automates specimen processing, reducing manual tasks and improving workflow efficiency. The system's flexibility allows labs to create custom configurations to optimize space and scalability. Additionally, BD's offerings include advanced informatics solutions for performance analysis, further supporting laboratory operations.
Read more →BDXBD, CerTest Biotec Announce Emergency Use Authorization for Mpox Diagnostic Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec have announced Emergency Use...
BD and CerTest Biotec have received Emergency Use Authorization from the FDA for a molecular PCR assay for Mpox virus detection. This test, designed for use with the BD MAX™ System, aims to improve diagnosis and potentially curb the spread of the Mpox virus. The assay's rapid development reflects the companies' commitment to addressing global health emergencies. However, it is important to note that the test remains under emergency use authorization, with limitations on its application.
Read more →BDXMichelle Quinn Named Acting General Counsel for BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Michelle Quinn has been named...
Becton, Dickinson and Company (BD) has announced the appointment of Michelle Quinn as acting general counsel, succeeding Samrat Khichi effective February 3, 2023. Quinn, who has been with BD since 2019 as senior vice president and deputy general counsel, will lead the Law Group and be part of the Executive Leadership Team. The leadership changes also include organizational shifts in reporting for various teams at BD, aiming to enhance alignment with the company's strategic goals.
Read more →BDXBD Announces Webcast of Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a live webcast of its...
BD (Becton, Dickinson and Company) has announced it will host a live webcast of its Annual Meeting of Shareholders on January 24, 2023. The webcast can be accessed through the company’s investor relations website. Following the meeting, a replay will be available, allowing stakeholders to catch up on discussions and updates from the event. BD emphasizes its role in advancing medical technology and improving healthcare delivery worldwide.
Read more →BDXBD to Announce Financial Results for its First Quarter of Fiscal 2023 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will report financial results...
Becton, Dickinson and Company (BD) will announce its financial results for the first quarter of fiscal year 2023 on February 2, 2023. The company will provide a news release and host an audio webcast to discuss the results and updates on operations. BD, a leader in global medical technology, focuses on improving health through innovative solutions. The webcast will be accessible via their investor relations website, which will also host a replay after the event.
Read more →BDXNew Harris Poll Reveals Significant Gaps in Women's Knowledge About Cervical Cancer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released findings from a survey conducted by The...
BD (Becton, Dickinson and Company) released results from a Harris Poll survey highlighting substantial gaps in U.S. women's knowledge about cervical cancer causes and prevention. The survey revealed that many women have delayed necessary screenings, with Hispanic and Black women disproportionately affected. Despite a resolution among many to improve their health screenings in 2023, knowledge deficits about Pap and HPV tests persist, creating barriers to timely care. BD emphasizes the importance of educational outreach and improved access to screenings to address these issues.
Read more →BDXBD to Present at the 41st Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the 41st Annual...
FRANKLIN LAKES, N.J. , Dec. 20, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 12:45 pm E
Read more →BDXBD Releases 2022 Global Inclusion, Diversity and Equity Annual Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the release of its second annual Global...
FRANKLIN LAKES, N.J. , Dec. 8, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the release of its second annual Global Inclusion, Diversity and Equity (ID&E) Report for fiscal year 2022. The repor
Read more →BDXBD Named in top 25% of Newsweek's 2023 List of America's Most Responsible Companies BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been named among the top 25% of...
FRANKLIN LAKES, N.J. , Dec. 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has been named among the top 25% of Newsweek's list of America's Most Responsible Companies. This is the fourth con
Read more →BDXBD to Present at Evercore ISI 5th Annual HealthCONx Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present virtually at the...
FRANKLIN LAKES, N.J. , Nov. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present virtually at the Evercore ISI 5th Annual HealthCONx Conference on Tuesday, November 29, 2022 at
Read more →BDX▲ +5%on this newsshared move
BD Board Increases Dividend for 51st Consecutive Year The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.91 per common share, an increase of...
FRANKLIN LAKES, N.J. , Nov. 10, 2022 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.91 per common share, an increase of 4.6% from the previous quarter. The dividend will be payable on Dec. 30, 2022
Read more →BDX▲ +5%on this newsshared move
BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results Execution of BD 2025 Strategy Driving Consistent Durable Growth Q4 revenue from continuing operations of $4.8 billion decreased 1.8% as reported and...
Execution of BD 2025 Strategy Driving Consistent Durable Growth FRANKLIN LAKES, N.J. , Nov. 10 , 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced results for its fourth quarter and full year of fis
Read more →BDX▲ +5%on this newsshared move
Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Fourth Quarte
Franklin Lakes, NJ 07417 Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD Reports Fourth Quarter and Full Year Fiscal 2022 Financial Results Execution of BD 2025 Strategy Driving Consi
Read more →BDXBD, Magnolia Medical Technologies Announce Commercial Collaboration to Help Reduce Blood Culture Contamination and Improve Testing Accuracy BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced ...
FRANKLIN LAKES, N.J. , Oct. 18, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Magnolia Medical Technologies, Inc., today announced a co-exclusive commercial agreement aimed at helping U.S. hospitals reduce b
Read more →BDXBD TO ANNOUNCE FISCAL 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report its fiscal 2022 fourth quarter and full year financial results on...
FRANKLIN LAKES, N.J. , Oct. 13, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report its fiscal 2022 fourth quarter and full year financial results on Thursday, November 10, 2022 . A news release will be issued at approximately
Read more →BDXBD Recognized Among World's Best Employers by Forbes BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was named to Forbes' 2022 list of the World's Best ...
FRANKLIN LAKES, N.J. , Oct. 11, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today was named to Forbes' 2022 list of the World's Best Employers. "Empowering our teams to excel in their careers has been a longs
Read more →BDXBD, Heart to Heart International, NAFC and Henry Schein Cares Award Critical Lab Equipment to Six U.S. Free and Charitable Clinics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, in conjunction with Heart to Heart International (HHI),...
Public-Private Partnership Supporting Diagnostic Testing in Vulnerable Communities has Provided $2.6 Million to U.S. Clinics Since 2017 to Help Improve Patient Outcomes and Health Equity FRANKLIN LAKES, N.J. , Sept. 29, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NY
Read more →BDXNew BD Innovation Center at the University of Maryland BioPark Offers Researchers and Students Access to Cutting-Edge Technology BD (Becton, Dickinson and Company), a leading global medical technology company, today officially opened the BD Innovation Center in collaboration...
Diagnostic Research Center Enables Students to Test and Develop Clinical Workflows to Help Shape Laboratory Performance and Patient Outcomes FRANKLIN LAKES, N.J. , Sept. 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, tod
Read more →BDXBD Launches State-of-the-Art Cloud Software Solution to Streamline Flow Cytometry Research BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched BD® Research Cloud, a cloud-based...
New BD® Research Cloud provides scientists with an integrated ecosystem that allows for optimizing panel design, collaboration and analysis FRANKLIN LAKES, N.J. , Sept. 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology
Read more →BDXBD, CerTest Biotec Announce US Commercial Launch of Monkeypox Assay BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec today announced their newly developed ...
Research Use Only (RUO) assay now globally available for BD MAX ™ System FRANKLIN LAKES, N.J. , Sept. 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and CerTest Biotec today announced their newly developed m
Read more →BDXBD Foundation Advances Health Equity, Education through Support of International Council of Nurses The BD Foundation, the philanthropic arm of global medical technology company BD (Becton, Dickinson and Company), today announced a three-year...
Announcement Made at Clinton Global Initiative 2022 Commits $360,000 to Support Nurses in Africa FRANKLIN LAKES, N.J. , Sept. 19, 2022 /PRNewswire/ -- The BD Foundation, the philanthropic arm of global medical technology company BD (Becton, Dickinson and Company), today announce
Read more →BDXBD Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a next-generation glass prefillable...
BD Effivax TM Glass Prefillable Syringe Features Enhanced Technology that Builds on Company's Decades of Expertise in the Prefillable Syringe Market and Supports Customers' Manufacturing Needs FRANKLIN LAKES, N.J. , Sept. 13, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Compan
Read more →BDXbdpressreleaseaugus NEWS RELEASE FOR IMMEDIATE RELEASE BD Promotes Two Senior Executives to Segment Leadership Roles Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventiona
EX-99.1 2 ex991bdpressreleaseaugus.htm EX-99.1 ex991bdpressreleaseaugus NEWS RELEASE FOR IMMEDIATE RELEASE BD Promotes Two Senior Executives to Segment Leadership Roles Mike Garrison Named EVP and President, Medical segment Rick Byrd Named EVP and President, Interventional segmen
Read more →BDXBD Promotes Two Senior Executives to Segment Leadership Roles BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of two senior leaders to ...
FRANKLIN LAKES, N.J. , Aug. 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the appointment of two senior leaders to segment president roles. Michael (Mike) Garrison has been named executive v
Read more →BDXBD to Present at the Wells Fargo 2022 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo...
FRANKLIN LAKES, N.J. , Aug. 24, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the Wells Fargo 2022 Healthcare Conference on Wednesday, September 7, 2022 at 12:30pm Eastern
Read more →BDXBecton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap
Becton, Dickinson and Company Announces Early Tender Results and Upsizing of Offer SubCap FRANKLIN LAKES, NJ, August 22, 2022 - Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced Tender Offers
Read more →BDXBD Announces Pricing of the Tender Offers Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced the consideration payable in connection with its previously...
FRANKLIN LAKES, N.J. , Aug. 22, 2022 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced the consideration payable in connection with its previously announced Tender Offers (as defined below) to purchase for cash up to $500,000,0
Read more →BDXBD Announces Early Tender Results and Upsizing of Offer SubCap Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced the early tender results for its previously announced Tender Offers ...
FRANKLIN LAKES, N.J. , Aug. 22, 2022 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced the early tender results for its previously announced Tender Offers (as defined below) to purchase for cash certain of its outstanding debt
Read more →BDXBD, Accelerate Diagnostics Announce Global Commercial Collaboration BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an...
Companies will work together to bring rapid antimicrobial identification and susceptibility diagnostics to more clinicians and patients worldwide FRANKLIN LAKES, N.J. and TUCSON, Ariz. , Aug. 15, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading glo
Read more →BDXBD, Labcorp Collaborate to Develop Flow Cytometry-Based Companion Diagnostics for Matching Patients with Treatments BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp...
Companies combine key capabilities to advance flow cytometry as an essential companion diagnostic modality for cancer and other diseases FRANKLIN LAKES, N.J. , Aug. 9, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology compa
Read more →BDXBD Announces Tender Offers for Outstanding Debt Securities Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced that it has commenced tender offers to purchase for cash the debt...
FRANKLIN LAKES, N.J. , Aug. 8, 2022 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, t
Read more →BDXBD, Direct Relief and National Association of Community Health Centers Advance Health Equity in the U.S. with $1 Million Grant BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community...
Funding to Four Community Health Centers Advances Medication Management Programs for Vulnerable Patients Managing Chronic Disease FRANKLIN LAKES, N.J. , Aug. 8, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direc
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contacts Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD REPORTS THIRD QUARTER
Franklin Lakes, NJ 07417 Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS Revenue from continuing operations of $4.6 billion increas
Read more →BDXBD REPORTS THIRD QUARTER FISCAL 2022 FINANCIAL RESULTS BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its third quarter of fiscal...
FRANKLIN LAKES, N.J. , Aug. 4, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced results for its third quarter of fiscal year 2022, which ended June 30, 2022. "Our BD2025 strategy continues to serve
Read more →BDXBD Acquires MedKeeper to Offer Cloud-based, Connected Pharmacy Software BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired MedKeeper, a provider of ...
Acquisition adds to company's recent growth in high-technology pharmacy solutions and further accelerates the company's commitment to Smart, Connected Care – offering a customizable platform to optimize IV workflow FRANKLIN LAKES, N.J. , July 28, 2022 /PRNewswire/ -- BD (Becton,
Read more →BDXBD, CerTest Biotec Announce Commercial Launch of Monkeypox Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and CerTest Biotec today announced their newly developed ...
Research Use Only (RUO) assay now available for BD MAX™ System users FRANKLIN LAKES, N.J. , July 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and CerTest Biotec today announced their newly developed molecu
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on...
FRANKLIN LAKES, N.J. , July 26, 2022 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.87 per common share, payable on September 30, 2022 to holders of record on September 9, 2022 . The indicated annu
Read more →BDXBD Earns Recognition as a Best Place to Work for Disability Inclusion BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today was recognized as a Best Place to Work for...
Top Score on Disability Equality Index Demonstrates Progress in Removing Barriers and Creating Employment Opportunities for People with Disabilities FRANKLIN LAKES, N.J. , July 20, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical tec
Read more →BDXBD Completes Acquisition of Parata Systems BD (Becton, Dickinson and Company) (NYSE: BDX) today announced it has completed the acquisition of Parata Systems....
- BD enters growing pharmacy automation market segment by offering a comprehensive set of technologies across the care continuum - Addition of Parata aligns with two key tenets of BD's innovation strategy: driving smart, connected care and enabling new care settings FRANKLIN LA
Read more →BDXBD TO ANNOUNCE FINANCIAL RESULTS FOR ITS THIRD QUARTER OF FISCAL 2022 BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its third quarter of fiscal year 2022 on...
FRANKLIN LAKES, N.J. , July 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report financial results for its third quarter of fiscal year 2022 on Thursday, August 4, 2022 . A news release will be issued at approximately 6:30 a.
Read more →BDXBD Names Rishi Grover as Chief Integrated Supply Chain Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Rishi Grover has been named...
FRANKLIN LAKES, N.J. , July 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Rishi Grover has been named executive vice president (EVP) and chief integrated supply chain officer for BD, effe
Read more →BDXBD Issues 2021 ESG Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its Fiscal Year 2021 Environmental, Social...
Company makes notable progress toward 2030+ ESG commitments, addressing energy, water and waste reduction, environmental impact of product portfolio and supplier diversification FRANKLIN LAKES, N.J. , July 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ),
Read more →BDXBD Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel...
BD MAX™ Molecular Diagnostic Respiratory Viral Panel CE Marked to IVD Directive FRANKLIN LAKES, N.J. , June 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced that the BD MAX™ Respiratory Viral Panel (
Read more →BDXBD Announces Voluntary Recall on Intraosseous Products BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on the BD™ Intraosseous Needle Set...
FRANKLIN LAKES, N.J. , June 22, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on the BD™ Intraosseous Needle Set Kits, BD™ Intraosseous Manual Driver Kits and BD™ Intraosseous Powered Drivers. C
Read more →BDXBD Collaborates with Mayo Clinic Platform, Leveraging Real-World Clinical Data to Improve Post-Market Device Surveillance, Drive Innovation for Patient Care BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Mayo Clinic...
BD is among the first companies to enter innovative partnership with Mayo Clinic Platform for access to world's largest collection of clinical data FRANKLIN LAKES, N.J. , June 13, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical tech
Read more →BDXCerTest Biotec and BD Announce Collaboration on Molecular Diagnostic Test for Monkeypox CerTest Biotec and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration to...
CerTest Biotec Uses the BD MAX™ Molecular Diagnostic System Open System Reagent Suite to Develop RT-PCR Detection Kit ZARAGOZA, Spain and FRANKLIN LAKES, N.J. , June 8, 2022 /PRNewswire/ -- CerTest Biotec and BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medi
Read more →BDXBD Names Simon Campion as Medical Segment President BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has appointed Simon Campion as...
FRANKLIN LAKES, N.J. , June 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has appointed Simon Campion as executive vice president (EVP) and president of the Medical segment for BD, effectiv
Read more →BDXBD TO ACQUIRE PARATA SYSTEMS TO ENTER NEW PHARMACY AUTOMATION SOLUTIONS MARKET BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Frazier Healthcare Partners, a leading private...
FRANKLIN LAKES, N.J. and DURHAM, N.C. , June 6, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Frazier Healthcare Partners, a leading private equity firm focused exclusively on the health care sector, today a
Read more →BDXBD Unveils World's First Spectral Cell Sorter with High-Speed Imaging Technology that Sorts Cells Based on Visual Characteristics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it will introduce new cell sorting...
BD FACSDiscover™ S8 Cell Sorter with BD CellView™ Image Technology First to Combine Spectral Flow Cytometry with Sort-Capable Imaging FRANKLIN LAKES, N.J. , June 3, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company,
Read more →BDXBD to Present at Goldman Sachs 43rd Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the Goldman...
FRANKLIN LAKES, N.J. , June 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the Goldman Sachs 43 rd Annual Global Healthcare Conference on Thursday, June 16, 2022 at 11:0
Read more →BDXBECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited Amounts in millions, except share and per share data) Three Months Ended
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited Amounts in millions, except share and per share data) Three Months Ended March 31, 2022 2021 REVENUES $ 4,750 $ 4,634 Cost of products sold 2,637 2,584 Selling and administrative expe
Read more →BDXBD Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of its new, fully...
510(k) Clearance of BD COR™ MX Instrument Elevates Standard of Care for Sexually Transmitted Infections FRANKLIN LAKES, N.J. , May 12, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. laun
Read more →BDXBabson, BD Expand Strategic Partnership to Advance Diagnostic Blood Collection in New Care Settings Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical...
Expanded Collaboration Agreement to Make Less Invasive Blood Sample Collection More Convenient and Patient Centered AUSTIN, Texas and FRANKLIN LAKES, N.J. , May 11, 2022 /PRNewswire/ -- Babson Diagnostics, a science-first, health care technology company, and BD (Becton, Dickinso
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD REPORTS SECOND QUARTER
Franklin Lakes, NJ 07417 Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD REPORTS SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS Revenue of $5.0 billion increased 2.1% as reported and 3.
Read more →BDXBD REPORTS SECOND QUARTER FISCAL 2022 FINANCIAL RESULTS BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its second quarter of fiscal ...
FRANKLIN LAKES, N.J. , May 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced results for its second quarter of fiscal year 2022, which ended March 31, 2022. "We delivered another quarter of stron
Read more →BDXBD Announces Inaugural Members of Scientific Advisory Board BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the inaugural members of the BD...
Scientific Advisory Board Will Review Company Innovation Pipeline and Advise on Emerging Trends in Health Care, Science and Technology FRANKLIN LAKES, N.J. , May 2, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company,
Read more →BDXBD to Present at the BofA Securities 2022 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the BofA...
FRANKLIN LAKES, N.J. , April 29, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 12:00 p.m. Paci
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, payable on June ...
FRANKLIN LAKES, N.J. , April 26, 2022 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.87 per common share, payable on June 30, 2022 to holders of record on June 9, 2022 . The indicated annual divide
Read more →BDXBD Named to Forbes' 2022 List of Best Employers for Diversity BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been recognized by Forbes as ...
Demonstrates Progress in Advancing 2030+ ESG Goals FRANKLIN LAKES, N.J. , April 26, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has been recognized by Forbes as one of the top employer
Read more →BDXNew BD Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new family of reagents...
Developed with novel dye technology and AI guidance, new BD Horizon RealYellow™ 586 Reagents have potential to accelerate discovery and drug development in oncology, autoimmune disorders and infectious diseases FRANKLIN LAKES, N.J. , April 25, 2022 /PRNewswire/ -- BD (Becton, Di
Read more →BDXBD Forms Sustainable Medical Technology Institute to Reduce the Environmental Impact of its Product Portfolio BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of the Sustainable Medical ...
Institute will drive sustainable innovation in three areas of environmental stewardship, furthering progress toward the company's 2030+ environmental, social and governance (ESG) commitments FRANKLIN LAKES, N.J. , April 22, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company)
Read more →BDXBECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited Amounts in millions, except share and per share data) Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Fiscal Year 2019 Three Months Ende
BECTON DICKINSON AND COMPANY CONDENSED CONSOLIDATED INCOME STATEMENTS (Unaudited Amounts in millions, except share and per share data) Fiscal Year 2022 Fiscal Year 2021 Fiscal Year 2020 Fiscal Year 2019 Three Months Ended December 31, 2021 Three Months Ended December 3
Read more →BDXBD TO ANNOUNCE FINANCIAL RESULTS FOR ITS SECOND QUARTER OF FISCAL 2022 BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will report financial results for its second quarter of fiscal year 2022 on...
FRANKLIN LAKES, N.J. , April 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report financial results for its second quarter of fiscal year 2022 on Thursday, May 5, 2022 . A news release will be issued at approximately 6:30 a.m
Read more →BDXBD Announces Completion of Embecta Corp. Spinoff BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of...
FRANKLIN LAKES, N.J. , April 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta) (NASDAQ: EMBC ), which holds BD's former Diabetes Care b
Read more →BDXBD Announces Completion of Embecta Corp. Spinoff FRANKLIN LAKES, N.J. (
FOR IMMEDIATE RELEASE BD Announces Completion of Embecta Corp. Spinoff FRANKLIN LAKES, N.J. (April 1, 2022) BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has completed its spinoff of Embecta Corp. (embecta)
Read more →BDXAlberto Mas Announces Intent to Retire from BD at End of Fiscal Year FRANKLIN LAKES, N.J. (
FOR IMMEDIATE RELEASE Alberto Mas Announces Intent to Retire from BD at End of Fiscal Year FRANKLIN LAKES, N.J. (March 31, 2022) BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the compan
Read more →BDXAlberto Mas Announces Intent to Retire from BD at End of Fiscal Year BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Alberto Mas has informed the...
FRANKLIN LAKES, N.J. , March 31, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company's fis
Read more →BDXBD Announces Early Tender Results for Cash Tender Offers by Morgan Stanley & Co. LL BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced the early results and pricing terms of...
FRANKLIN LAKES, N.J. , March 30, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company today announced the early results and pricing terms of Morgan Stanley & Co. LLC's ("Morgan Stanley") previously announced cash tender
Read more →BDXBD Named One of America's Most Trusted Companies by Newsweek BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been named to Newsweek's...
FRANKLIN LAKES, N.J. , March 25, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has been named to Newsweek's inaugural list of "America's Most Trusted Companies " in the Health Care and Li
Read more →BDXBD Provides Update Regarding the Planned Spinoff of Embecta Corp. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided additional details related to the planned ...
FRANKLIN LAKES, N.J. , March 21, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today provided additional details related to the planned spinoff of Embecta Corp. ("embecta"). Shareholder Distributions BD has se
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com BD Provides Update Regarding the Planned Spinoff of Embecta Corp.
Franklin Lakes, NJ 07417 BD Provides Update Regarding the Planned Spinoff of Embecta Corp. FRANKLIN LAKES, NJ (March 21, 2022) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided additional details related to the planned
Read more →BDXBD Announces Cash Tender Offers by Morgan Stanley & Co. LLC BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ( Morgan...
FRANKLIN LAKES, N.J. , March 16, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company today announced that Morgan Stanley & Co. LLC ("Morgan Stanley") has commenced cash tender offers (each, an "Offer" and collectively,
Read more →BDXBD Names William 'Bill' Brown to Board of Directors BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William Bill Brown...
FRANKLIN LAKES, N.J. , March 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the appointment of William "Bill" Brown to its board of directors, effective Feb. 28, 2022 . Brown, 59, is currently
Read more →BDXBD to Present at the Cowen 42nd Annual Health Care Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will virtually present at the...
FRANKLIN LAKES, N.J. , Feb. 24, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will virtually present at the Cowen 42 nd Annual Health Care Conference via webcast. BD's management is sched
Read more →BDXBD Appoints Shana Neal as Chief People Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Shana Neal has been appointed chief ...
FRANKLIN LAKES, N.J. , Feb. 23, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Shana Neal has been appointed chief people officer, effective April 4, 2022 . Neal, who held HR leadership posi
Read more →BDXembecta to Host Virtual Investor Event Ahead of Planned Spinoff from BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that embecta, the diabetes care business that...
FRANKLIN LAKES, N.J. , Feb. 23, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced that embecta, the diabetes care business that is expected to spin off from BD on April 1, 2022 , will host a virtual Invest
Read more →BDXBD Collaborates with ReturnSafe to Help Employers Manage COVID-19 Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with ReturnSafe, the...
FRANKLIN LAKES, N.J. , Feb. 8, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a collaboration with ReturnSafe, the all-in-one software solution for COVID-19 employee health, safety and compliance,
Read more →BDX▲ +5.4%on this newsshared move
Becton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD REPORTS FIRST QUARTER
Franklin Lakes, NJ 07417 Investors Francesca DeMartino, SVP, Head of Investor Relations - 201-847-5743 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS Revenue of $5.0 billion declined 6.0% as reported and 5.9%
Read more →BDX▲ +5.4%on this newsshared move
BD REPORTS FIRST QUARTER FISCAL 2022 FINANCIAL RESULTS BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its first quarter of fiscal...
FRANKLIN LAKES, N.J. , Feb. 3, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced results for its first quarter of fiscal year 2022, which ended December 31, 2021. "Our first quarter results reflect
Read more →BDXBD Expands from Cancer Discovery and Diagnosis into Post-Treatment Monitoring with Acquisition of Cytognos from Vitro S.A. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of...
FRANKLIN LAKES, N.J. , Feb. 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain , specializin
Read more →BDXBD Board of Directors Approves embecta Spinoff and Declares Distribution of embecta Stock BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has approved the...
FRANKLIN LAKES, N.J. , Feb. 1, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its board of directors has approved the planned spinoff of its diabetes care business, which will be known as Embecta
Read more →BDXBD Recognized for Equality by Bloomberg, Human Rights Campaign BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has been included in the 2022...
FRANKLIN LAKES, N.J. , Jan. 27, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has been included in the 2022 Bloomberg Gender-Equality Index (GEI) for the third straight year and has also
Read more →BDXNew Study Finds Up to One-Third of Women Receive Clinical Misdiagnosis of Vaginitis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the outcome of a peer-reviewed study...
In the paper, Performance of a Vaginal Panel Assay Compared With the Clinical Diagnosis of Vaginitis — which reports the findings from a BD clinical trial — the three causes of vaginitis (bacterial vaginosis [BV], vulvovaginal candidiasis [VVC] or Trichomonas vaginalis [TV]) were
Read more →BDXBD Innovation Profiled in Cover Story of 'Science' Demonstrates Landmark Advancement in Flow Cytometry Technology BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that a study conducted in collaboration...
Cell sorting through flow cytometry is a technique that enables scientists to identify and sort individual cells based on specific characteristics of each cell in order to study them in more detail, evaluate how each cell may react to a new drug or perform other single cell exper
Read more →BDXBD, Pfizer, Wellcome Collaborate to Improve Global Hospital Antimicrobial Stewardship Practices BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and...
FRANKLIN LAKES, N.J. , Jan. 11, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a collaboration with Pfizer Inc. and global charitable foundation Wellcome to better understand the role of diagnosti
Read more →BDXBD Named One of America's Most Just Companies in Annual JUST 100 Ranking BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it was named to the JUST 100 list of...
FRANKLIN LAKES, N.J. , Jan. 11, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it was named to the JUST 100 list of America's most just companies by JUST Capital and its media partner CNBC. The a
Read more →BDXBD Introduces Smart Connected Robotics to Automate Microbial Identification BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance...
FRANKLIN LAKES, N.J. , Jan. 7, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD Kiestra™ IdentifA sy
Read more →BDXBD Announces Change to Virtual 2022 Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that in the interest of the health and...
FRANKLIN LAKES, N.J. , Jan. 6, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that in the interest of the health and safety of its shareholders, directors, officers, employees and meeting attendee
Read more →BDXBD Publishes 2021 Cybersecurity Annual Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released its second annual cybersecurity report to ...
FRANKLIN LAKES, N.J. , Jan. 6, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today released its second annual cybersecurity report to update stakeholders on the state of health care cybersecurity, the company's
Read more →BDXBD TO ANNOUNCE FINANCIAL RESULTS FOR ITS FIRST QUARTER OF FISCAL YEAR 2022 BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report financial results for its first quarter of fiscal year 2022 on...
FRANKLIN LAKES, N.J. , Jan. 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report financial results for its first quarter of fiscal year 2022 on Thursday, Feb. 3, 2022 . A news release will be issued at approximately 6 a.m. Ea
Read more →BDXBD to Present at the 40th Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will virtually present at the...
FRANKLIN LAKES, N.J. , Dec. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will virtually present at the 40th Annual J.P. Morgan Healthcare Conference via webcast. BD's management is s
Read more →BDXBD Announces New Distribution and Retail Partners for BD Veritor™ At-Home COVID-19 Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical company, today announced the BD Veritor™ At-Home COVID-19 Test is now...
FRANKLIN LAKES, N.J. , Dec. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical company, today announced the BD Veritor™ At-Home COVID-19 Test is now available for purchase through Everly Health, a digital health company at the foref
Read more →BDXBD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of...
FRANKLIN LAKES, N.J. , Dec. 21, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medic
Read more →BDXBD Announces Board of Directors for embecta, the Planned Spinoff of its Diabetes Care Business BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Embecta Corp. ( embecta ), the...
FRANKLIN LAKES, N.J. , Dec. 21, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Embecta Corp. ("embecta"), the independent, publicly-traded company that will hold BD's Diabetes Care business u
Read more →BDXBD Expands Fully Automated High-Throughput Molecular Diagnostic Platform for Core Labs BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has expanded the BD COR™ System to...
FRANKLIN LAKES, N.J. , Dec. 17, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has expanded the BD COR™ System to include a new MX instrument for high-throughput molecular testing for infectiou
Read more →BDXBD Acquires Tissuemed, Ltd. To Add Advanced Sealant To Its Portfolio Of Surgical Solutions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a...
FRANKLIN LAKES, N.J. , Dec. 9, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired Tissuemed, Ltd., a privately held firm headquartered in Leeds, England that is an industry leader in d
Read more →BDXBD Selects embecta as Name of New Company for Planned Spinoff of Diabetes Care Business; Announces Remainder of Leadership Team BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that embecta [pronounced em-BECK-tah]...
FRANKLIN LAKES, N.J. , Dec. 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that " embecta " [pronounced em-BECK-tah] will be the name of the independent, publicly-traded company that will hold
Read more →BDXBD Acquires Venclose, Inc. To Extend Treatment Innovations In Chronic Venous Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Venclose, Inc., a...
FRANKLIN LAKES, N.J. , Dec. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired Venclose, Inc., a provider of solutions for the treatment of chronic venous insufficiency (CVI) — a di
Read more →BDXBD Issues 2021 Global Inclusion, Diversity and Equity Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the release of its 2021 Global...
FRANKLIN LAKES, N.J. , Dec. 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the release of its 2021 Global Inclusion, Diversity and Equity (ID&E) Report . The report, titled "Together We Advanc
Read more →BDXBD Statement on Testing for the COVID-19 Omicron Variant of Concern BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding testing...
FRANKLIN LAKES, N.J. , Nov. 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued the following statement regarding testing for the COVID-19 Omicron variant of concern. Dave Hickey , president of Life
Read more →BDXBD Names Dr. Joseph M. Smith as Chief Scientific Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Joseph M. Smith has been named...
FRANKLIN LAKES, N.J. , Nov. 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Dr. Joseph M. Smith has been named senior vice president and chief scientific officer for the company, effective
Read more →BDXBD Names Francesca DeMartino as Senior Vice President of Investor Relations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Francesca DeMartino has been named...
FRANKLIN LAKES, N.J. , Nov. 24, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced Francesca DeMartino has been named senior vice president of investor relations for the company, effective Nov. 29 .
Read more →BDXBD to Highlight Progress Against BD 2025 Strategy and Plans for Long-Term Growth BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will begin its Investor Day at 8 a.m. ET today to share...
FRANKLIN LAKES, N.J. , Nov. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, will begin its Investor Day at 8 a.m. ET today to share how it plans to leverage the breadth and depth of its core portfolio to fuel
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Investors Nadia Goncalves, BD Investor Relations - 201-847-5934 Media Troy Kirkpatrick, BD Public Relations - 858-617-2361 BD ANNOUNCES FOURTH FISCAL QUARTER AND F
Franklin Lakes, NJ 07417 Investors Nadia Goncalves, BD Investor Relations - 201-847-5934 Media Troy Kirkpatrick, BD Public Relations - 858-617-2361 BD ANNOUNCES FOURTH FISCAL QUARTER AND FULL YEAR 2021 RESULTS ISSUES FISCAL YEAR 2022 GUIDANCE Fourth fiscal quarter revenues of
Read more →BDXBD Announces Fourth Fiscal Quarter And Full Year 2021 Results; Issues Fiscal Year 2022 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for the fourth fiscal quarter...
FRANKLIN LAKES, N.J. , Nov. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced results for the fourth fiscal quarter and full fiscal year ended September 30, 2021. "Our strong performance in fisca
Read more →BDXBD Board Increases Dividend for 50th Consecutive Year, Authorizes 10 Million Additional Share Repurchases The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.87 per common share, an increase of...
FRANKLIN LAKES, N.J. , Nov. 4, 2021 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.87 per common share, an increase of 4.8% from the previous quarter. The dividend will be payable on Dec. 31, 2021
Read more →BDXBD Collaborates with U.S. Government on Development of COVID-19 Combination Diagnostic Tests BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic,...
FRANKLIN LAKES, N.J. , Oct. 28, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Author
Read more →BDXBD to Host Investor Day on November 12 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will host a virtual investor day ...
FRANKLIN LAKES, N.J. , Oct. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will host a virtual investor day on Friday, Nov. 12, 2021 at 8 a.m. , which will last for approximately four
Read more →BDXBD Begins Shipments Of First Smartphone Interpreted Over-The-Counter Rapid COVID-19 Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has started to ship the first...
FRANKLIN LAKES, N.J. , Oct. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has started to ship the first over-the-counter (OTC) COVID-19 rapid antigen test to use computer vision technology
Read more →BDXBD Names Dr. Carrie Byington To Board Of Directors BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Dr. Carrie L. Byington has been...
FRANKLIN LAKES, N.J. , Oct. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Dr. Carrie L. Byington has been appointed to the company's board of directors, bringing the total number of dire
Read more →BDXBD Launches New 'Together We Advance' Environmental, Social, Governance Strategy; Announces 2030+ Goals to Enhance Stewardship of Human Health, Communities and the Planet BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new strategy to advance environmental, ...
FRANKLIN LAKES, N.J. , Oct. 18, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a new strategy to advance environmental, social and governance (ESG) initiatives, as well as a suite of goals for 203
Read more →BDXBD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Vaccination Agility and Preparedness BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has strengthened the U.S....
FRANKLIN LAKES, N.J. , Oct. 7, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has strengthened the U.S. government's access to safety injection devices through increased manufacturing capacity
Read more →BDXBD Announces 510(k) Clearance of Expanded Indications for the Rotarex™ Atherectomy System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance for...
FRANKLIN LAKES, N.J. , Oct. 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received 510(k) clearance for expanded indications from the U.S. Food and Drug Administration (FDA) for the Rot
Read more →BDXBD To Announce Fiscal 2021 Fourth Quarter And Full Year Financial Results BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its fiscal 2021 fourth quarter and full year financial results on...
FRANKLIN LAKES, N.J. , Oct. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report its fiscal 2021 fourth quarter and full year financial results on Thursday, Nov. 4, 2021 . BD will issue a press release detailing the quarter's
Read more →BDXBD Joins the Race to Zero: Largest Alliance Dedicated to Achieving Net Zero Emissions by 2050 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, with support from a number of partners including Global...
FRANKLIN LAKES, N.J. , Sept. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, with support from a number of partners including Global Citizen, is proud to announce the company has officially signed on to the Ra
Read more →BDXBD Partners with Washington State in Back-to-School Testing Effort BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has been selected by the state of...
FRANKLIN LAKES, N.J. , Sept. 21, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has been selected by the state of Washington as a digitally read, rapid antigen test option for COVID-19 testing
Read more →BDXBD to Present at Two Upcoming Virtual Healthcare Investor Conferences in September BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will present at the...
FRANKLIN LAKES, N.J. , Aug. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that BD management will present at the following upcoming virtual investor conferences: Live webcasts of BD's presen
Read more →BDXBD Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the BD Veritor ™ At-H
Read more →BDXBD Launches Fully Automated High-Throughput Molecular Diagnostic Platform for U.S. Laboratories BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has launched a new, fully...
FRANKLIN LAKES, N.J. , Aug. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has launched a new, fully automated high-throughput diagnostic system using robotics and sample management so
Read more →BDXBecton, Dickinson and Company Announces Early Tender Results
Becton, Dickinson and Company Announces Early Tender Results FRANKLIN LAKES, NJ, August 19, 2021 - Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash (i) any
Read more →BDXBD Announces Pricing of Tender Offers Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced the consideration payable in connection with its previously...
FRANKLIN LAKES, N.J. , Aug. 19, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash (i) any and all of the Company's 2.
Read more →BDXChristopher DelOrefice to Join BD as Chief Financial Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher DelOrefice has been...
FRANKLIN LAKES, N.J. , Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Christopher DelOrefice has been named executive vice president and chief financial officer (CFO), effective Sept
Read more →BDXNew BD Benchtop Cell Analyzer Enhances Laboratory Access and Accelerates Scientific Research BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new benchtop cell...
FRANKLIN LAKES, N.J. , Aug. 11, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of a new benchtop cell analyzer that brings sophisticated flow cytometry capabilities to laboratories of a
Read more →BDXBD Announces Upsizing of Tender Offers FRANKLIN LAKES, NJ (
BD Announces Upsizing of Tender Offers FRANKLIN LAKES, NJ (August 10, 2021) - Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has amended its previously announced tender offers to purchase for cash each of its 3.875% Senior Notes due 2
Read more →BDXBD Announces Upsizing of Tender Offers Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced that it has amended its previously announced tender offers to...
FRANKLIN LAKES, N.J. , Aug. 10, 2021 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced that it has amended its previously announced tender offers to purchase for cash each of its 3.875% Senior Notes due 2024, 3.734% Senior Note
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Investors Kristen M. Stewart, CFA, SVP, Strategy Investor Relations - 201-847-5378 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD ANNOUNCES THIRD F
Franklin Lakes, NJ 07417 Investors Kristen M. Stewart, CFA, SVP, Strategy Investor Relations - 201-847-5378 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD ANNOUNCES THIRD FISCAL QUARTER RESULTS STRONG BASE GROWTH DRIVES BETTER PERFORMANCE IN QUARTER AND HIGHER
Read more →BDXBD Announces Third Fiscal Quarter Results; Strong Base Growth Drives Better Performance In Quarter And Higher Guidance For Fiscal 2021 Third fiscal quarter revenues of $4.9 billion grew 26.9% on a reported basis. On a currency-neutral basis, revenues increased 22.0%. BD's COVID-19...
FRANKLIN LAKES, N.J. , Aug. 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4 .9 billion for the third fiscal quarter ended June 30, 2021. This represents a year-over-year
Read more →BDXChristopher Reidy Announces Intent to Retire from BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Christopher Reidy, 64, executive...
FRANKLIN LAKES, N.J. , Aug. 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Christopher Reidy , 64, executive vice president, chief financial officer (CFO) and chief administrative officer
Read more →BDXBD to Present at UBS Genomics 2.0 and MedTech Innovations Summit BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that management will be presenting at...
FRANKLIN LAKES, N.J. , July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that management will be presenting at the UBS Genomics 2.0 and MedTech Innovations Summit on Wednesday, August 11, 20
Read more →BDXBD to Begin Remediation for BD Alaris™ System Software BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the company will begin remediation for...
FRANKLIN LAKES, N.J. , July 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the company will begin remediation for the February 4, 2020 BD Alaris™ System 1 recall through a new version of softw
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on...
FRANKLIN LAKES, N.J. , July 27, 2021 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.83 per common share, payable on September 30, 2021 to holders of record on September 9, 2021 . The indicated annu
Read more →BDXBD Acquires Tepha, Inc., to Drive New Innovations in Soft Tissue Repair and Regeneration BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired Tepha, Inc., a leading...
FRANKLIN LAKES, N.J. , July 27, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology. Te
Read more →BDXBD Seeks to Transform Patient Experience through Vision of 'One-Stick Hospital Stay' BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has taken a large step forward in...
FRANKLIN LAKES, N.J. , July 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has taken a large step forward in transforming the patient experience through a vision of a "One-Stick Hospital St
Read more →BDXBD Announces Two Future Directors for Diabetes Care Spinoff Company David F. Melcher to be non-executive chair; Claire Pomeroy, MD, MBA, to be a director FRANKLIN LAKES, N.J. (
BD Announces Two Future Directors for Diabetes Care Spinoff Company David F. Melcher to be non-executive chair; Claire Pomeroy, MD, MBA, to be a director FRANKLIN LAKES, N.J. (July 12, 2021) BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology co
Read more →BDXBD Announces Two Future Directors for Diabetes Care Spinoff Company BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that David F. Melcher will be...
FRANKLIN LAKES, N.J. , July 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that David F. Melcher will be non-executive chair of the board of directors, and Claire Pomeroy , MD, MBA, will be a
Read more →BDXBD Launches Reimagined Digital Marketplace for Flow Cytometry BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of a new...
FRANKLIN LAKES, N.J. , July 7, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the commercial release of a new bdbiosciences.com web and eCommerce site, an entirely "reimagined" digital marketplace
Read more →BDXBD To Announce Financial Results For Its Third Quarter Of Fiscal 2021 BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the third quarter of fiscal year 2021 on...
FRANKLIN LAKES, N.J. , June 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report its financial results for the third quarter of fiscal year 2021 on Thursday, August 5, 2021 . BD will issue a press release detailing the quart
Read more →BDXBD Announces Expanded 510(k) Clearance for At-Home System for Ascites BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from...
FRANKLIN LAKES, N.J. , June 23, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the PeritX™ Peritoneal Catheter
Read more →BDXBD Highlights Five-Year ESG Achievements in 2020 Sustainability Report, Setting the Foundation for 2030+ Strategy BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2020 Sustainability Report,...
FRANKLIN LAKES, N.J. , June 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued its 2020 Sustainability Report, highlighting significant achievements in environmental, social and governance (ESG) fact
Read more →BDXUSA Swimming Partners with BD to Provide COVID-19 Screening for the Olympic Trials and Other Competitive Swimming Events USA Swimming, the national governing body for the sport of swimming in the United States, and BD (Becton, Dickinson and Company) (NYSE: BDX), a...
FRANKLIN LAKES, N.J. , June 11, 2021 /PRNewswire/ -- USA Swimming, the national governing body for the sport of swimming in the United States , and BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, have partnered to provide COVID-19 tes
Read more →BDXBD Hits 2 Billion Injection Device Milestone in Support of Global COVID-19 Vaccination Efforts BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for ...
FRANKLIN LAKES, N.J. , June 8, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling 2 billion injection devices to support global C
Read more →BDXBD Advances Leadership in Cybersecurity Preparedness, Transparency BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has become the first medical...
FRANKLIN LAKES, N.J. , June 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has become the first medical technology company authorized as a Common Vulnerability and Exposures (CVE ® ) Nu
Read more →BDXBD to Present at Upcoming Investor Conferences in June BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following...
FRANKLIN LAKES, N.J. , May 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences during the month of June: Live webcasts o
Read more →BDXBD Leverages Artificial Intelligence To Transform Microbiology Urine Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. launch of a Urine Culture...
FRANKLIN LAKES, N.J. , May 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. launch of a Urine Culture Application for use with the BD Kiestra™ lab automation incubation and imaging syst
Read more →BDXBD Launches Industry First Ready-to-Use Iodine-Based Surgical Irrigation System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the availability of BD Surgiphor™...
FRANKLIN LAKES, N.J. , May 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the availability of BD Surgiphor™ Sterile Wound Irrigation System, the first and only ready-to-use aqueous povidone-io
Read more →BDXBD to Build New €165 Million Manufacturing Facility in Zaragoza, Spain To Support Ongoing Strong Growth of Pre-Filled Drug Delivery Business BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will build a €165 million ($200 million USD) high-tech...
MADRID , May 18, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, will build a €165 million ( $200 million USD ) high-tech manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain , tha
Read more →BDXBD Announces Industry-First CE Marked Assay for HPV Screening from At-Home Self-Collected Vaginal Samples BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the industry's first self-collection...
FRANKLIN LAKES, N.J. , May 13, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the industry's first self-collection claim for HPV screening has been CE marked to the IVD directive 98/79/EC. The ne
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Investors Kristen M. Stewart, CFA, SVP, Strategy Investor Relations - 201-847-5378 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD ANNOUNCES SECOND
Franklin Lakes, NJ 07417 Investors Kristen M. Stewart, CFA, SVP, Strategy Investor Relations - 201-847-5378 Media Troy Kirkpatrick, VP, Public Relations - 858-617-2361 BD ANNOUNCES SECOND FISCAL QUARTER RESULTS REAFFIRMS FISCAL 2021 GUIDANCE Second fiscal quarter revenues of
Read more →BDXBD Announces Intent to Spin Off Diabetes Care Business to Enhance Focus on Innovation and Priority Growth Markets BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously...
FRANKLIN LAKES, N.J. , May 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its board of directors has unanimously authorized management to proceed with a plan to spin off the company's Diabetes
Read more →BDXBD Announces Second Fiscal Quarter Results; Reaffirms Fiscal 2021 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.9 billion for...
FRANKLIN LAKES, N.J. , May 6, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4 .9 billion for the second fiscal quarter ended March 31, 2021. This represents an increase of 1
Read more →BDXBD Announces Enrollment in Post-Market Studies of the WavelinQ™ Arteriovenous Endovascular Fistula BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that enrollment has begun and the first...
FRANKLIN LAKES, N.J. , April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that enrollment has begun and the first patients have been treated in the post-market surveillance study, CONNECT-AV
Read more →BDXBD to Present at Upcoming Investor Health Care Conferences in May BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following...
FRANKLIN LAKES, N.J. , April 29, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor healthcare conferences during the month of May: Liv
Read more →BDXElizabeth McCombs Appointed Chief Technology Officer at BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as...
FRANKLIN LAKES, N.J. , April 28, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2
Read more →BDXCerTest Biotec, BD Announce Addition of Saliva to the CE Marked VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ Molecular Diagnostic System CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the VIASURE...
ZARAGOZA , Spain and FRANKLIN LAKES, N.J. , April 27, 2021 /PRNewswire/ -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit for the
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, payable on June ...
FRANKLIN LAKES, N.J. , April 27, 2021 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to holders of record on June 9, 2021 . The indicated annual divide
Read more →BDXBD Announces FDA 510(k) Submission for BD Alaris™ System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted a 510(k) premarket...
FRANKLIN LAKES, N.J. , April 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for the BD Alaris™ S
Read more →BDXBD's Commitment to Address Climate Change In recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, reinforces its commitment...
FRANKLIN LAKES, N.J. , April 22, 2021 /PRNewswire/ -- In recognition of Earth Day, BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, reinforces its commitment to Advancing the world of health ™ by affirming the first phase of its 2030 +
Read more →BDXBD Commits $1M To Fight Maternal And Neonatal Tetanus BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $1 million commitment over five years...
FRANKLIN LAKES, N.J. , April 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a $1 million commitment over five years to UNICEF USA in support of UNICEF's work to uphold the rights of all childr
Read more →BDXBD Announces the Voluntary Recall of Specified Lots of ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator in the United States and U.S. Territories Due to Defective Applicator BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrep™ Hi-Lite...
FRANKLIN LAKES, N.J. , April 20, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, is voluntarily recalling specified lots of the ChloraPrep ™ Hi-Lite Orange™ 26 mL Applicator (2% w/w chlorhexidine gluconate (CHG) and 70% v/v is
Read more →BDXBD Announces 510(k) Clearance of Pristine™ Long-Term Hemodialysis Catheter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from...
FRANKLIN LAKES, N.J. , April 14, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Pristine™ Long-Term Hemodi
Read more →BDXBD MAX™ Molecular Multi-Drug Resistant Tuberculosis Test To Be Included In WHO Updated Consolidated Guidelines On Tuberculosis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug...
FRANKLIN LAKES, N.J. , April 13, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was included in the moderate complexity
Read more →BDXBD To Announce Financial Results For Its Second Quarter Of Fiscal 2021 BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will report its financial results for the second quarter of fiscal year 2021 on ...
FRANKLIN LAKES, N.J. , April 5, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will report its financial results for the second quarter of fiscal year 2021 on Thursday, May 6, 2021 . BD will issue a press release detailing the quarter
Read more →BDXBD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct...
TUCSON, Ariz. , April 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company's
Read more →BDXBD Receives Emergency Use Authorization for Asymptomatic Screening for SARS-CoV-2 through Serial Rapid Antigen Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , April 1, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its rapid antigen test
Read more →BDXBD Announces FDA Emergency Use Authorization for Combination COVID-19, Flu Rapid Antigen Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , March 30, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for a new, rapid antigen test
Read more →BDXBD Expands Voluntary Recall of ChloraPrep™ 3 mL Applicator Nationwide to Include All U.S. States BD (Becton, Dickinson and Company), a leading global medical technology company, has expanded a voluntary recall that was initiated on June 23, 2020...
FRANKLIN LAKES, N.J. , March 24, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, has revised its press release dated March 19, 2021 relating to an expanded voluntary recall that was initiated on June 23 , 2020 for specified ca
Read more →BDXBD Announces Collaboration with ImageMover for Rapid Antigen Test Reporting BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement with ImageMover, a software ...
FRANKLIN LAKES, N.J. , March 9, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced an agreement with ImageMover, a software platform that automates and simplifies medical data collection and managemen
Read more →BDXBD Acquires GSL Solutions, Inc., Broadening Medication Management Offerings for Retail, Outpatient Pharmacy Settings BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc....
FRANKLIN LAKES, N.J. , March 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired GSL Solutions, Inc. ("GSL"), a privately-held company that develops smart medication devices for the
Read more →BDXBD Announces Collaboration for At-Home Rapid Test for COVID-19 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Scanwell Health, a leader in smartphone-enabled...
FRANKLIN LAKES, N.J. , Feb. 22, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Scanwell Health , a leader in smartphone-enabled at-home medical tests, today announced a collaboration to create an at-home rapi
Read more →BDXBD Announces Emergency Use Authorization, CE Mark for Combination Molecular Diagnostic to Detect SARS-CoV-2, Influenza A+B in Single Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug...
FRANKLIN LAKES, N.J. , Feb. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for a new molecular di
Read more →BDXBD to Present at Upcoming Investor Conferences BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it will present at the following...
FRANKLIN LAKES, N.J. , Feb. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it will present at the following upcoming virtual investor conferences: Live webcasts of BD's presentations can
Read more →BDXBD Announces First Fiscal Quarter Results; Raises Fiscal 2021 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for...
FRANKLIN LAKES, N.J. , Feb. 4, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $5.315 billion for the first fiscal quarter ended December 31, 2020. This represents an increase
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Kristen M. Stewart, CFA, Strategy Investor Relations - 201-847-5378 Troy Kirkpatrick, Corporate Communications - 858-617-2361 BD ANNOUNCES FIRST FISCAL QUARTER RES
Franklin Lakes, NJ 07417 Kristen M. Stewart, CFA, Strategy Investor Relations - 201-847-5378 Troy Kirkpatrick, Corporate Communications - 858-617-2361 BD ANNOUNCES FIRST FISCAL QUARTER RESULTS RAISES FISCAL 2021 GUIDANCE First fiscal quarter revenues of $5.315 billion grew 25
Read more →BDXDie erste randomisierte klinische Studie ihrer Art, die in der Fachzeitschrift „The Lancet Infectious Diseases veröffentlicht wurde, skizziert einen möglichen neuen Standard für periphere IV-Katheter - Es gibt stichhaltige Beweise dafür, dass die BD-Gefäßpflegelösung und das Hautantiseptikum für periphere intravenöse Katheter, die in der...
- Es gibt stichhaltige Beweise dafür, dass die BD-Gefäßpflegelösung und das Hautantiseptikum für periphere intravenöse Katheter, die in der randomisierten klinischen Studie CLEAN3 verwendet wurden, zur Verbesserung der Patientenergebnisse beitragen können - Im Vergleich zu Stand
Read more →BDXPrimer ensayo clínico aleatorio describe las mejores prácticas para catéteres periféricos IV -Primer ensayo clínico aleatorio publicado en The Lancet Infectious Diseases describe las posibles nuevas mejores prácticas de establecimiento de...
- Primer ensayo clínico aleatorio publicado en "The Lancet Infectious Diseases" describe las posibles nuevas mejores prácticas de establecimiento de normas para catéteres periféricos IV - Hay pruebas sólidas de que la solución de cuidado vascular BD y el antiséptico de la piel p
Read more →BDXLe premier essai clinique randomisé du genre publié dans « The Lancet Infectious Diseases » décrit les nouvelles pratiques exemplaires potentielles en matière de normalisation des cathéters IV périphériques - Il est avéré que la solution de soins vasculaires BD et l'antiseptique cutané pour cathéters intraveineux périphériques utilisés dans l'essai...
- Il est avéré que la solution de soins vasculaires BD et l'antiseptique cutané pour cathéters intraveineux périphériques utilisés dans l'essai clinique randomisé CLEAN3 peuvent contribuer à améliorer les résultats chez les patients - Par rapport aux approches standard, la solut
Read more →BDXFirst-of-its-Kind Randomized Clinical Trial Published in The Lancet Infectious Diseases Outlines Potential New Standard-Setting Best Practices for Peripheral IV Catheters BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that new clinical data have found robust ...
FRANKLIN LAKES, N.J. , Feb. 2, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that new clinical data have found robust evidence that using a vascular care solution can help improve outcomes for pa
Read more →BDXBD Names CEO Tom Polen as Chairman of the Board BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced Tom Polen, BD CEO and president, will...
FRANKLIN LAKES, N.J. , Jan. 26, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced Tom Polen , BD CEO and president, will assume additional responsibility as chairman of the BD board of directors, eff
Read more →BDXNew Clinical Data Shows BD Antigen Test May Be More Selective In Detecting Infectious COVID-19 Patients Than Molecular Tests BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a peer-reviewed study ...
FRANKLIN LAKES, N.J. , Jan. 25, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the publication of a peer-reviewed study that shows BD's antigen test may be more selective than PCR (polymerase chai
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Kristen M. Stewart, CFA, Strategy Investor Relations - 201-847-5378 Troy Kirkpatrick, Corporate Communications - 858-617-2361 BD PROVIDES UPDATES TO ITS FISCAL 202
Franklin Lakes, NJ 07417 Kristen M. Stewart, CFA, Strategy Investor Relations - 201-847-5378 Troy Kirkpatrick, Corporate Communications - 858-617-2361 BD PROVIDES UPDATES TO ITS FISCAL 2021 FINANCIAL OUTLOOK AND INTENDS TO COMMENT ON ITS PRELIMINARY FIRST FISCAL QUARTER REVENU
Read more →BDXBD Provides Updates To Its Fiscal 2021 Financial Outlook And Intends To Comment On Its Preliminary First Fiscal Quarter Revenue Performance During Today's Webcast At The 39th Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported, preliminary unaudited financial...
FRANKLIN LAKES, N.J. , Jan. 12, 2021 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported, preliminary unaudited financial information for the first fiscal quarter ended Dec. 31 , 2020. "We have entered fisc
Read more →BDXBD to Present at the 39th Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 39th Annual...
FRANKLIN LAKES, N.J. , Dec. 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 39 th Annual J.P. Morgan Healthcare Conference via webcast. BD's CEO and president is sch
Read more →BDXBD dépasse le milliard de commandes de dispositifs d'injection afin de soutenir les efforts de vaccination COVID-19 dans le monde BD (Becton, Dickinson and Company) (NYSE: BDX), une entreprise mondiale leader dans le domaine des technologies médicales, a annoncé aujourd'hui...
Les engagements comprennent plus de 400 millions de doses dans toute l' Europe avec 125 millions d'appareils livrés à ce jour EYSINS, Suisse, 17 décembre 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), une entreprise mondiale leader dans le domaine des tech
Read more →BDXBD übertrifft 1 Milliarde Bestellungen für Injektionsgeräte zur Unterstützung der COVID-19-Impfung auf der ganzen Welt BD (Becton, Dickinson and Company) (NYSE: BDX), ein weltweit führendes Medizintechnikunternehmen, gab heute bekannt, dass es Pandemie-Bestellungen...
Die Verpflichtungen umfassen mehr als 400 Millionen Dosiseinheiten in ganz Europa mit bisher 125 Millionen ausgelieferten Geräten EYSINS, Schweiz, 17. Dezember 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), ein weltweit führendes Medizintechnikunternehmen,
Read more →BDXBD supera los mil millones de pedidos de dispositivos de inyección para la COVID-19 BD (Becton, Dickinson and Company) (NYSE: BDX), empresa líder en tecnología médica a escala mundial, ha anunciado hoy que ha recibido pedidos de...
- BD supera los mil millones de pedidos de dispositivos de inyección para apoyar los esfuerzos de vacunación de la COVID-19 en todo el mundo Los compromisos incluyen más de 400 millones de unidades de dosis en Europa con 125 millones de dispositivos entregados hasta la fecha EY
Read more →BDXBD Surpasses 1 Billion Injection Device Orders in Support of COVID-19 Vaccination Efforts Around the World BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pandemic orders for ...
FRANKLIN LAKES, N.J. , Dec. 16, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has received pandemic orders for needles and syringes totaling more than 1 billion injection devices to suppo
Read more →BDXNew Clinical Trial Data Demonstrates BD Libertas™ Wearable Injector as a Drug Delivery System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced publication of the results from a...
FRANKLIN LAKES, N.J. , Dec. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced publication of the results from a 52-subject human clinical trial with the BD Libertas™ Wearable Injector. The subcuta
Read more →BDXBD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced plans to invest approximately $1.2...
- Investment includes new manufacturing facility in Europe FRANKLIN LAKES, N.J. , Dec. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced plans to invest approximately $1.2 billion over a 4-year p
Read more →BDXBD Board Increases Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.83 per common share, an increase of...
FRANKLIN LAKES, N.J. , Nov. 24, 2020 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.83 per common share, an increase of 5.1% from the previous quarter. The dividend will be payable on December 31,
Read more →BDXBD Announces Streamlined Reporting Capabilities for COVID-19 Data BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new reporting capabilities for COVID-19...
FRANKLIN LAKES, N.J. , Nov. 23, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced new reporting capabilities for COVID-19 data, enabling scheduled reports to be generated from BD Synapsys™ Informatic
Read more →BDXBD to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI...
FRANKLIN LAKES, N.J. , Nov. 19, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Evercore ISI 3 rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 , a
Read more →BDXBD Acquires the Medical Business Assets of CUBEX LLC, Broadening Automated Dispensing Portfolio Across Care Continuum BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has acquired the Medical Business...
FRANKLIN LAKES, N.J. , Nov. 12, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has acquired the Medical Business assets of CUBEX LLC, which is a privately-held company that develops cloud-based
Read more →BDXBD Announces Canadian Government Order of More Than 7 Million Portable, Rapid Point-of-Care Antigen Tests to Detect SARS-CoV-2 in 15 minutes BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2...
MISSISSAUGA, ON , Nov. 10, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been authorized for use by He
Read more →BDXBD to Present at Investor Virtual Healthcare Conferences BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following...
FRANKLIN LAKES, N.J. , Nov. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the following upcoming virtual healthcare conferences: Stifel 2020 Virtual Healthcare Confere
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Kristen M. Stewart, CFA, Strategy Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES FISCAL FOURTH QUARTER AN
Franklin Lakes, NJ 07417 Kristen M. Stewart, CFA, Strategy Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES FISCAL FOURTH QUARTER AND FULL YEAR 2020 RESULTS PROVIDES FISCAL 2021 GUIDANCE Fiscal fourth quarter revenues of
Read more →BDXBD Announces Fiscal Fourth Quarter And Full Year 2020 Results; Provides Fiscal 2021 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for...
FRANKLIN LAKES, N.J. , Nov. 5, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.784 billion for the fourth fiscal quarter ended September 30, 2020. This represents an increas
Read more →BDXBD Receives Order from Dutch Ministry of Health for More than Nine Million 15-minute COVID-19 Antigen Tests BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the receipt of an order from the Dutch...
THE HAGUE, NETHERLANDS and FRANKLIN LAKES, N.J. , Nov. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the receipt of an order from the Dutch Ministry of Health for 9.2 million of its rapid, poi
Read more →BDXBD Announces Executive Leadership Appointments BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as ...
FRANKLIN LAKES, N.J. , Oct. 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the appointment of Patrick Kaltenbach as executive vice president and chief technology officer, and the promotion of
Read more →BDXCerTest Biotec und BD geben CE-Kennzeichnung für Kombinationstest COVID-19, Influenza, RSV auf dem molekulardiagnostischen System BD MAX™ bekannt CerTest Biotec gab heute zusammen mit BD (Becton, Dickinson and Company) (NYSE: BDX), einem weltweit führenden Medizintechnikunternehmen, bekannt,...
ZARAGOZA , Spanien und FRANKLIN LAKES, New Jersey , 21. Oktober 2020 /PRNewswire/ -- CerTest Biotec gab heute zusammen mit BD (Becton, Dickinson and Company) (NYSE: BDX ), einem weltweit führenden Medizintechnikunternehmen, bekannt, dass das VIASURE SARS-CoV-2 (N1 + N2) Echtzeit-
Read more →BDXCerTest Biotec y BD anuncian la CE Mark para la combinación de test de COVID-19, gripe y VSR CerTest Biotec, junto con BD (Becton, Dickinson and Company) (NYSE: BDX), una compañía de tecnología médica global líder, ha anunciado hoy que el kit ...
- CerTest Biotec y BD anuncian la CE Mark para la combinación de test de COVID-19, gripe y VSR en el sistema de diagnóstico molecular BD MAX™ ZARAGOZA, España y FRANKLIN LAKES, Nueva Jersey , 21 de octubre de 2020 /PRNewswire/ -- CerTest Biotec, junto con BD (Becton, Dickinson a
Read more →BDXCerTest Biotec et BD présentent la marque CE pour la combinaison de test COVID-19, grippe, VRS sur le système de diagnostic moléculaire BD MAX™ CerTest Biotec, ainsi que BD (Becton, Dickinson and Company) (NYSE: BDX), société mondiale de technologie médicale de premier plan, a annoncé...
SARAGOSSE, Espagne et FRANKLIN LAKES, New Jersey , 21 octobre 2020 /PRNewswire/ -- CerTest Biotec, ainsi que BD (Becton, Dickinson and Company) (NYSE: BDX ), société mondiale de technologie médicale de premier plan, a annoncé aujourd'hui que le kit de détection PCR en temps réel
Read more →BDXCerTest Biotec and BD Announce CE Mark for Combination COVID-19, Influenza, RSV Test on BD MAX™ Molecular Diagnostic System CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the...
ZARAGOZA , Spain and FRANKLIN LAKES, N.J., Oct. 21, 2020 /PRNewswire/ -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit adap
Read more →BDXBD marks 25 years with Mercy Ships: Donates $1M to support launch of world's largest NGO hospital ship BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, this year celebrates its 25 year of philanthropic...
FRANKLIN LAKES, N.J. , Oct. 7, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, this year celebrates its 25 year of philanthropic partnership with the global nonprofit, Mercy Ships, by announcing its donation of $1
Read more →BDXBD Granted FDA 510(k) Clearance for BD FACSLyric™ Flow Cytometer with Newly Integrated BD FACSDuet™ Sample Preparation System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from...
FRANKLIN LAKES, N.J. , Oct. 5, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ Flow Cytometer
Read more →BDXBD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year...
FRANKLIN LAKES, N.J. , Oct. 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2020 earnings conference call on Thursday, November 5, 2020 , at 8:00 a.m. (ET
Read more →BDXBD Announces CE Mark of Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2...
FRANKLIN LAKES, N.J. , Sept. 30, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor™ Plus System has been CE marked to the I
Read more →BDXBD Submits Pre-Market Approval Supplement to FDA to Enable ThinPrep® Pap Test™ PreservCyt® Solution to be Used with the BD Onclarity™ HPV Assay BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market...
FRANKLIN LAKES, N.J. , Sept. 23, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for the
Read more →BDXBD Announces FDA Classifications for August 4th Recalls of BD Alaris™ System Hardware for Keypads, Incorrect Module Types and/or Sizes, and Channel Error BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on previously announced...
FRANKLIN LAKES, N.J. , Sept. 21, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today provided an update on previously announced voluntary recalls of the BD Alaris™ System. Three of the recalls, which BD announc
Read more →BDXNew Head-to-Head Study Demonstrates Equivalency and Accuracy of COVID-19 Rapid Point-of-Care Tests, Despite Different Test Sensitivity Claims BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the results of a new research study that ...
FRANKLIN LAKES, N.J. , Sept. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the results of a new research study that demonstrated performance of the BD Veritor™ System for Rapid Detection of SA
Read more →BDXBD to Present at Investor Healthcare Conferences BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following...
FRANKLIN LAKES, N.J. , Aug. 31, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the following upcoming virtual investor healthcare conferences: Wells Fargo Securities 2020
Read more →BDXBD Provides Update on Previously Disclosed Recall of BD Alaris System Hardware BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on a previously announced...
FRANKLIN LAKES, N.J. , Aug. 20, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today provided an update on a previously announced voluntary recall of the BD Alaris™ System. Three of the situations described in t
Read more →BDXKristen Stewart to Join BD as Senior Vice President of Strategy and Investor Relations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Kristen Stewart to...
FRANKLIN LAKES, N.J. , Aug. 17, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the appointment of Kristen Stewart to the newly created position of senior vice president of Strategy and Investor Re
Read more →BDXBD to Present at UBS Genomics 2.0 and MedTech Innovations Virtual Summit BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the UBS Genomics...
FRANKLIN LAKES, N.J. , Aug. 13, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the UBS Genomics 2.0 and MedTech Innovations Virtual Summit on Thursday, August 13, 2020 , at
Read more →BDXBD and BD Foundation commit $7.8 million to helping community health centers expand innovative care to patients BD (NYSE: BDX), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million...
FRANKLIN LAKES, N.J. , Aug. 10, 2020 /PRNewswire/ -- BD (NYSE: BDX ), a leading global medical technology company, together with the BD Foundation, its charitable affiliate, today committed $7.8 million in monetary grants and product donations over the next three years to support
Read more →BDXBD anuncia retiro voluntario del aplicador ChloraPrep™ 3 mL en determinados territorios estadounidenses y países BD (Becton, Dickinson and Company), una empresa global líder que se especializa en tecnología médica, anunció el retiro voluntario del mercado el 23...
FRANKLIN LAKES , Nueva Jersey , 7 de agosto de 2020 /PRNewswire-HISPANIC PR WIRE/ -- BD (Becton, Dickinson and Company), una empresa global líder que se especializa en tecnología médica, anunció el retiro voluntario del mercado el 23 de junio de 2020 de números de catálogo especi
Read more →BDXBD Announces Voluntary Recall of ChloraPrep™ 3 mL Applicator in Specific U.S. Territories and Countries BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on June 23, 2020 for specified catalog...
FRANKLIN LAKES, N.J. , Aug. 7, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, announced a voluntary recall on June 23, 2020 for specified catalog numbers of the ChloraPrep ™ 3 mL applicator due to possible fungal contaminatio
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2020 THIRD FISCAL QUARTER
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2020 THIRD FISCAL QUARTER PROVIDES FISCAL 2020 GUIDANCE As reported, revenues of $3.855 billion decreased 11.4 per
Read more →BDXBD Announces Results For 2020 Third Fiscal Quarter; Provides Fiscal 2020 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for...
FRANKLIN LAKES, N.J. , Aug. 6, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $3.855 billion for the third fiscal quarter ended June 30, 2020. This represents a decrease of 11
Read more →BDXBD releases FY 2019 Sustainability Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on ...
FRANKLIN LAKES, N.J. , Aug. 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support
Read more →BDXBD Announces $24 Million U.S. Government Investment to Support Scale Up of U.S. Manufacturing of COVID-19 Diagnosic Tests BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a $24 million investment from the U.S....
FRANKLIN LAKES, N.J. , July 30, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a $24 million investment from the U.S. Department of Defense in collaboration with the U.S. Department of Health and
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on...
FRANKLIN LAKES, N.J. , July 27, 2020 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.79 per common share, payable on September 30, 2020 to holders of record on September 9 , 2020. The indicated annu
Read more →BDXBD receives FDA Approval for HPV Test with Extended Genotyping Capabilities BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it received approval for a...
FRANKLIN LAKES, N.J. , July 22, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it received approval for a pre-market approval (PMA) supplement from the U.S. Food and Drug Administration (FDA)
Read more →BDXBD Receives Additional Orders For 177 Million Injection Devices For U.S., Canada COVID-19 Vaccine Preparations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced additional pandemic orders for needles...
FRANKLIN LAKES, N.J. , July 21, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced additional pandemic orders for needles and syringes from the United States and Canada totaling 177 million injection
Read more →BDXBD Supports U.S. Government Efforts to Increase COVID-19 Testing Capacity with Point-of-Care Tests BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today a commitment from the U.S. Department of ...
FRANKLIN LAKES, N.J. , July 15, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today a commitment from the U.S. Department of Health and Human Services (HHS) to purchase BD diagnostic solutions in expan
Read more →BDXBD Partners with U.S. Government on $70 Million Manufacturing Infrastructure Project for Mass Vaccination Campaigns BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the formation of a strategic,...
FRANKLIN LAKES, N.J. , July 8, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the formation of a strategic, public-private partnership with the Biomedical Advanced Research and Development Authori
Read more →BDXBD Launches First and Only Fully Sterile Povidone-Iodine and Isopropyl Alcohol Skin Preparation BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of BD PurPrep™ patient...
FRANKLIN LAKES, N.J. , July 7, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the availability of BD PurPrep™ patient preoperative skin preparation with sterile solution, the first and only fully
Read more →BDXBD Launches Portable, Rapid Point-of-Care Antigen Test to Detect SARS-CoV-2 in 15 minutes, Dramatically Expanding Access to COVID-19 Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug...
The BD Veritor™ System, which is slightly larger than a cell phone, is currently in use at more than 25,000 hospitals, clinician offices, urgent care centers and retail pharmacies in all 50 U.S. states. Its one-button functionality, workflow flexibility, and ease-of-use make it a
Read more →BDXCME America Announces a Follow-Up on the Voluntary Recall of BodyGuard® Infusion System Administration Sets CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), announced a voluntary recall for all CME America BodyGuard® Infusion...
GOLDEN, Colo. , July 3, 2020 /PRNewswire/ -- CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), announced a voluntary recall for all CME America BodyGuard ® Infusion System Administration Sets (infusion sets)—used with the company's BodyGuard ® infusion
Read more →BDXBD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2020 earnings...
FRANKLIN LAKES, N.J. , July 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2020 earnings conference call on Thursday, August 6, 2020 , at 8:00 a.m. (ET) . BD will issue a pres
Read more →BDXBD to Present at Investor Conferences BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the following...
FRANKLIN LAKES, N.J. , June 1, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the following upcoming investor conferences: Goldman Sachs 41 st Annual Global Healthcare Con
Read more →BDXBD to Present at Jefferies Virtual Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Jefferies...
FRANKLIN LAKES, N.J. , May 26, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 , at 11:00 a.m. ET . A
Read more →BDXBD Prices Offerings of $1.5 Billion of Common Stock and $1.5 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has priced its previously announced registered offerings of $1.5 billion of...
FRANKLIN LAKES, N.J. , May 21, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it has priced its previously announced registered offerings of $1.5 billion of common stock, par value $1.00 per share, at a public offering price of $240.00 p
Read more →BDXBD Announces Offerings of $1.5 billion of Common Stock and $1.5 billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value...
FRANKLIN LAKES, N.J. , May 19, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it has commenced registered offerings of $1.5 billion of common stock, par value $1.00 per share, and $1.5 billion of depositary shares, each representing a 1/
Read more →BDXBD Announces Results For 2020 Second Fiscal Quarter; Withdraws Fiscal Year 2020 Guidance Due To COVID-19 Pandemic BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.253 billion for...
FRANKLIN LAKES, N.J. , May 7, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.253 billion for the second fiscal quarter ended March 31, 2020. This represents an increase of
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2020 SECOND FISCAL QUARTE
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2020 SECOND FISCAL QUARTER; WITHDRAWS FISCAL YEAR 2020 GUIDANCE DUE TO COVID-19 PANDEMIC Franklin Lakes, NJ (May
Read more →BDXBD to Present at the Bank of America Securities Virtual Healthcare Conference 2020 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Bank of...
FRANKLIN LAKES, N.J. , May 5, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Bank of America Securities Virtual Healthcare Conference 2020 on Wednesday, May 13, 2020 ,
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 per common share, payable on June ...
FRANKLIN LAKES, N.J. , April 28, 2020 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.79 per common share, payable on June 30, 2020 to holders of record on June 9 , 2020. The indicated annual divide
Read more →BDXCME America Provides Update on Two Previously Announced Voluntary Recalls Related to Ambulatory Infusion Pumps and Sets CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), a leading global medical technology company, today issued the following ...
GOLDEN, Colo. , April 27, 2020 /PRNewswire/ -- CME America, a wholly owned subsidiary of BD (Becton, Dickinson and Company), a leading global medical technology company, today issued the following update regarding two previously announced voluntary recalls, one related to all mod
Read more →BDXBECTON DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Becton, Dickinson and Company To Contact The Firm
NEW YORK, April 25, 2020 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Becton, Dickinson and Company (“Becton” or the “Company”) (NYSE:BDX) of the April 27, 2020 deadline to seek the role of lead plaintiff in a federal secu
Read more →BDXBD Announces Second FDA Emergency Use Authorization, CE Mark for New COVID-19 Molecular Diagnostic for Global Use BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S. Food and Drug...
FRANKLIN LAKES, N.J. , April 13, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for an additional mol
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2020 earnings...
FRANKLIN LAKES, N.J. , April 6, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2020 earnings conference call on Thursday, May 7, 2020 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD, BioGX Announce FDA Emergency Use Authorization for New COVID-19 Diagnostic for Use in U.S. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, today...
FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala. , April 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, today announced that the U.S. Food and Drug Administration (FDA
Read more →BDXBD, BioMedomics Announce Launch of Rapid Serology Test to Detect Exposure to COVID-19 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioMedomics, a privately held, North Carolina-based...
FRANKLIN LAKES, N.J. and MORRISVILLE, N.C. , March 31, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and BioMedomics, a privately held, North Carolina -based clinical diagnostics company, today announced the rel
Read more →BDXBD, BioGX Announce FDA Emergency Use Authorization Submissions for New COVID-19 Diagnostics for Use in U.S. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and BioGX Inc, a molecular diagnostics company, today...
FRANKLIN LAKES, N.J. and BIRMINGHAM, Ala. , March 16, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and BioGX Inc, a molecular diagnostics company, today announced that the companies have submitted Emergency Use
Read more →BDXBD Statement on White House Meeting on COVID-19 Testing BD (Becton, Dickinson and Company) (NYSE: BDX), today issued the following statement after a White House meeting with CEOs of companies who have been ...
FRANKLIN LAKES, N.J. , March 13, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), today issued the following statement after a White House meeting with CEOs of companies who have been involved in the effort to expand access to COVID-19 (coronavirus) testing a
Read more →BDXCerTest Biotec and BD Announce COVID-19 Diagnostic Test CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the...
ZARAGOZA , Spain and FRANKLIN LAKES, N.J., March 10, 2020 /PRNewswire/ -- CerTest Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the VIASURE SARS-CoV-2 Real Time PCR Detection Kit adapted for t
Read more →BDXBECTON, DICKINSON AND COMPANY CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey against Becton, Dickinson and Company
NEW YORK, March 05, 2020 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a federal securities class action lawsuit in the United States District Court for the District of New Jersey on behalf of purchasers of the securities of Becton, Dickins
Read more →BDXBD to Present at the Barclays Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Barclays...
FRANKLIN LAKES, N.J. , March 2, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Barclays Global Healthcare Conference on Wednesday, March 11, 2020 , at 10:45 a.m. ET .
Read more →BDXBD Collaborates with Fleming Fund to Help Combat Threat of Antimicrobial Resistance in Asia and sub-Saharan Africa BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new, $6 million contract with the...
FRANKLIN LAKES, N.J. , Feb. 13, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a new, $6 million contract with the Fleming Fund , a U.K. aid program that helps low- and middle-income countries aro
Read more →BDXBD, Babson Diagnostics Announce Strategic Partnership Agreement to Enable Small-Volume Blood Collection for Diagnostic Testing in Retail Settings BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood ...
FRANKLIN LAKES, N.J. and AUSTIN, Texas , Feb. 12, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company and Babson Diagnostics, a transformative diagnostic blood testing company, today announced a long-term strategic par
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2020 FIRST FISCAL QUARTER
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2020 FIRST FISCAL QUARTER; LOWERS FISCAL 2020 GUIDANCE Franklin Lakes, NJ (February 6, 2020) - BD (Becton, Dickin
Read more →BDXBD Announces Results For 2020 First Fiscal Quarter; Lowers Fiscal 2020 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for...
FRANKLIN LAKES, N.J. , Feb. 6, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.225 billion for the first fiscal quarter ended December 31, 2019. This represents an increase
Read more →BDXBD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2020 earnings...
FRANKLIN LAKES, N.J. , Jan. 9, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2020 earnings conference call on Thursday, February 6, 2020 , at 8:00 a.m. (ET) . BD will issue a pr
Read more →BDXBD to Present at the 38th Annual J.P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 38th Annual...
FRANKLIN LAKES, N.J. , Jan. 3, 2020 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 38 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 at 6:00 p.m. E
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.79 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 25, 2019 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.79 cents per common share, an increase of 2.6 percent from the previous quarter. The dividend will be payable on
Read more →BDXBD to Present at Evercore ISI 2nd Annual HealthCONx Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Evercore ISI...
FRANKLIN LAKES, N.J. , Nov. 22, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Evercore ISI 2 nd Annual HealthCONx Conference on Wednesday, December 4, 2019 , at 11:45
Read more →BDXBD Launches Enhanced Antimicrobial Stewardship Analytics Capabilities BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its latest advancement in combating...
FRANKLIN LAKES, N.J. , Nov. 21, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its latest advancement in combating antimicrobial resistance (AMR) with new analytics integrated into the company's c
Read more →BDXBD Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Investment Corporation BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital...
FRANKLIN LAKES, N.J. , Nov. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it has been notified of an unsolicited mini-tender offer by TRC Capital Investment Corporation ("TRC") to purchase up to 500,000 shares of BDX common stock at
Read more →BDXBD to Present at Jefferies 2019 London Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Jefferies...
FRANKLIN LAKES, N.J. , Nov. 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Jefferies 2019 London Healthcare Conference on Thursday, November 21, 2019 , at 6:20 a.m.
Read more →BDXBD Submits Pre-Market Approval Supplement to FDA for BD Onclarity™ HPV Test with Extended Genotyping Capabilities BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has submitted a pre-market...
FRANKLIN LAKES, N.J. , Nov. 12, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has submitted a pre-market approval (PMA) supplement to the U.S. Food and Drug Administration (FDA) for an ex
Read more →BDXBD Announces Results For 2019 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2020 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for...
FRANKLIN LAKES, N.J. , Nov. 5, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.584 billion for the fourth fiscal quarter ended September 30, 2019. This represents an increas
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 FOURTH FISCAL QUARTE
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 FOURTH FISCAL QUARTER AND FULL YEAR; PROVIDES FISCAL 2020 GUIDANCE Franklin Lakes, NJ (November 5, 2019) - B
Read more →BDXBD Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the publication of a company-initiated,...
FRANKLIN LAKES, N.J. , Sept. 28, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the publication of a company-initiated, independent analysis of the LUTONIX ® 035 Drug Coated Balloon (DCB) femoropo
Read more →BDXBD Announces Leadership Succession Plan BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Vincent A. Forlenza, chairman and...
FRANKLIN LAKES, N.J. , Sept. 26, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Vincent A. Forlenza , chairman and CEO, will retire as CEO on Jan. 28, 2020 , following the company's annual me
Read more →BDXBD to Present at Investor Healthcare Conferences BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the following...
FRANKLIN LAKES, N.J. , Aug. 21, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the following upcoming investor healthcare conferences: Wells Fargo Securities 2019 Healthca
Read more →BDXBD Announces Results For 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for...
FRANKLIN LAKES, N.J. , Aug. 6, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019. This represents an increase of 1
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 THIRD FISCAL QUARTER
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 THIRD FISCAL QUARTER; REAFFIRMS FISCAL 2019 GUIDANCE Franklin Lakes, NJ (August 6, 2019) - BD (Becton, Dicki
Read more →BDXBD releases 2018 Sustainability Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on ...
FRANKLIN LAKES, N.J. , July 23, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued its 2018 Sustainability Report, focusing on management of the environmental, social and governance factors that support
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on...
FRANKLIN LAKES, N.J. , July 22, 2019 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on September 9 , 2019. The indicated annu
Read more →BDXBD Provides Update on Voluntary Recalls of Alaris™ Pump Module Model 8100 and Certain Alaris™ Pump Infusion Sets BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today provided an update on two voluntary recalls...
FRANKLIN LAKES, N.J. , July 18, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100 manufactured between April 2011
Read more →BDXBD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings...
FRANKLIN LAKES, N.J. , July 2, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement following the U.S....
FRANKLIN LAKES, N.J. , June 20, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued the following statement following the U.S. Food and Drug Administration (FDA) Circulatory System Devices Panel of the Me
Read more →BDXBD desvela una nueva solución para pruebas de diagnóstico molecular de alto rendimiento BD (Becton, Dickinson and Company) (NYSE: BDX), empresa líder en tecnología médica a escala mundial, ha anunciado hoy la certificación CE-IVDD de BD...
El BD COR™ System automatizado consigue el estado CE-IVD y ya está disponible en Europa FRANKLIN LAKES , Nueva Jersey , 18 de junio de 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), empresa líder en tecnología médica a escala mundial, ha anunciado hoy la c
Read more →BDXBD stellt neues Produkt für molekulardiagnostische Tests mit hohem Durchsatz vor BD (Becton, Dickinson and Company) (NYSE: BDX), ein weltweit führendes Unternehmen des Medizinbereichs, hat heute die CE-IVDD-Zertifizierung seines...
Automatisiertes System BD COR™ erhält CE-IVD-Status; jetzt in Europa verfügbar FRANKLIN LAKES, New Jersey , 18. Juni 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), ein weltweit führendes Unternehmen des Medizinbereichs, hat heute die CE-IVDD-Zertifizierung
Read more →BDXBD présente une nouvelle solution pour les tests de diagnostic moléculaire à haut rendement Aujourd'hui, BD (Becton, Dickinson and Company) (NYSE : BDX), une grande entreprise mondiale de technologie médicale, a annoncé la certification...
Le système BD COR™ automatisé obtient la certification CE-IVD ; il est désormais disponible en Europe FRANKLIN LAKES, New Jersey , 18 juin 2019 /PRNewswire/ -- Aujourd'hui, BD (Becton, Dickinson and Company) (NYSE : BDX ), une grande entreprise mondiale de technologie médicale,
Read more →BDXBD Announces Pricing and Upsizing of Tender Offers Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced the consideration payable in connection with its previously...
FRANKLIN LAKES, N.J. , June 4, 2019 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash, in the order of priority set forth
Read more →BDXNew Report Sheds Light on Health Care's 'Hidden' Epidemic - Hospital Drug Diversion - and its Role in the Opioid Crisis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today released a new report based on an independent...
FRANKLIN LAKES, N.J. , June 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today released a new report based on an independent national survey that examines drug diversion in U.S. hospitals, an underreported c
Read more →BDXBD Announces Early Tender Results
BD Announces Early Tender Results FRANKLIN LAKES, NJ, June 3, 2019 - Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority set forth i
Read more →BDXBD Announces Early Tender Results Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced the early tender results for its previously announced tender offers ...
FRANKLIN LAKES, N.J. , June 3, 2019 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority set forth in the table bel
Read more →BDXBD to Present at the Goldman Sachs 40th Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman...
FRANKLIN LAKES, N.J. , May 31, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Goldman Sachs 40 th Annual Global Healthcare Conference on Thursday, June 13, 2019 , at 12
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 SECOND FISCAL QUARTE
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 SECOND FISCAL QUARTER; UPDATES FISCAL 2019 GUIDANCE Franklin Lakes, NJ (May 9, 2019) - BD (Becton, Dickinson
Read more →BDXBD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.195 billion for...
FRANKLIN LAKES, N.J. , May 9, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.195 billion for the second fiscal quarter ended March 31, 2019. This represents a decrease of 0
Read more →BDXBD to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Bank of...
FRANKLIN LAKES, N.J. , May 1, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Bank of America Merrill Lynch 2019 Global Healthcare Conference on Tuesday, May 14, 2019 ,
Read more →BDXBD Receives FDA Approval for Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug...
FRANKLIN LAKES, N.J. , April 30, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for BD ChloraPrep™ skin preparation with sterile so
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 per common share, payable on June ...
FRANKLIN LAKES, N.J. , April 29, 2019 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.77 per common share, payable on June 28, 2019 to holders of record on June 7 , 2019. The indicated annual divide
Read more →BDXBD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global availability of BD BACTEC™...
FRANKLIN LAKES, N.J. , April 8, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the global availability of BD BACTEC™ platelet quality control media , which allows microbiology laboratories, blood
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2019 earnings...
FRANKLIN LAKES, N.J. , April 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2019 earnings conference call on Thursday, May 9, 2019 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD Launches New Automated Flow Cytometry Sample Preparation Instrument with CE-IVD Certification BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the CE-IVD certification for the BD...
FRANKLIN LAKES, N.J. , March 26, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the CE-IVD certification for the BD FACSDuet™ automated flow cytometry system. The new fully automated sample prepar
Read more →BDXBD Statement on Paclitaxel-Coated Devices BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement related to the...
FRANKLIN LAKES, N.J. , March 21, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued the following statement related to the recent letter from FDA to health care providers regarding paclitaxel-coated devi
Read more →BDXBD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , March 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. Food and Drug Administration has granted premarket approval for the Venovo™ venous stent, the first stent i
Read more →BDXBD to Present at the Barclays Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Barclays...
FRANKLIN LAKES, N.J. , March 4, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Barclays Global Healthcare Conference on Tuesday, March 12, 2019 , at 2:05 p.m. ET . A l
Read more →BDXBD to Present at Leerink Partners 8th Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at Leerink Partners ...
FRANKLIN LAKES, N.J. , Feb. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at Leerink Partners 8 th Annual Global Healthcare Conference on Thursday, February 28, 2019 , at
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 FIRST FISCAL QUARTER
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2019 FIRST FISCAL QUARTER; REAFFIRMS FISCAL 2019 GUIDANCE Franklin Lakes, NJ (February 5, 2019) - BD (Becton, Dic
Read more →BDXBD Announces Results for 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for...
FRANKLIN LAKES, N.J. , Feb. 5, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.160 billion for the first fiscal quarter ended December 31, 2018. This represents an increase
Read more →BDXBD Launches Ergonomic Pen Needle Technology to Help Optimize Injection Technique BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the U.S. Food and Drug Administration 510(k)...
FRANKLIN LAKES, N.J. , Jan. 24, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced the U.S. Food and Drug Administration 510(k) clearance of its second generation BD Nano™ pen needle, designed for more reli
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES PRELIMINARY RESULTS FOR 2019 FIRST FI
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES PRELIMINARY RESULTS FOR 2019 FIRST FISCAL QUARTER; REAFFIRMS FISCAL 2019 GUIDANCE Franklin Lakes, NJ (January 17, 2019) - BD
Read more →BDXBD Announces Preliminary Results For 2019 First Fiscal Quarter; Reaffirms Fiscal 2019 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported preliminary financial results for the...
FRANKLIN LAKES, N.J. , Jan. 17, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported preliminary financial results for the first fiscal quarter ended December 31, 2018. Subject to the completion of its f
Read more →BDXBD Announces Webcast of Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will host a live webcast of its Annual...
FRANKLIN LAKES, N.J. , Jan. 15, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 22, 2019 , at 1 p.m. (ET) . The w
Read more →BDXBD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings...
FRANKLIN LAKES, N.J. , Jan. 8, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2019 earnings conference call on Tuesday, February 5, 2019 , at 8:00 a.m. (ET) . BD will issue a pre
Read more →BDXBD Completes Molecular Portfolio for GI Infection With New Viral Panel BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , Dec. 20, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of its BD MAX™ enteric viral panel, a molecular diagnostic tes
Read more →BDXBD Announces Completion Of Enterprise Level Cybersecurity Assessment From UL BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of an enterprise level...
FRANKLIN LAKES, N.J. , Dec. 11, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the completion of an enterprise level cybersecurity assessment from UL. This independent assessment evaluates corpora
Read more →BDXBD Expands Integrated Medication Management to Help Tackle Hospital Drug Diversion BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of a new software application ...
FRANKLIN LAKES, N.J. , Nov. 29, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of a new software application designed to help hospitals and health systems identify drug diversion at the
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.77 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 19, 2018 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.77 cents per common share, an increase of 2.7 percent from the previous quarter. The dividend will be payable on
Read more →BDXNew Diagnostic Test Helps Hospitals More Quickly Identify and Treat Emerging Antibiotic-Resistant Bacteria BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , Nov. 13, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. Food and Drug Administration 510(k) clearance of the BD Phoenix™ CPO detect test, which will allow hospitals
Read more →BDXBD Announces Clinical Trial Data for the LUTONIX® 014 Drug-Coated Balloon Below-The-Knee IDE Trial BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the safety and efficacy data from the...
FRANKLIN LAKES, N.J. , Nov. 7, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the safety and efficacy data from the LUTONIX ® Drug-Coated Balloon (DCB) IDE, level 1 clinical trial for a below-the-
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 FOURTH FISCAL QUARTE
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 FOURTH FISCAL QUARTER AND FULL YEAR; PROVIDES FISCAL 2019 GUIDANCE Franklin Lakes, NJ (November 6, 2018) - B
Read more →BDXBD to Present at the Stifel 2018 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Stifel 2018...
FRANKLIN LAKES, N.J. , Nov. 6, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 , at 11:45 AM ET . A li
Read more →BDXBD Announces Results For 2018 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2019 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for...
FRANKLIN LAKES, N.J. , Nov. 6, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.402 billion for the fourth fiscal quarter ended September 30, 2018. This represents an increas
Read more →BDXBD To Invest $200 Million In Nebraska Operations Creating 300 More Jobs BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state...
COLUMBUS, Neb. , Oct. 23, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to announce a $200 million investment in its facilities in Nebrask
Read more →BDXBD Donates 20 Million Syringes to Support Polio Eradication BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a donation of 20 million syringes valued ...
FRANKLIN LAKES, N.J. , Oct. 17, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a donation of 20 million syringes valued at $1 million to Rotary, a nonprofit organization dedicated to tackling the
Read more →BDXBD Launches Molecular Test For Detecting Tuberculosis And Multi-Drug Resistant TB BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the availability of the BD MAX™ MDR-TB...
FRANKLIN LAKES, N.J. , Oct. 16, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the availability of the BD MAX™ MDR-TB panel in Europe . Clinicians can use the test to simultaneously detect bacteri
Read more →BDXBD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year...
FRANKLIN LAKES, N.J. , Oct. 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2018 earnings conference call on Tuesday, November 6, 2018 , at 8:00 a.m. (ET)
Read more →BDXBD Breaks Ground at I.D.E.A. Tempe Campus Officials from BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, were joined today by Gov. Doug Ducey,...
TEMPE, Ariz. , Oct. 3, 2018 /PRNewswire/ -- Officials from BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, were joined today by Gov. Doug Ducey , Tempe Mayor Mark Mitchell and representatives of The Boyer Company to officially break g
Read more →BDXTom Polen Promoted to Chief Operating Officer of BD BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Tom Polen will add the...
FRANKLIN LAKES, N.J. , Oct. 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Tom Polen will add the responsibility of chief operating officer of BD, in addition to his current role as presid
Read more →BDXBD Statement on Divestiture of Advanced Bioprocessing Business BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued the following statement regarding the sale...
FRANKLIN LAKES, N.J. , Sept. 7, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued the following statement regarding the sale of its Advanced Bioprocessing business to Thermo Fisher Scientific: "The sal
Read more →BDXBD to Present at the Morgan Stanley 2018 Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan...
FRANKLIN LAKES, N.J. , Aug. 30, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Morgan Stanley 2018 Global Healthcare Conference on Wednesday, September 12, 2018 , at 11
Read more →BDXBD Awards $1 Million in Grants to Help Community Health Centers Drive Effective Medication Use Among Vulnerable Patients BD (Becton, Dickinson and Company), Direct Relief, and the National Association of Community Health Centers (NACHC) recently awarded five community...
FRANKLIN LAKES, N.J. , Aug. 28, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) , Direct Relief , and the National Association of Community Health Centers ( NACHC ) recently awarded five community health centers with a total of $1 million in grant funding, which will be u
Read more →BDXBD to Present at the Wells Fargo Securities 2018 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Wells Fargo...
FRANKLIN LAKES, N.J. , Aug. 22, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Wells Fargo Securities 2018 Healthcare Conference on Wednesday, September 5, 2018 , at 3:
Read more →BDXBD Elects Jeffrey Henderson to Board of Directors BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Jeffrey W. Henderson has been...
FRANKLIN LAKES, N.J. , Aug. 16, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that Jeffrey W. Henderson has been elected to the company's board of directors. Henderson, 53, is the non-executive
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 THIRD FISCAL QUARTER
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 THIRD FISCAL QUARTER; RAISES FISCAL 2018 REVENUE GUIDANCE Franklin Lakes, NJ (August 2, 2018) - BD (Becton,
Read more →BDXBD Announces Results For 2018 Third Fiscal Quarter; Raises Fiscal 2018 Revenue Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.278 billion for...
FRANKLIN LAKES, N.J. , Aug. 2, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.278 billion for the third fiscal quarter ended June 30, 2018. This represents an increase of 4
Read more →BDXBD Appoints Simon Campion to Interventional Segment President BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed Simon Campion as executive vice...
FRANKLIN LAKES, N.J. , Aug. 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today appointed Simon Campion as executive vice president of BD and president, BD Interventional segment, effective Sept. 4 . Campion
Read more →BDXBD Drives the Future of Immunology Research with Expanded Offerings for Simultaneous RNA and Protein Expression Analysis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial release of the BD® AbSeq...
FRANKLIN LAKES, N.J. , July 26, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the commercial release of the BD ® AbSeq assay to analyze protein expression at the single-cell level using high-thro
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on...
FRANKLIN LAKES, N.J. , July 24, 2018 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.75 per common share, payable on September 28, 2018 to holders of record on September 7, 2018 . The indicated annu
Read more →BDXBD Shares Progress towards Achieving 2020 Sustainability Goals BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2017 Sustainability Performance Update...
FRANKLIN LAKES, N.J. , July 12, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today issued its 2017 Sustainability Performance Update that focuses on four key strategic areas that support the company's 2020 Sust
Read more →BDXBD Acquires TVA Medical to Advance Leadership in Solutions for Chronic Kidney Disease BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of TVA...
FRANKLIN LAKES, N.J. , July 9, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has completed the acquisition of TVA Medical, Inc., a company that develops minimally invasive vascular access solu
Read more →BDXBD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2018 earnings...
FRANKLIN LAKES, N.J. , July 5, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2018 earnings conference call on Thursday, August 2, 2018 , at 8:00 a.m. (ET) . BD will issue a pres
Read more →BDXBD fremviser sit udvidede sortiment til vaskulær adgang fra anlæggelse til fjernelse på den 5. WoCoVA-verdenskonference (World Congress on Vascular Access) I forbindelse med den 5. årlige World Congress on Vascular Access (WoCoVA), som finder sted den 20.-22. juni i København, vil BD (Becton, Dickinson...
Besøg BD's stand nr. 9 og 10 for at se, hvordan det mest almindelige invasive indgreb ikke behøver være et af de mest komplekse KØBENHAVN, Danmark, 21. juni 2018 /PRNewswire/ -- I forbindelse med den 5. årlige World Congress on Vascular Access (WoCoVA), som finder sted den 20.-2
Read more →BDXBD to Demonstrate Expanded Vascular Access Offerings from Insertion to Removal during the 5th World Congress on Vascular Access (WoCoVA) During the 5th annual World Congress on Vascular Access (WoCoVA) being held June 20-22 in Copenhagen, BD (Becton, Dickinson and Company) (NYSE: BDX), ...
Visit BD Booth #9 and 10 to Learn how the Most Common Invasive Procedure doesn't Need to be One of the Most Complex COPENHAGEN, Denmark , June 20, 2018 /PRNewswire/ -- During the 5 th annual World Congress on Vascular Access (WoCoVA) being held June 20-22 in Copenhagen , BD (Bec
Read more →BDXBD, Helmer Scientific Collaborate to Introduce First Fully Integrated Refrigerated Automated Dispensing Solution BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Helmer Scientific, a leading provider of integrated...
DENVER , June 4, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Helmer Scientific, a leading provider of integrated solutions to safeguard temperature-sensitive medications, today announced a collaboration to
Read more →BDXBD Names John DeFord Chief Technology Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today appointed John A. DeFord as executive vice...
FRANKLIN LAKES, N.J. , June 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today appointed John A. DeFord as executive vice president and chief technology officer. DeFord, 56, will report to Tom Polen , presi
Read more →BDXBD Announces Results For 2018 Second Fiscal Quarter; Raises Fiscal 2018 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for...
FRANKLIN LAKES, N.J. , May 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $4.222 billion for the second fiscal quarter ended March 31, 2018. This represents an increase of
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTE
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 SECOND FISCAL QUARTER; RAISES FISCAL 2018 GUIDANCE Franklin Lakes, NJ (May 3, 2018) - BD (Becton, Dickinson a
Read more →BDXBD Launches BD FACSymphony™ S6 High Parameter Cell Sorter to Enable Sorting of Rare Cell Types BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSymphony™ S6...
FRANKLIN LAKES, N.J. , April 26, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of the BD FACSymphony ™ S6 cell sorter, which will be on display at the 33rd Congress of the Internationa
Read more →BDXBD Board Declares Dividends The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on June ...
FRANKLIN LAKES, N.J. , April 23, 2018 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.75 per common share, payable on June 29, 2018 to holders of record on June 8 , 2018. The indicated annual divide
Read more →BDXBD Unveils Suite of Diagnostic Informatics and Automation Innovations BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced several new informatics and automation...
FRANKLIN LAKES, N.J. , April 19, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today introduced several new informatics and automation solutions for clinical laboratories, which may play a critical role in the f
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2018 earnings...
FRANKLIN LAKES, N.J. , April 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2018 earnings conference call on Thursday, May 3, 2018 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD to Demonstrate Enhanced Integration Offerings that Target Key Gaps Across the Medication Management Process at HIMSS18 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will demonstrate its comprehensive approach to...
LAS VEGAS , March 5, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, will demonstrate its comprehensive approach to integrated, enterprise medication management to help close the communication gaps across the medi
Read more →BDXBD Announces Results of Offer to Repurchase its 3.000% Notes Due 2026
BD Announces Results of Offer to Repurchase its 3.000% Notes Due 2026 FRANKLIN LAKES, N.J., March 1, 2018 -- BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the results of its previously announced offer to repurchase (the "Offer") any and all of its outstanding 3.
Read more →BDXBD Announces Results of Offer to Repurchase its 3.000% Notes Due 2026 BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the results of its previously announced offer to repurchase (the Offer ) any and all...
FRANKLIN LAKES, N.J. , March 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today the results of its previously announced offer to repurchase (the "Offer") any and all of its outstanding 3.000% Notes due May 15, 2026 (the "Notes") in accordance
Read more →BDXBD to Present at the Raymond James 39th Annual Institutional Investors Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Raymond...
FRANKLIN LAKES, N.J. , Feb. 28, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Raymond James 39 th Annual Institutional Investors Conference on Tuesday, March 6, 2018 ,
Read more →BDXBD Launches Circulating Cell-Free DNA Blood Collection Tube for Cancer and Non-Invasive Prenatal Testing Applications BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial availability of the...
FRANKLIN LAKES, N.J. and EYSINS, Switzerland , Feb. 20, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the commercial availability of the CE-IVD marked PAXgene ® Blood ccfDNA tube within the Europ
Read more →BDXBD Completes Asset Divestitures to Merit Medical BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed the previously...
FRANKLIN LAKES, N.J. , Feb. 15, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has completed the previously announced divestitures of its soft tissue core needle biopsy product line and As
Read more →BDXFDA Approves New HPV Test that Detects and Identifies HPV Genotypes that put Women at High Risk for Cervical Cancer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pre-market approval ...
FRANKLIN LAKES, N.J. , Feb. 13, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has received pre-market approval from the U.S. Food and Drug Administration (FDA) for the BD Onclarity™ HPV a
Read more →BDXBD to Present at Leerink Partners 7th Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at Leerink Partners...
FRANKLIN LAKES, N.J. , Feb. 8, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at Leerink Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018 , at
Read more →BDXBD Announces Results For 2018 First Fiscal Quarter; Provides Fiscal 2018 Guidance Updated For Inclusion Of Bard BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.080 billion for...
FRANKLIN LAKES, N.J. , Feb. 6, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $3.080 billion for the first fiscal quarter ended December 31, 2017. This represents an increase
Read more →BDXBecton Drive Franklin Lakes, NJ 07417 www.bd.com Contact: Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER
Franklin Lakes, NJ 07417 Monique N. Dolecki, Investor Relations - 201-847-5378 Kristen Cardillo, Corporate Communications - 201-847-5657 BD ANNOUNCES RESULTS FOR 2018 FIRST FISCAL QUARTER; PROVIDES FISCAL 2018 GUIDANCE UPDATED FOR INCLUSION OF BARD Franklin Lakes, NJ (Februa
Read more →BDXBECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE UNITED STATES (Unaudited; Amounts in millions) A B C D E F G H I=A+B+C+D +E+F+G+H BDX as Reported BD Realign
BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED REVENUE TO COMPARABLE REVENUE UNITED STATES (Unaudited; Amounts in millions) Footnote Explanations BECTON DICKINSON AND COMPANY SUPPLEMENTAL INFORMATION RECONCILIATION OF REPORTED REVENUE TO C
Read more →BDXComparable Historical Revenue Schedules Inclusive of C. R. Bard Posted to BD Website As previously disclosed, on December 29, 2017, BD (Becton, Dickinson and Company) (NYSE: BDX) completed the acquisition of C. R. Bard, Inc. ( Bard ). ...
FRANKLIN LAKES, N.J. , Feb. 2, 2018 /PRNewswire/ -- As previously disclosed, on December 29, 2017 , BD (Becton, Dickinson and Company) (NYSE: BDX ) completed the acquisition of C. R. Bard, Inc. ("Bard"). In relation to the acquisition, BD has provided supplemental, unaudited hist
Read more →BDXBD Launches New Los Angeles County Program to Equip Patients with Essential Resources for Safe Sharps Disposal BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today launched a new LA County program to help ensure...
LOS ANGELES , Feb. 1, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company , today launched a new LA County program to help ensure proper containment and disposal of household sharps, a health concern that when disposed
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 per common share, payable on...
FRANKLIN LAKES, N.J. , Jan. 22, 2018 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.75 per common share, payable on March 30, 2018 to holders of record on March 9 , 2018. The indicated annual divid
Read more →BDXBD Announces Completion of Enrollment in the Lutonix™ 014 Drug Coated Balloon Below-The-Knee Trial BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of enrollment in the...
FRANKLIN LAKES, N.J. , Jan. 18, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the completion of enrollment in the Lutonix below-the-knee (BTK) trial and plans to submit a pre-market approval appl
Read more →BDXBD and Check-Points Receive CE Mark for Next-generation Resistant Bacteria Screening Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today...
FRANKLIN LAKES, N.J. , and WAGENINGEN, The Netherlands , Jan. 15, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a next
Read more →BDXBD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2018 earnings...
FRANKLIN LAKES, N.J. , Jan. 11, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2018 earnings conference call on Tuesday, February 6, 2018 , at 8:00 a.m. (ET) . BD will issue a pr
Read more →BDXBD Announces Commencement of Offer to Repurchase its 3.000% Notes Due 2026 BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, following its acquisition of C. R. Bard, Inc. ( Bard ), which was consummated on ...
FRANKLIN LAKES, N.J. , Jan. 8, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that, following its acquisition of C. R. Bard, Inc. ("Bard"), which was consummated on December 29, 2017 , BD has commenced an offer to repurchase (the "Offer") any
Read more →BDXBD to Present at the 36th Annual J. P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the 36th Annual J....
FRANKLIN LAKES, N.J. , Jan. 3, 2018 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 36th Annual J. P. Morgan Healthcare Conference on Tuesday, January 9, 2018 , at 12:00 p.m.
Read more →BDXTroy Kirkpatrick Monique N. Dolecki BD Public Relations BD Investor Relations 858.617.2361 201.847.5378 troy.kirkpatrick@bd.com Monique_Dolecki@bd.com BD COMPLETES BARD ACQUIS
BD COMPLETES BARD ACQUISITION, CREATING NEW GLOBAL HEALTH CARE LEADER FRANKLIN LAKES, N.J., Dec. 29, 2017 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR
Read more →BDXBD Announces Expiration and Final Results of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes BD (Becton, Dickinson and Company) (NYSE: BDX) announced today the expiration and final results of its previously announced offers to exchange (the...
FRANKLIN LAKES, N.J. , Dec. 29, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today the expiration and final results of its previously announced offers to exchange (the "Exchange Offers") any and all outstanding 4.400% Notes due 2021, 3.000% Notes
Read more →BDXBD Completes Bard Acquisition, Creating New Global Health Care Leader BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of C. R....
FRANKLIN LAKES, N.J. , Dec. 29, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has completed the acquisition of C. R. Bard, Inc. (NYSE: BCR ), creating a new health care industry leader with ap
Read more →BDXBD Statement On MOFCOM Clearance Of Bard Acquisition BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's...
FRANKLIN LAKES, N.J. , Dec. 28, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, issued the following statement regarding today's clearance by the Ministry of Commerce of the People's Republic of China (MOFCOM) for
Read more →BDXBD Announces Extension of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, in connection with its previously announced offers to exchange (the Exchange...
FRANKLIN LAKES, N.J. , Dec. 28, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that, in connection with its previously announced offers to exchange (the "Exchange Offers") any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 a
Read more →BDXBD Statement On FTC Clearance Of Bard Acquisition BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's...
FRANKLIN LAKES, N.J. , Dec. 22, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, issued the following statement regarding today's clearance by the U.S. Federal Trade Commission (FTC) for BD to acquire C. R. Bard (N
Read more →BDXBD Establishes Product Security Partnership Program to Enhance Cybersecurity of Medical Technology BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has established a Product Security...
FRANKLIN LAKES, N.J. , Dec. 11, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has established a Product Security Partnership Program that emphasizes collaboration across the health care indust
Read more →BDXBD Announces New Offerings to Help Customers Deliver Safer, Simpler and Smarter Medication Management BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today revealed several technology innovations to further ...
ORLANDO, Fla. , Dec. 4, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today revealed several technology innovations to further optimize the entire medication management process at this year's American Society of
Read more →BDXBD Board Increases Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.75 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 20, 2017 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.75 cents per common share, an increase of 2.7 percent from the previous quarter. The dividend will be payable on
Read more →BDXBD Statement On Merit Medical Agreement To Purchase BD, Bard Product Lines BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's...
FRANKLIN LAKES, N.J. , Nov. 16, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, issued the following statement regarding today's announcement by Merit Medical Systems, Inc. that it has signed a definitive agreemen
Read more →BDXBD to Introduce Integrated Medication Management Platform Designed to Address Hospitals' Greatest Challenges at #ASHP17 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive...
FRANKLIN LAKES, N.J. , Nov. 16, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication managem
Read more →BDXBD Announces Results For 2017 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2018 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.166 billion for...
FRANKLIN LAKES, N.J. , Nov. 2, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $3.166 billion for the fourth fiscal quarter ended September 30, 2017. This represents a decrease
Read more →BDXBD Breaks Ground on $60 Million Expansion of Nebraska Manufacturing Facility BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state...
COLUMBUS, Neb. , Oct. 25, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to break ground on a $60 million upgrade of its Columbus-East faci
Read more →BDXBD Statement On European Commission Conditional Clearance Of Bard Acquisition BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, issued the following statement regarding today's...
FRANKLIN LAKES, N.J. , Oct. 18, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, issued the following statement regarding today's clearance by the European Commission for BD to acquire C.R. Bard (NYSE: BCR ), conti
Read more →BDXBD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year...
FRANKLIN LAKES, N.J. , Oct. 5, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2017 earnings conference call on Thursday, November 2, 2017 , at 8:00 a.m. (ET
Read more →BDXBD Expands Efforts to Combat Antimicrobial Resistance with New Diagnostic Test in Europe BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated...
FRANKLIN LAKES, N.J. , Sept. 26, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch 1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO).
Read more →BDXBD and Euroclone Announce Development and Global Distribution Agreement for Tests to Detect Emerging Sexually-Transmitted Pathogens BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Euroclone (Euroclone Diagnostica Srl) today...
FRANKLIN LAKES, N.J. and SIZIANO, Italy , Sept. 20, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Euroclone (Euroclone Diagnostica Srl) today announced a development and global distribution agreement for mol
Read more →BDXBD Introduces New 6mm Pen Needle for Injection Pens BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the BD Ultra-Fine™...
FRANLIN LAKES, N.J., Sept. 19, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the introduction of the BD Ultra-Fine™ micro pen needle 6mm x 32G for use with leading pen injection devices, that is
Read more →BDXBD Expands Genomics Portfolio with New Single Cell Platform for RNA Expression Analysis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform...
FRANKLIN LAKES, N.J. , Sept. 12, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of BD Rhapsody, a platform for single cell analysis with the ability to detect rare molecules responsible
Read more →BDXBD to Present at the Morgan Stanley Global Healthcare Conference 2017 BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Morgan...
FRANKLIN LAKES, N.J. , Sept. 8, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2017 on Tuesday, September 12, 2017 , at 9:10
Read more →BDXBard Shareholders Approve Proposed Merger With Becton, Dickinson C. R. Bard, Inc. (NYSE: BCR) ( Bard ) and Becton, Dickinson and Company (NYSE: BDX) ( BD ) today announced the results of Bard's special meeting of...
MURRAY HILL, N.J. and FRANKLIN LAKES, N.J. , Aug. 8, 2017 /PRNewswire/ -- C. R. Bard, Inc. (NYSE: BCR ) ("Bard") and Becton, Dickinson and Company (NYSE: BDX ) ("BD") today announced the results of Bard's special meeting of shareholders, held on August 8, 2017 and at which a quor
Read more →BDXBD Announces Results For 2017 Third Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $3.035 billion for...
FRANKLIN LAKES, N.J. , Aug. 3, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $3.035 billion for the third fiscal quarter ended June 30, 2017. This represents a decrease of 5.
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 73 cents per common share, payable on...
FRANKLIN LAKES, N.J. , July 25, 2017 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 73 cents per common share, payable on September 29, 2017 to holders of record on September 8 , 2017. The indicated a
Read more →BDXBD Receives FDA 510(k) Clearance for New Immunological Diagnostic System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received 510(k) clearance...
FRANKLIN LAKES, N.J. , July 19, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD FACSLyric™ flow cyt
Read more →BDXBD Transforms Microbiology Urine Testing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced new technology that can automatically...
FRANKLIN LAKES, N.J. , July 18, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced new technology that can automatically report and release negative urine cultures. Every day, medical laboratory prof
Read more →BDXBD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2017 earnings...
FRANKLIN LAKES, N.J. , July 6, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2017 earnings conference call on Thursday, August 3, 2017 , at 8:00 a.m. (ET) . BD will issue a pres
Read more →BDXBD Receives FDA 510(k) Clearance for New Line of Customizable, 3.0mm Micro-Laparoscopic Instruments BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its new line of Snowden-Pencer™...
FRANKLIN LAKES, N.J. , June 20, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that its new line of Snowden-Pencer ™ 3.0mm laparoscopic ergonomic take-apart instruments received U.S. Food and Drug
Read more →BDXBD and Bard Receive Second Requests from FTC under HSR Act BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology...
FRANKLIN LAKES, N.J. , and MURRAY HILL, N.J. , June 9, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR ), a medical technology leader in the fields of vascular, urology, oncology an
Read more →BDXBD Receives FDA 510(K) Clearance for Molecular Test for Harmful Intestinal Bacteria Causing Infectious Diarrhea BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its newly developed molecular test...
FRANKLIN LAKES, N.J. , June 5, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that its newly developed molecular test for detecting harmful intestinal bacteria causing infectious diarrhea has rece
Read more →BDXBD Announces Results of Early Tenders and Amendments to Exchange Offers BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, in connection with its previously announced offers to exchange (the Exchange...
FRANKLIN LAKES, N.J. , May 19, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that, in connection with its previously announced offers to exchange (the "Exchange Offers") any and all outstanding 4.400% Notes due 2021, 3.000% Notes due 2026 an
Read more →BDXBD Announces Exercise of Option to Purchase Additional Shares by Underwriters of Public Equity Offerings Increasing Total Gross Proceeds to $4.95 Billion BD (Becton, Dickinson and Company) (NYSE:BDX) announced today the underwriters in its previously announced registered offerings of $2.25 billion of...
FRANKLIN LAKES, N.J. , May 12, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today the underwriters in its previously announced registered offerings of $2.25 billion of common stock, par value $1.00 per share, and $2.25 billion of depositary share
Read more →BDXBD Prices Offerings of $2.25 Billion of Common Stock and $2.25 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it has priced its previously announced registered offerings of $2.25 billion of...
FRANKLIN LAKES, N.J. , May 10, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it has priced its previously announced registered offerings of $2.25 billion of common stock, par value $1.00 per share, at a public offering price of $176.50
Read more →BDXBD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and UniteOR, Inc., announced today the integration...
FRANKLIN LAKES, N.J. , May 9, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company and UniteOR, Inc., announced today the integration between BD's IMPRESS™ instrument management system and UniteOR's cloud-based surgical
Read more →BDXBD Announces Offerings of $2.25 Billion of Common Stock and $2.25 Billion of Depositary Shares Representing Interests in Mandatory Convertible Preferred Stock BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it has commenced registered offerings of $2.25 billion of common stock, par value...
FRANKLIN LAKES, N.J. , May 7, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it has commenced registered offerings of $2.25 billion of common stock, par value $1.00 per share, and $2.25 billion of depositary shares, each representing a 1
Read more →BDXBD Announces Commencement of Exchange Offers and Consent Solicitations for C. R. Bard, Inc. Notes BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that, in connection with BD's previously announced acquisition of C. R. Bard, Inc....
FRANKLIN LAKES, N.J. , May 5, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that, in connection with BD's previously announced acquisition of C. R. Bard, Inc. ("Bard"), BD has commenced offers to exchange (each an "Exchange Offer" and collec
Read more →BDXBD Announces Results For 2017 Second Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.969 billion for...
FRANKLIN LAKES, N.J. , May 2, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.969 billion for the second fiscal quarter ended March 31, 2017. This represents a decrease of 3
Read more →BDXBD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global distribution of a complete...
FRANKLIN LAKES, N.J. , April 27, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the global distribution of a complete portfolio of products for mass spectrometry that provides high-speed and high-
Read more →BDXBD Licenses Novel Molecular Indexing Technology to Roche BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has non-exclusively licensed its ...
FRANKLIN LAKES, N.J. , April 26, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has non-exclusively licensed its patented stochastic labelling technology to Roche for multiple commercial a
Read more →BDXBD Announces Appointment Of Tom Polen As President BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as...
FRANKLIN LAKES, N.J. , April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the appointment of Tom Polen , 43, as president of BD, effective immediately. In his new role, Mr. Polen will overse
Read more →BDXBD To Acquire Bard For $24 Billion BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology...
FRANKLIN LAKES, N.J. and MURRAY HILL, N.J. , April 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR ), a medical technology leader in the fields of vascular, urology, oncology an
Read more →BDXBD Receives FDA 510(k) Clearance for New Flow Cytometer System with Leucocount Reagent Assay BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received 510(k) clearance from...
FRANKLIN LAKES, N.J. , April 6, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a flow cytometer system with a
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2017 earnings...
FRANKLIN LAKES, N.J. , April 4, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2017 earnings conference call on Thursday, May 4, 2017 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD Launches Power in Prevention Program to Help Minimize Risk of Infections during Surgical Process at 2017 AORN Annual Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its quality improvement program, BD Power...
BOSTON , April 3, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, will launch its quality improvement program, BD "Power in Prevention" at the Association of periOperative Registered Nurses (AORN) annual conferenc
Read more →BDXPyxis™ ES System to Help U.S. Department of Defense Advance Medication Safety and Patient Care
BD (Becton, Dickinson and Company) has secured a contract with the U.S. Department of Defense worth up to $100 million to implement its Pyxis ES System across 115 military health facilities. This initiative aims to modernize medication management and enhance patient care. The system will enable remote medication management and improve workflow for healthcare professionals.
Read more →BDXBD To Present At Inaugural CECP CEO Investor Forum BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the inaugural...
FRANKLIN LAKES, N.J. , Feb. 22, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the inaugural CEO Investor Forum hosted by CECP: The CEO Force for Good on Monday, February 2
Read more →BDXBD Veritor™ System Meets FDA's New Performance Requirements for Rapid Influenza Antigen Detection Tests Effective Feb. 13, 2017, the Food and Drug Administration (FDA) has reclassified antigen based rapid influenza virus antigen detection systems...
FRANKLIN LAKES, N.J. , Feb. 22, 2017 /PRNewswire/ -- Effective Feb. 13, 2017 , the Food and Drug Administration (FDA) has reclassified antigen based rapid influenza virus antigen detection systems (RIDTs) intended to detect influenza virus directly from clinical specimens from Cl
Read more →BDXBD Partnership Honored by U.S. Chamber of Commerce Foundation at the Health Means Business National Summit with Healthy10 Award A partnership among BD (Becton Dickinson and Company) (NYSE: BDX), Direct Relief and the National Association of Community Health Centers was...
WASHINGTON , Feb. 21, 2017 /PRNewswire/ -- A partnership among BD ( Becton Dickinson and Company) (NYSE: BDX ), Direct Relief and the National Association of Community Health Centers was selected as one of three winners for the Healthy10 Healthy Community award. The BD Helping Bu
Read more →BDXBD Demonstrates Synchronized Technology Platform at HIMSS17 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will demonstrate its approach to a synchronized...
ORLANDO, Fla., Feb. 20, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, will demonstrate its approach to a synchronized medication management technology platform aimed to help close the communication gaps between
Read more →BDXBD Initiates New Industry Alliance To Combat Rising Opioid Crisis BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new alliance dedicated to help address ...
FRANKLIN LAKES, N.J. , Feb. 16, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a new alliance dedicated to help address the rising opioid crisis in acute care settings. Comprised of top health sy
Read more →BDXBD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an early access program for the BD...
FRANKLIN LAKES, N.J. , Feb. 13, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced an early access program for the BD Resolve™ Single-Cell Gene Expression platform that has the flexibility to capture
Read more →BDXBD Announces Results For 2017 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.922 billion for...
FRANKLIN LAKES, N.J. , Feb. 2, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.922 billion for the first fiscal quarter ended December 31 , 2016. This represents a decrease
Read more →BDXNew BD Institute For Medication Management Excellence Aims To Improve Patient Safety And Outcomes Through Collaboration BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its new BD Institute for...
FRANKLIN LAKES, N.J. , Jan. 26, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of its new BD Institute for Medication Management Excellence, developed to help advance the safe and effic
Read more →BDXPleurX™ Catheter System Receives FDA 510(k) Clearance for Specific Non-Malignant Recurrent Pleural Effusions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its PleurX™ catheter system received U.S....
FRANKLIN LAKES, N.J. , Jan. 23, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its PleurX™ catheter system received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use in specific
Read more →BDXBD Announces Webcast of Annual Meeting of Shareholders BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company, announced today that it will host a live webcast of its Annual...
FRANKLIN LAKES, N.J. , Jan. 18, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 24, 2017 , at 1 p.m. (ET) . The w
Read more →BDXBD Launches Reagents to Simplify Single Cell Research BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the commercial availability of its new...
FRANKLIN LAKES, N.J. , Jan. 17, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the commercial availability of its new kits that provide an easier method to identify and quantify genetic informatio
Read more →BDXBD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2017 earnings...
FRANKLIN LAKES, N.J. , Jan. 11, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2017 earnings conference call on Thursday, February 2, 2017 , at 8:00 a.m. (ET) . BD will issue a p
Read more →BDXBD to Present at the 35th Annual J. P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the 35th Annual J....
FRANKLIN LAKES, N.J. , Jan. 9, 2017 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 35th Annual J. P. Morgan Healthcare Conference on Wednesday, January 11, 2017 , at 11:30 a
Read more →BDXBD Launches Advanced Prefillable Syringe for Higher Volume Injection of Biologics BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD Neopak™ 2.25 mL...
FRANKLIN LAKES, N.J. , Dec. 15, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of the BD Neopak™ 2.25 mL prefillable glass syringe, specifically designed for biopharmaceutical manufactu
Read more →BDXBD Announces Adoption of Windows 10 'Internet of Things' for the Pyxis™ ES System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced adoption of Windows 10 Internet of...
FRANKLIN LAKES, N.J. , Dec. 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced adoption of Windows 10 Internet of Things (IoT) operating system (OS) for its enterprise-wide Pyxis™ ES System. The ne
Read more →BDXBD to Offer Euro-denominated Senior Unsecured Notes BD (Becton, Dickinson and Company) (NYSE: BDX) announced today its intention to offer senior unsecured notes under a shelf registration statement on...
FRANKLIN LAKES, N.J. , Dec. 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today its intention to offer senior unsecured notes under a shelf registration statement on Form S-3 (File No. 333-206020) on file with the Securities and Exchange Commis
Read more →BDXBD Announces Pricing of Tender Offers BD (Becton, Dickinson and Company) (NYSE: BDX) (the Company ) today announced the consideration payable in connection with its previously announced...
FRANKLIN LAKES, N.J. , Dec. 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) (the " Company ") today announced the consideration payable in connection with its previously announced tender offers to purchase for cash (i) any and all of the Company's 1.450% s
Read more →BDXBD Announces Early Tender Results and Upsizing of Maximum Tender Offers BD (Becton, Dickinson and Company) (NYSE: BDX) (the Company ) today announced the early tender results for its previously announced tender offers to ...
FRANKLIN LAKES, N.J. , Dec. 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) (the " Company ") today announced the early tender results for its previously announced tender offers to purchase for cash (i) any and all of the Company's 1.450% senior notes due
Read more →BDXBD to Present at the 28th Annual Piper Jaffray Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 28th Annual...
FRANKLIN LAKES, N.J. , Nov. 23, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 28 th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016 , at 9:30
Read more →BDXBD Board Increases Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.73 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 21, 2016 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.73 cents per common share, an increase of 10.6 percent from the previous quarter. The dividend will be payable on
Read more →BDXBecton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities Becton, Dickinson and Company (NYSE: BDX) (the Company or BD ) today announced that it has commenced tender offers to purchase for cash the debt...
FRANKLIN LAKES, N.J. , Nov. 16, 2016 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) (the " Company " or " BD ") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the tables below (collectively,
Read more →BDXBD Announces 2016 Analyst Day And Webcast BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will host an institutional investor and analyst meeting on Thursday, November...
FRANKLIN LAKES, N.J. , Nov. 14, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will host an institutional investor and analyst meeting on Thursday, November 17, 2016 in New York City from 8:30 a.m. – 3:30 p.m. (ET) . The meeting will
Read more →BDXBD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company today announced a new research collaboration supported by ...
FRANKLIN LAKES, N.J. , Nov. 10, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company today announced a new research collaboration supported by JDRF, the leading global organization funding type 1 diabetes (T1D) research
Read more →BDXBD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company announced today the launch of the BD™ U-500 Insulin...
FRANKLIN LAKES, N.J. , Nov. 8, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company announced today the launch of the BD™ U-500 Insulin Syringe, the first insulin syringe developed for people with diabetes taking Humuli
Read more →BDXBD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.231 billion, as ...
FRANKLIN LAKES, N.J. , Nov. 3, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced quarterly revenues of $3.231 billion , as reported, for the fourth fiscal quarter ended September 30, 2016 , an increa
Read more →BDXBD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA)...
FRANKLIN LAKES, N.J. , Oct. 31, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) market authorization for a first-of-its-kind molecular test to detect the mos
Read more →BDXBD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Apax Partners, today announced the launch of a joint ...
FRANKLIN LAKES, N.J. , LONDON , and CHICAGO , Oct. 4, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Apax Partners, today announced the launch of a joint venture – Vyaire Medical – a standalone, global respir
Read more →BDXBD Announces Live Webcast of Fourth Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year...
FRANKLIN LAKES, N.J. , Oct. 4, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2016 earnings conference call on Thursday, November 3, 2016 , at 8:00 a.m. (ET
Read more →BDXBD Expands Efforts To Combat Antimicrobial Resistance With New Automated ID/AST System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its next generation...
FRANKLIN LAKES, N.J. , Sept. 30, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of its next generation diagnostic instrument for the rapid identification of bacteria and detection of an
Read more →BDXBD Receives FDA 510(k) Clearance for Innovative Next Generation Blood Collection and Separation Technology Designed to Improve Laboratory Efficiency BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it received U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , Sept. 29, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, announced today that it received U.S. Food and Drug Administration (FDA) 510(k) clearance for the BD Vacutainer ® Barricor™ plasma blood collecti
Read more →BDXBD Invests $100 Million In Nebraska Plant To Expand Insulin Syringe Manufacturing BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it is investing $100 million in its...
FRANKLIN LAKES, N.J. , Sept. 22, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it is investing $100 million in its Holdrege, Neb. facility to expand capacity for its insulin syringe manufacturing
Read more →BDXBD Unveils Next Generation Wireless Point-of-Care Diagnostic Device BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of its next generation...
FRANKLIN LAKES, N.J. , Sept. 21, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory s
Read more →BDXBD and Vancive Medical Technologies Launch New Vascular Dressings with CHG Antimicrobial BD (Becton, Dickinson and Company) (NYSE: BDX) and Vancive Medical Technologies™, an Avery Dennison (NYSE: AVY) business, today launched a line of...
FRANKLIN LAKES, N.J. , Sept. 16, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) and Vancive Medical Technologies™, an Avery Dennison (NYSE: AVY ) business, today launched a line of transparent vascular dressings with chlorhexidine gluconate (CHG) antimicrobi
Read more →BDXBD Expands Portfolio of Reproductive and Sexually Transmitted Infections Solutions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it obtained U.S. Food and Drug...
FRANKLIN LAKES, N.J. , Sept. 14, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it obtained U.S. Food and Drug Administration (FDA) clearance for the BD MAX™ CT/GC/TV assay, which is also CE
Read more →BDXBD Announces New Software Release For Pyxis Enterprise Solution BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced general availability of the latest...
FRANKLIN LAKES, N.J. , Sept. 12, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced general availability of the latest software release of Pyxis™ ES System, delivering patient safety and workflow bene
Read more →BDXBD Submits Pre-Market Approval Application to FDA for BD Onclarity™ HPV Test BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has submitted a pre-market...
FRANKLIN LAKES, N.J. , Sept. 6, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has submitted a pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the
Read more →BDXBD to Present at the Morgan Stanley Global Healthcare Conference 2016 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan...
FRANKLIN LAKES, N.J. , Sept. 6, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2016 on Tuesday, September 13, 2016 , at 10:3
Read more →BDXMayo Clinic Proceedings Publishes New Insulin Injection and Infusion Recommendations The prestigious medical journal, Mayo Clinic Proceedings, today published new insulin delivery recommendations for health care professionals caring...
FRANKLIN LAKES, N.J. , Sept. 1, 2016 /PRNewswire/ -- The prestigious medical journal, Mayo Clinic Proceedings , today published new insulin delivery recommendations for health care professionals caring for insulin-using patients, including the results from the largest injection t
Read more →BDXBD Celebrates 60 Years In Sandy, Utah BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined by senior public officials today to celebrate ...
SANDY, Utah , Aug. 18, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, was joined by senior public officials today to celebrate the 60th anniversary of its manufacturing facility in Sandy, Utah . BD also announced
Read more →BDXBD Cited As Infusion Pump EMR Integration Leader In KLAS Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its Alaris™ System infusion...
FRANKLIN LAKES, N.J. , Aug. 16, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that its Alaris™ System infusion platform was cited as having the most customers live with bidirectional electronic m
Read more →BDXBD Announces Results For 2016 Third Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced quarterly revenues of $3.198 billion, as ...
FRANKLIN LAKES, N.J. , Aug. 4, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced quarterly revenues of $3.198 billion , as reported, for the third fiscal quarter ended June 30, 2016 , an increase of
Read more →BDXBD Names R. Andrew Eckert To Board Of Directors BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that R. Andrew Andy Eckert has been...
FRANKLIN LAKES, N.J. , July 28, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that R. Andrew "Andy" Eckert has been appointed to the company's Board of Directors, effective Sept. 26 , bringing th
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 66 cents per common share, payable on...
FRANKLIN LAKES, N.J. , July 26, 2016 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 66 cents per common share, payable on September 30, 2016 to holders of record on September 9 , 2016. The indicated a
Read more →BDXBD Hits Century Mark With Infusion Pump Interoperability BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that more than 100 hospitals and health...
FRANKLIN LAKES, N.J. , July 19, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that more than 100 hospitals and health systems have implemented the company's electronic medical record (EMR) intero
Read more →BDXBD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2016 earnings...
FRANKLIN LAKES, N.J. , July 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2016 earnings conference call on Thursday, August 4, 2016 , at 8:00 a.m. (ET) . BD will issue a pres
Read more →BDXBD and Check-Points Announce Development and Global Distribution Agreement for BD MAX™ Assays that Detect Carbapenem-resistant Organisms BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a development and global distribution...
FRANKLIN LAKES, N.J. , and WAGENINGEN, The Netherlands , June 16, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a development and global distribution agreement with Check-Points for BD MAX™ assay
Read more →BDXBD Expands its Portfolio of Easy-to-Use Cell Sorters with Introduction of BD FACSMelody™ System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, continues to reinforce its commitment to making flow...
FRANKLIN LAKES, N.J. , May 26, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, continues to reinforce its commitment to making flow cytometry easier and more affordable with the introduction of its newest cell sor
Read more →BDXBD Expands Reproductive and Sexually Transmitted Infections Portfolio with CE Mark for the BD MAX™ Vaginal Panel BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it obtained CE mark for the BD MAX™ ...
FRANKLIN LAKES, N.J. , May 13, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it obtained CE mark for the BD MAX™ Vaginal Panel. The new in vitro diagnostic (IVD) assay will provide laborator
Read more →BDXBD Announces Results For 2016 Second Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly adjusted revenues of $3.071...
FRANKLIN LAKES, N.J. , May 5, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly adjusted revenues of $3.071 billion for the second fiscal quarter ended March 31, 2016 , an increase of 49.7 p
Read more →BDXBD to Present at the Bank of America Merrill Lynch 2016 Health Care Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Bank of...
FRANKLIN LAKES, N.J. , May 4, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 , at 1
Read more →BDXBD Extends Longstanding Expertise in Diabetes Management to Benefit Pets BD (Becton, Dickinson and Company), a leading medical technology company, announced today that it has launched BD Pet Syringes – veterinary insulin...
FRANKLIN LAKES, N.J. , April 26, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading medical technology company, announced today that it has launched BD Pet Syringes – veterinary insulin syringes for use with U-40 insulins that are administered to dogs and cats wit
Read more →BDXBD Introduces New Low-Temperature Sterilization Containers BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a new line of surgical instrument...
FRANKLIN LAKES, N.J. , April 22, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a new line of surgical instrument sterilization containers that are validated for the latest low-temperature sterili
Read more →BDXBD Divests Vertebral Augmentation Solutions Business to Stryker BD (Becton, Dickinson and Company) (NYSE: BDX), a leading medical technology company, announced today that it has sold its vertebral augmentation...
FRANKLIN LAKES, N.J. , April 21, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading medical technology company, announced today that it has sold its vertebral augmentation solutions business, which includes all AVAmax®, AVAflex®, AVAtex® and AVAprep®
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2016 earnings...
FRANKLIN LAKES, N.J. , April 1, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2016 earnings conference call on Thursday, May 5, 2016 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXMedMined® Surveillance Advisor Wins 2015/2016 KLAS Category Leader Award BD (Becton, Dickinson and Company) (NYSE: BDX), a leading medical technology company, announced today that BD MedMined® Surveillance Advisor has been ...
FRANKLIN LAKES, N.J. , March 15, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading medical technology company, announced today that BD MedMined ® Surveillance Advisor has been named a 2015/2016 Category Leader for Infection Control and Monitoring in
Read more →BDXBD, Apax Partners to Form Joint Venture for Respiratory Solutions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a definitive agreement to sell 50.1...
FRANKLIN LAKES, N.J. AND LONDON , March 8, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a definitive agreement to sell 50.1 percent of its Respiratory Solutions business to funds advised by Apax
Read more →BDXBD Receives FDA Approval for New Automated Cervical Cancer Screening System BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has received U.S. Food and Drug...
FRANKLIN LAKES, N.J. , March 7, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) approval for its BD Totalys™ MultiProcessor and BD Totalys™ S
Read more →BDXAlaris® System Named 2015 Best In KLAS for Smart Pumps BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the Alaris® System has been named...
FRANKLIN LAKES, N.J. , Feb. 24, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the Alaris ® System has been named 2015 Best in KLAS for Smart Pumps in the 2015 Best in KLAS: Medical Equipment
Read more →BDXBD Receives FDA 510(k) Clearance for New Blood Collection Device to Help Enhance Patient and Clinician Experience BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the U.S. Food and Drug Administration...
FRANKLIN LAKES, N.J. , Feb. 17, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and European CE marking for a new safety blood collectio
Read more →BDXBD Unveils New Next Generation Sequencing Library Prep System at the 2016 Advances in Genome Biology and Technology Meeting BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD CLiC™ System during ...
FRANKLIN LAKES, N.J. , Feb. 12, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of the BD CLiC™ System during the 2016 Advances in Genome Biology and Technology (AGBT) Meeting. The BD C
Read more →BDXBD Launches BD FACSymphony™ High-Speed Cell Analyzer to Enable Identification and Analysis of Rare Cell Types BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSymphony™...
FRANKLIN LAKES, N.J. , Feb. 8, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of the BD FACSymphony™ system, a novel cell analyzer enabling the simultaneous measurement of up to 50 diff
Read more →BDXBD Announces Results For 2016 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly adjusted revenues of $2.992...
FRANKLIN LAKES, N.J. , Feb. 3, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly adjusted revenues of $2.992 billion for the first fiscal quarter ended December 31, 2015 , an increase of 45.
Read more →BDXBD Divests BD Rx Business, Adding IV Solutions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Fresenius Kabi USA has acquired the ...
FRANKLIN LAKES, N.J. , Jan. 8, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that Fresenius Kabi USA has acquired the BD Rx business, which includes a pharmaceutical manufacturing plant in Wilson
Read more →BDXBD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2016 earnings...
FRANKLIN LAKES, N.J. , Jan. 7, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2016 earnings conference call on Wednesday, February 3, 2016 , at 8:00 a.m. (ET) . BD will issue a p
Read more →BDXBD to Present at the 34th Annual J. P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 34th Annual...
FRANKLIN LAKES, N.J. , Jan. 4, 2016 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 34th Annual J. P. Morgan Healthcare Conference on Wednesday, January 13, 2016 , at 12:00 p
Read more →BDXBD Unveils New BD FACSCelesta™ Flow Cytometer During the 2015 American Society for Cell Biology Annual Meeting BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch of the BD FACSCelesta™ flow...
SAN JOSE, Calif. , Dec. 12, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of the BD FACSCelesta™ flow cytometer during the 2015 American Society for Cell Biology (ASCB) annual meeting.
Read more →BDXBD Introduces Simplified Comprehensive IV Management BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today introduced a simplified way for hospitals to...
FRANKLIN LAKES, N.J. , Dec. 7, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today introduced a simplified way for hospitals to manage intravenous (IV) medication to help improve safety and reduce waste. Nation
Read more →BDXBD Showcases Expanded Portfolio to Support Enterprise Medication Management at the ASHP 2015 Midyear Meeting BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company and CareFusion, a BD company, will present its combined,...
FRANKLIN LAKES, N.J. , Dec. 2, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company and CareFusion, a BD company, will present its combined, strengthened solutions together as one company, at the 50 th Annual American S
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.66 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 23, 2015 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.66 cents per common share, an increase of 10.0 percent from the previous quarter. The dividend will be payable on
Read more →BDXBD to Present at the Stifel 2015 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Stifel 2015...
FRANKLIN LAKES, N.J. , Nov. 12, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Stifel 2015 Healthcare Conference Tuesday, November 17, 2015 at 9:30 a.m. EST. A live we
Read more →BDXBD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly adjusted revenues of $3.067...
FRANKLIN LAKES, N.J. , Nov. 4, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly adjusted revenues of $3.067 billion for the fourth fiscal quarter ended September 30, 2015 , an increase of 3
Read more →BDXBD Launches the BD FACSseq™ Cell Sorter with BD™ Precise Assays for High Precision Single Cell Genomics BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today launched its first...
BALTIMORE and SAN JOSE, Calif. , Oct. 6, 2015 /PRNewswire/ -- BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX ), today launched its first dedicated product specifically for single cell genomics applications wi
Read more →BDXBD Celebrates National Health Information Technology (NHIT) Week BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its participation in National Health...
FRANKLIN LAKES, N.J. , Oct. 5, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its participation in National Health Information Technology (NHIT) Week. During the week of Oct. 5-9 , BD will join h
Read more →BDXBD MAX™ Enteric Parasite Panel Receives FDA Clearance for Detection of Common and Pathogenic Intestinal Parasites BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the availability of...
SPARKS, Md. , Sept. 24, 2015 /PRNewswire/ -- BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX ), today announced the availability of the U.S. Food and Drug Administration (FDA) cleared BD MAX™ Enteric Parasite Panel fo
Read more →BDXBD to Present at the Morgan Stanley Global Healthcare Conference 2015 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan...
FRANKLIN LAKES, N.J. , Sept. 11, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference 2015 on Thursday, September 17, 2015 , at 10
Read more →BDXBD to Acquire Cellular Research to Develop a Leading Genomics Platform for Single Cell Analysis BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), today announced it has...
FRANKLIN LAKES, N.J. , Aug. 25, 2015 /PRNewswire/ -- BD Life Sciences, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX ), today announced it has completed the acquisition of Cellular Research, Inc. BD is a global leader in cha
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 60 cents per common share, payable on...
FRANKLIN LAKES, N.J. , July 28, 2015 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 60 cents per common share, payable on September 30, 2015 to holders of record on September 9 , 2015. The indicated a
Read more →BDXBD Opens Advance Diabetes Care Headquarters in Andover, Mass. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, officially opened its Advanced Diabetes Care facility in ...
ANDOVER, Mass. , July 15, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, officially opened its Advanced Diabetes Care facility in Andover, Mass. , which will house research and development (R&D) and manufacturing
Read more →BDXBD Announces Sustainability Goals for 2020 BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today an updated sustainability strategy and...
FRANKLIN LAKES, N.J. , July 13, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today an updated sustainability strategy and goals for 2020 as part of the release of its 2014 Sustainability Report. The
Read more →BDXDe nouvelles données cliniques indiquent que le cathéter de perfusion équipé de la technologie FlowSmart™ de BD peut améliorer le débit d'insuline et réduire les occlusions silencieuses BD Medical, division de l'entreprise mondiale leader en technologie médicale, BD (Becton, Dickinson and Company) (NYSE : BDX), a publié ses...
-- Des études présentées lors des 75èmes sessions scientifiques de l'Association américaine du diabète mettent en avant les avantages potentiels d'uncathéter de perfusion breveté dont la canule est équipée d'une voie latérale supplémentaire BOSTON , 10 juillet 2015 /PRNewswire/
Read more →BDXLos nuevos datos clínicos sugieren que el set de infusión con tecnología BD FlowSmart™ podría mejorar el flujo de insulina BD Medical, un segmento de BD (Becton, Dickinson, and Company) (NYSE: BDX), destacada compañía global de tecnología médica, ha publicado su...
- Los nuevos datos clínicos sugieren que el set de infusión con tecnología BD FlowSmart™ podría mejorar el flujo de insulina y reducir las oclusiones silenciosas -- Los estudios presentados en la 75a sesión científica de la American Diabetes Association demuestran los beneficios
Read more →BDXNeue klinische Daten weisen auf mögliche Verbesserung von Insulinfluss und Reduzierung unbemerkter Verstopfungen ( Silent Occlusion ) durch Infusions-Set mit BD FlowSmart™-Technologie hin BD Medical, ein Segment des weltweit führenden Medizintechnologie-Unternehmens BD (Becton, Dickinson and Company) (NYSE: BDX), hat...
-- Im Rahmen der 75. Scientific Sessions der American Diabetes Association präsentierte Studien zeigen potenzielle Vorteile des proprietären Katheters mit seitlichem "Schlupfloch" BOSTON , 10. Juli 2015 /PRNewswire/ -- BD Medical, ein Segment des weltweit führenden Medizintechno
Read more →BDXBD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2015 earnings...
FRANKLIN LAKES, N.J. , July 1, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2015 earnings conference call on Thursday, August 6, 2015 , at 8:00 a.m. (ET) . BD will issue a pres
Read more →BDXNew Study Shows Higher Rates of C. difficile Infection in Hospitals that Use Reusable Sharps Containers BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that results...
FRANKLIN LAKES, N.J. , June 27, 2015 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that results from a new independent study of acute care hospitals shows higher rates of C. d
Read more →BDXNew Clinical Data Suggest Infusion Set with BD FlowSmart™ Technology May Improve Insulin Flow and Reduce Silent Occlusions BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), released research on infusion sets ...
Studies Presented at the American Diabetes Association's 75 th Scientific Sessions Demonstrate Potential Benefits of Proprietary Side-Ported Catheter BOSTON , June 6, 2015 /PRNewswire/ -- BD Medical, a segment of leading global medical technology company BD (Becton, Dickinson an
Read more →BDXBD Participates in White House Forum on Antibiotic Stewardship BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its participation in the White House...
FRANKLIN LAKES, N.J. , June 2, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its participation in the White House Forum on Antibiotic Stewardship and outlined multiple steps the company will take
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 60.0 cents per common share payable on...
FRANKLIN LAKES, N.J. , May 19, 2015 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 60.0 cents per common share payable on June 30, 2015 to holders of record on June 9, 2015 . The indicated annual divi
Read more →BDXBD Announces Results For 2015 Second Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for...
FRANKLIN LAKES, N.J. , May 7, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the second fiscal quarter ended March 31, 2015 , representing a decrease of 1.0
Read more →BDXBD to Present at the Bank of America Merrill Lynch 2015 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Bank of...
FRANKLIN LAKES, N.J. , May 4, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Bank of America Merrill Lynch 2015 Healthcare Conference on Wednesday, May 13, 2015 , at 11
Read more →BDXBecton, Dickinson and Company Announces Final Results of Exchange Offers Becton, Dickinson and Company (NYSE: BDX) ( BD ) announced today the final results of its previously announced offers to exchange all validly...
FRANKLIN LAKES, N.J. , April 23, 2015 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") announced today the final results of its previously announced offers to exchange all validly tendered and accepted notes of each series listed in the table below (collectively,
Read more →BDXBecton, Dickinson and Company Announces Results of Early Tenders and Consents in Exchange Offers Becton, Dickinson and Company (NYSE: BDX) ( BD ) announced today that, as of 5:00 p.m., New York City time, on April 8, 2015 (the Early Consent...
FRANKLIN LAKES, N.J. , April 9, 2015 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") announced today that, as of 5:00 p.m. , New York City time, on April 8, 2015 (the "Early Consent Date"), the aggregate principal amounts listed in the table below of each series
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2015 earnings...
FRANKLIN LAKES, N.J. , April 6, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2015 earnings conference call on Thursday, May 7, 2015 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBecton, Dickinson and Company to Commence Exchange Offers Becton, Dickinson and Company (NYSE: BDX) ( BD ) announced today that it will commence offers to exchange all validly tendered and accepted notes of...
FRANKLIN LAKES, N.J. , March 26, 2015 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") announced today that it will commence offers to exchange all validly tendered and accepted notes of the following series issued by CareFusion Corporation, a wholly owned subsid
Read more →BDXBecton Dickinson Completes Acquisition Of CareFusion Becton, Dickinson and Company (NYSE: BDX) ( BD ) today announced that it completed its acquisition of CareFusion Corporation ( CareFusion ) pursuant...
FRANKLIN LAKES, N.J. , March 17, 2015 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") today announced that it completed its acquisition of CareFusion Corporation ("CareFusion") pursuant to the terms of its previously announced Agreement and Plan of Merger, dated
Read more →BDXEuropean Commission Clears BD Acquisition Of CareFusion Becton, Dickinson and Company (NYSE: BDX) ( BD ) and CareFusion Corporation (NYSE: CFN) ( CareFusion ) announced today that the companies have...
FRANKLIN LAKES, N.J. and SAN DIEGO , March 13, 2015 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") and CareFusion Corporation (NYSE: CFN ) ("CareFusion") announced today that the companies have received clearance from the European Commission under the EU Merger
Read more →BDXBD Acquires CRISI Medical Systems BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the acquisition of CRISI Medical...
FRANKLIN LAKES, N.J. , March 2, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the acquisition of CRISI Medical Systems, a San Diego -based medical technology company dedicated to improving the sa
Read more →BDXBD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing BD Life Sciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Cellular Research, an ...
SAN JOSE, Calif. , Feb. 26, 2015 /PRNewswire/ -- BD Life Sciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Cellular Research, an innovative company focused on enabling high-resolution biology, today announced
Read more →BDXBD Announces Results For 2015 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for...
FRANKLIN LAKES, N.J. , Feb. 5, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the first fiscal quarter ended December 31, 2014 , representing an increase of
Read more →BDXCareFusion Stockholders Approve Proposed Merger With Becton, Dickinson Becton, Dickinson and Company (NYSE: BDX) ( BD ) and CareFusion Corporation (NYSE: CFN) ( CareFusion ) today announced the results of the CareFusion...
FRANKLIN LAKES, N.J. and SAN DIEGO , Jan. 21, 2015 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") and CareFusion Corporation (NYSE: CFN ) ("CareFusion") today announced the results of the CareFusion special meeting of stockholders, held on January 21, 2015 , fo
Read more →BDXBD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2015 earnings...
FRANKLIN LAKES, N.J. , Jan. 8, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2015 earnings conference call on Thursday, February 5, 2015 , at 8:00 a.m. (ET) . BD will issue a pr
Read more →BDXBD to Present at the 33rd Annual J. P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 33rd Annual...
FRANKLIN LAKES, N.J. , Jan. 7, 2015 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 33 rd Annual J. P. Morgan Healthcare Conference on Wednesday, January 14, 2015 , at 12:30
Read more →BDXThe BD™ Intelliport® Medication Management System Receives Clearance from the Food and Drug Administration (FDA) BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the U.S....
FRANKLIN LAKES, N.J. , Jan. 7, 2015 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the BD™ Intelliport® Medication
Read more →BDXBD to Present Total Hospital Pharmacy Solutions at the 2014 American Society of Health-System Pharmacists Midyear Clinical Meeting BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, is presenting its comprehensive ...
FRANKLIN LAKES, N.J. , Dec. 8, 2014 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, is presenting its comprehensive solutions for the hospital pharmacy during the 49th American Society of Healt
Read more →BDXBecton Dickinson and CareFusion Announce Date of Special Meeting in Proposed Merger Becton, Dickinson and Company (NYSE: BDX) ( BD ) and CareFusion Corporation (NYSE: CFN) ( CareFusion ) today announced that CareFusion expects to...
FRANKLIN LAKES, N.J. and SAN DIEGO , Dec. 8, 2014 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") and CareFusion Corporation (NYSE: CFN ) ("CareFusion") today announced that CareFusion expects to hold a special meeting on January 21, 2015 for CareFusion stockhol
Read more →BDXBecton, Dickinson and Company to Offer Senior Unsecured Notes Becton, Dickinson and Company (NYSE: BDX) ( BD ) announced today its intention to offer senior unsecured notes under a shelf registration statement...
FRANKLIN LAKES, N.J. , Dec. 4, 2014 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") announced today its intention to offer senior unsecured notes under a shelf registration statement on Form S-3 (File No. 333-183059) on file with the Securities and Exchange Comm
Read more →BDXBD to Present at the 26th Annual Piper Jaffray Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that the company's presentation at the...
FRANKLIN LAKES, N.J. , Dec. 1, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that the company's presentation at the 26 th Annual Piper Jaffray Healthcare Conference has been rescheduled to Wednes
Read more →BDXBD to Present at the 26th Annual Piper Jaffray Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 26th Annual...
FRANKLIN LAKES, N.J. , Nov. 25, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 26 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014 , at 9:00 a
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of $0.60 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 25, 2014 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of $0.60 cents per common share, an increase of about 10.0 percent from the previous quarter. The dividend will be paya
Read more →BDXBecton Dickinson And CareFusion Announce Expiration Of HSR Act Waiting Period In Proposed Transaction Becton, Dickinson and Company (NYSE: BDX) ( BD ) and CareFusion Corporation (NYSE: CFN) ( CareFusion ) today announced that the waiting period under...
FRANKLIN LAKES, N.J. and SAN DIEGO , Nov. 20, 2014 /PRNewswire/ -- Becton, Dickinson and Company (NYSE: BDX ) ("BD") and CareFusion Corporation (NYSE: CFN ) ("CareFusion") today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as a
Read more →BDXBD to Present at the Stifel 2014 Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Stifel 2014...
FRANKLIN LAKES, N.J. , Nov. 11, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Stifel 2014 Healthcare Conference on Tuesday, November 18 , at 10:20 a.m. ET . A live we
Read more →BDXBD Announces Results For 2014 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2015 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.202 billion for...
FRANKLIN LAKES, N.J. , Nov. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.202 billion for the fourth fiscal quarter ended September 30, 2014 , representing an increase
Read more →BDXBD Acquires GenCell Biosystems BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, ...
FRANKLIN LAKES, N.J. , Oct. 13, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has acquired GenCell Biosystems, a privately-held Irish biotech company that has developed proprietary techno
Read more →BDXBD To Acquire CareFusion For $12.2 Billion BD (NYSE: BDX) and CareFusion (NYSE: CFN) announced today a definitive agreement under which BD will acquire CareFusion for $58.00 per share in cash...
FRANKLIN LAKES, N.J. and SAN DIEGO , Oct. 5, 2014 /PRNewswire/ -- BD (NYSE: BDX ) and CareFusion (NYSE: CFN ) announced today a definitive agreement under which BD will acquire CareFusion for $58.00 per share in cash and stock, or a total of $12.2 billion , to create a global lea
Read more →BDXWorld Health Organization Issues Prequalification of BD FACSPresto™ Near-Patient CD4 Counter System for HIV/AIDS Monitoring BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that the...
SAN JOSE, Calif. , Sept. 23, 2014 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the World Health Organization (WHO) has issued a report prequalifying the BD FACSPrest
Read more →BDXBD to Present at the Morgan Stanley Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Morgan...
FRANKLIN LAKES, N.J. , Sept. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Morgan Stanley Global Healthcare Conference on Monday, September 8, 2014 , at 11:40 a.m.
Read more →BDXBD élargit sa gamme de kits d'extraction sur le système BD MAX™, permettant d'automatiser les tests moléculaires développés par l'utilisateur BD Diagnostics, un segment de BD (Becton, Dickinson and Company), a annoncé aujourd'hui la disponibilité de nouveaux kits d'extraction pour les...
- Les kits d'extraction pour acides nucléiques totaux, ainsi qu'un master mix lyophilisé de RT-PCR et PCR, sont désormais disponibles sur le système BD MAX™ et permettent de standardiser les tests moléculaires développés par l'utilisateur SPARKS, Maryland , 2 septembre 2014 /PRN
Read more →BDXBD amplía la gama de soluciones de sistema abierto con la plataforma completamente automática BD MAX™ BD Diagnostics, un segmento de BD (Becton, Dickinson, and Company) (NYSE: BDX), destacada compañía global de tecnología médica, anunció hoy la...
- Los reactivos para ácidos nucleicos totales ya están disponibles en todo el mundo – Flujo de trabajo más eficiente con los ensayos desarrollados internamente SPARKS, Maryland , 2 de septiembre de 2014 /PRNewswire/ -- BD Diagnostics, un segmento de BD (Becton, Dickinson, and Co
Read more →BDXBD erweitert das Portfolio an Open System -Lösungen auf der voll automatisierten BD MAX™ Plattform BD Diagnostics, ein Unternehmenssegment des weltweit tätigen Medizintechnikunternehmens BD (Becton, Dickinson, and Company) (NYSE: BDX), gab heute...
- Total Nucleic Acid-Reagenzien sind jetzt weltweit erhältlich – vereinfachter Arbeitsfluss für intern entwickelte Assays SPARKS, Maryland , 2. September 2014 /PRNewswire/ -- BD Diagnostics, ein Unternehmenssegment des weltweit tätigen Medizintechnikunternehmens BD (Becton, Dick
Read more →BDXBD - Together with Direct Relief and the National Association of Community Health Centers - Announce Winners of the 2014 BD Helping Build Healthy Communities(SM) Innovations in Care Awards BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company – together with Direct Relief and the National Association ...
FRANKLIN LAKES, N.J. , Aug. 25, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company – together with Direct Relief and the National Association of Community Health Centers (NACHC) – has announced the winners of the 2014
Read more →BDXBD AutoShield™ Duo Pen Needle Now Available through Retail Pharmacies for People with Diabetes BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the retail...
FRANKLIN LAKES, N.J. , Aug. 6, 2014 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the retail pharmacy launch of BD AutoShield™ Duo, the only pen needle with patented dual fron
Read more →BDXBD Expands its Suite of Open System Solutions on the Fully Automated BD MAX™ Platform BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson, and Company) (NYSE: BDX), announced today the...
SPARKS, Md. , Aug. 4, 2014 /PRNewswire/ -- BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson, and Company) (NYSE: BDX ), announced today the availability of the Total Nucleic Acid (TNA) suite of reagents for the BD MAX System. The BD MAX
Read more →BDXBD Announces Results For 2014 Third Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for...
FRANKLIN LAKES, N.J. , July 31, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.157 billion for the third fiscal quarter ended June 30, 2014 , representing an increase of 5.
Read more →BDXNeue Tests für Chlamydien und Gonorrhö auf dem BD Viper™ LT System erhalten CE/IVD-Kennzeichen BD Diagnostics, ein Bereich von BD (Becton, Dickinson and Company), hat heute den Erhalt des CE/IVD-Kennzeichens für den BD ProbeTec™ Chlamydia...
- Tests bringen innovative Lösung zu mikro- und molekularbiologischen Laboren BALTIMORE , 31. Juli 2014 /PRNewswire/ -- BD Diagnostics, ein Bereich von BD (Becton, Dickinson and Company), hat heute den Erhalt des CE/IVD-Kennzeichens für den BD ProbeTec™ Chlamydia trachomatis (CT
Read more →BDXLes nouveaux tests de dépistage de la chlamydiae Trachomatis et de la Neisseria gonorrhée sur le système BD Viper™ LT obtiennent le marquage CE-IVD BD Diagnostics, une division de la société BD (Becton, Dickinson and Company), a annoncé aujourd'hui qu'elle avait obtenu le marquage CE-IVD pour les ...
- Les tests apportent une solution innovante aux laboratoires de microbiologie et de biologie moléculaire BALTIMORE , 29 juillet 2014 /PRNewswire/ -- BD Diagnostics, une division de la société BD (Becton, Dickinson and Company), a annoncé aujourd'hui qu'elle avait obtenu le marq
Read more →BDXNew Chlamydia and Gonorrhea Assays on the BD Viper™ LT System Receive FDA 510k Clearance BD Diagnostics, a segment of BD (Becton, Dickinson and Company), (NYSE: BDX) announced today it has received 510(k) clearance from the U.S. Food and...
BALTIMORE , July 28, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company), (NYSE: BDX ) announced today it has received 510(k) clearance from the U.S. Food and Drug Administration for the BD ProbeTec™ Chlamydia trachomatis (CT) Q x Amplified DNA As
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 54.5 cents per common share payable on...
FRANKLIN LAKES, N.J. , July 22, 2014 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 54.5 cents per common share payable on September 30, 2014 to holders of record on September 9, 2014 . The indicated
Read more →BDXBD Signs Agreement for Installation of the BD Cato™ Workflow Solution in Leading Cancer Center BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced an agreement...
FRANKLIN LAKES, N.J. , June 17, 2014 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced an agreement with The University of Texas MD Anderson Cancer Center for BD Cato™, a system t
Read more →BDXLow-Volume Clinical Laboratories Now Have Access to Advanced Data Management with New Blood Culture Instrument Connectivity BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its launch...
BALTIMORE , June 11, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced its launch of the BD BACTEC™ FX40 Blood Culture System with connectivity to the BD EpiCenter™ Micro
Read more →BDXBD Issues 2013 Sustainability Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the publication of its 2013...
FRANKLIN LAKES, N.J. , June 5, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the publication of its 2013 Sustainability Report. This is BD's sixth annual Sustainability Report, highlighting progr
Read more →BDXBD MAX™ Enteric Parasite Panel zur Identifizierung der verbreitetsten pathogenen Darmparasiten erhält CE-Kennzeichnung BD Diagnostics, ein Segment des weltweit tätigen Medizintechnikunternehmens BD (Becton, Dickinson and Company), gab heute bekannt, dass das...
-- Unterstützt ein umfassendes Screening infektiöser Gastroenteritiden mit dem BD MAX™-System SPARKS, Maryland , 4. Juni 2014 /PRNewswire/ -- BD Diagnostics, ein Segment des weltweit tätigen Medizintechnikunternehmens BD (Becton, Dickinson and Company), gab heute bekannt, dass d
Read more →BDXLe test BD MAX™ Parasites Entériques obtient le marquage CE pour la détection des parasites intestinaux pathogènes et communs BD Diagnostics, un segment de la société internationale BD spécialisée dans les technologies médicales (Becton, Dickinson and Company), a annoncé...
- Ce test vient compléter le panel disponible sur le système BD MAX™ pour un dépistage complet des cas de gastroentérites infectieuses (bactériennes, virales et parasitaires) SPARKS, Maryland , 23 mai 2014 /PRNewswire/ -- BD Diagnostics, un segment de la société internationale B
Read more →BDXEl panel BD MAX™ Enteric Parasite obtiene marcado CE para la detección de parásitos intestinales patógenos más comunes BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), compañía global de tecnología médica, ha anunciado hoy la disponibilidad del panel ...
- Complementa el diagnóstico con el sistema BD MAX™ de la gastroenteritis infecciosa SPARKS, Maryland , 22 de mayo de 2014 /PRNewswire/ -- BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), compañía global de tecnología médica, ha anunciado hoy la disponibilidad
Read more →BDXRoyal Jubilee Hospital, Victoria, Vancouver Island, to Be the First Canadian Hospital to Install the BD Kiestra™ TLA Fully Automated Microbiology Lab System BD (Becton, Dickinson and Company), a leading global medical technology company, today announced an agreement with Island Health to install the BD...
MISSISSAUGA, Ontario , May 20, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, today announced an agreement with Island Health to install the BD Kiestra™ Total Lab Automation (TLA) system. This fully-automated microbiology sys
Read more →BDXLeading Hospital Shares How it Reduced Needlestick Injuries by Nearly 70 Percent An article published in the Spring 2014 issue of the Journal of the Association of Occupational Health Professionals in Healthcare discusses how a...
FRANKLIN LAKES, N.J. , May 13, 2014 /PRNewswire/ -- An article published in the Spring 2014 issue of the Journal of the Association of Occupational Health Professionals in Healthcare discusses how a systematic, data-driven approach and the subsequent adoption of a safety-engineer
Read more →BDXThe BD MAX™ Enteric Bacterial Panel Receives FDA Clearance to Detect the Most Common Causes of Bacterial Gastroenteritis BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today the...
SPARKS, Md. , May 7, 2014 /PRNewswire/ -- BD Diagnostics, a segment of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today the availability of the FDA-cleared BD MAX™ Enteric Bacterial Panel for use on the BD MAX System. The
Read more →BDXBD lanza un nuevo sistema Point-of-Care para los pacientes de VIH / SIDA BD Biosciences, un segment de BD (Becton, Dickinson and Company) (NYSE: BDX) una empresa líder de tecnología médica global, ha anunciado hoy el...
-- Plataforma de análisis de CD4 de fácil uso, diseñada para satisfacer las necesidades de los entornos con recursos limitados SAN JOSE, California, 6 de mayo de 2014 /PRNewswire/ -- BD Biosciences, un segment de BD (Becton, Dickinson and Company) (NYSE: BDX ) una empresa líder
Read more →BDXBD Launches New Point-of-Care System for HIV/AIDS Patients BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch...
SAN JOSE, Calif. , April 24, 2014 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the launch of the BD FACSPresto™ Near Patient CD4 Counter system that provides absolute and
Read more →BDXNouveau test de dépistage des infections à Neisseria gonorrhoeae (GC) intégrant une technologie PCR en temps réel BD Diagnostics, une division de BD (Becton, Dickinson and Company), société internationale de premier plan spécialisée dans les technologies...
-- Le test BD MAX™ de dépistage en temps réel des infections à gonocoque par PCR reçoit le marquage CE BALTIMORE , 10 avril 2014 /PRNewswire/ -- BD Diagnostics, une division de BD (Becton, Dickinson and Company), société internationale de premier plan spécialisée dans les techno
Read more →BDXBD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2014 earnings...
FRANKLIN LAKES, N.J. , April 3, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2014 earnings conference call on Thursday, May 1, 2014 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXDr. Claire Pomeroy Elected as BD Director BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced the election of Dr. Claire Pomeroy to its Board ...
FRANKLIN LAKES, N.J. , March 24, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced the election of Dr. Claire Pomeroy to its Board of Directors. Dr. Pomeroy, 58, is an expert in infectious diseases and a
Read more →BDXNew RSV Test Provides Healthcare Providers Objective Results in Minutes BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it...
FRANKLIN LAKES, N.J. , March 19, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA)
Read more →BDXLe test BD Onclarity™ HPV sur le système BD Viper™ LT obtient le marquage CE-IVD BD Diagnostics, une branche de la société internationale spécialisée dans les technologies médicales BD (Becton, Dickinson and Company), a annoncé...
BALTIMORE , 11 mars 2014 /PRNewswire/ -- BD Diagnostics, une branche de la société internationale spécialisée dans les technologies médicales BD (Becton, Dickinson and Company), a annoncé aujourd'hui que la société avait obtenu le marquage CE/IVD pour le test BD Onclarity™ HPV su
Read more →BDXHealthcare Providers Can Diagnose Group A Strep in Minutes with New Test BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it...
FRANKLIN LAKES, N.J. , Feb. 25, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it received 510(k) clearance and Clinical Laboratory Improvement Amendments (CLIA)
Read more →BDXDer für das BD Viper™ LT-System bestimmte BD Onclarity™ HPV-Test erhält die CE-IVD-Kennzeichnung BD Diagnostics, eine Sparte des weltweit führenden Medizintechnikunternehmens BD (Becton, Dickinson and Company), gab heute bekannt, dass der für das ...
BALTIMORE , 19. Februar 2014 /PRNewswire/ -- BD Diagnostics, eine Sparte des weltweit führenden Medizintechnikunternehmens BD (Becton, Dickinson and Company), gab heute bekannt, dass der für das neue BD Viper™ LT-System konzipierte BD Onclarity™ HPV-Test des Unternehmens die CE/I
Read more →BDXEl ensayo BD Onclarity™ HPV en el sistema BD Viper™ LT consigue la Marca CE-IVD BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), una destacada compañía global de tecnología médica, anunció hoy que la compañía ha ...
BALTIMORE , 19 de febrero de 2014 /PRNewswire/ -- BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), una destacada compañía global de tecnología médica, anunció hoy que la compañía ha conseguido el marcado CE/IVD para el ensayo BD Onclarity™ HPV en el nuevo sistem
Read more →BDXLeading Industry Analyst Amit Bhalla Joins BD as Vice President, Global Strategy and Development BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global technology company, today announced the appointment of Amit Bhalla as Vice...
FRANKLIN LAKES, N.J. , Feb. 7, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global technology company, today announced the appointment of Amit Bhalla as Vice President, Global Strategy and Development. Mr. Bhalla will join BD in March, 2014 and
Read more →BDXBD Announces Results For 2014 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for...
FRANKLIN LAKES, N.J. , Feb. 4, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the first fiscal quarter ended December 31, 2013 , representing an increase of 6
Read more →BDXNew Laboratory Test Helps Hospitals Detect Newly Emerging Strains of Drug-Resistant Superbug BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it has...
BALTIMORE , Jan. 13, 2014 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today it has received FDA clearance to market the BD MAX™ MRSA XT Assay for use on the fully-automated BD
Read more →BDXBD Acquires Alverix, Inc. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Alverix, Inc., a...
FRANKLIN LAKES, N.J. , Jan. 7, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has acquired Alverix, Inc., a privately-held diagnostic instrument company known for its optoelectronics exper
Read more →BDXBD Announces Live Webcast Of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2014 earnings...
FRANKLIN LAKES, N.J. , Jan. 7, 2014 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2014 earnings conference call on Tuesday, February 4, 2014 , at 8:00 a.m. (ET) . BD will issue a pre
Read more →BDXNovel Molecular Assay for Patient Screening Detects S. aureus and Newly Emerging MRSA Strains Available in the United States BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has...
BALTIMORE , Dec. 3, 2013 /PRNewswire/ -- BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has received FDA clearance to market the BD MAX™ StaphSR Assay for use on the fully-automated BD
Read more →BDXBD to Present at the 25th Annual Piper Jaffray Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company, announced today that it will present at the 25th Annual Piper...
FRANKLIN LAKES, N.J. , Nov. 27, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will present at the 25 th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013 at 12:00 p.m. EST .
Read more →BDXBD Board Increases Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 54.5 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 26, 2013 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 54.5 cents per common share, an increase of 5 cents per share, or about 10 percent, from the previous quarter. The d
Read more →BDXNeuartiger molekularer Assay für die aktive MRSA-Überwachung weist neu entdeckte Stämme arzneimittelresistenter Supererreger nach BD Diagnostics, eine Sparte von BD (Becton, Dickinson and Company), einem führenden globalen Unternehmen aus der Medizintechnik, gab heute die...
-- BD MAX™ MRSA-XT-Assay mit e XT ended Detection Technology erhält CE-Kennzeichnung BALTIMORE , 26. November 2013 /PRNewswire/ -- BD Diagnostics, eine Sparte von BD (Becton, Dickinson and Company), einem führenden globalen Unternehmen aus der Medizintechnik, gab heute die Verfü
Read more →BDXRapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that the BD...
FRANKLIN LAKES, N.J. , Nov. 19, 2013 /PRNewswire/ -- BD Medical, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that the BD Accelerate SM program now offers a solution for the biopharmaceutical injectable
Read more →BDXUn nouveau test moléculaire pour la surveillance active du SARM détecte les nouvelles souches d'une bactérie résistante aux antibiotiques BD Diagnostics, un segment de BD (Becton, Dickinson and Company), a annoncé aujourd'hui le marquage CE et le lancement en Europe du test BD MAX™ MRSA ...
-- Le test BD MAX™ MRSA XT avec technologie de détection eXTended obtient le marquage CE BALTIMORE , 19 novembre 2013 /PRNewswire/ -- BD Diagnostics, un segment de BD (Becton, Dickinson and Company), a annoncé aujourd'hui le marquage CE et le lancement en Europe du test BD MAX™
Read more →BDXUn nouveau test moléculaire pour le dépistage pré-chirurgical détecte les souches MRSA récemment découvertes BD Diagnostics, un segment de BD (Becton, Dickinson and Company), a annoncé aujourd'hui la disponibilité du test StaphSR BD MAX™ homologué CE avec...
-- Le test StaphSR BD MAX™ avec la technologie de détection eXTended reçoit l'homologation CE Les infections sur site opératoire (ISO) constituent l'infection nosocomiale la plus fréquente chez les patients chirurgicaux. [ii] Ces infections sont associées à une augmentation de l
Read more →BDXBD Joins National Patient Safety Foundation Corporate Council, Furthers Commitment to Safety BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has joined the National Patient...
FRANKLIN LAKES, N.J. and BOSTON , Nov. 13, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced it has joined the National Patient Safety Foundation (NPSF) Corporate Council. The membership will enable
Read more →BDXNuevo ensayo molecular de MRSA detecta cepas resistentes a medicamentos BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), una compañía líder global de tecnología médica, ha anunciado hoy la disponibilidad ...
- Nuevo ensayo molecular para vigilancia activa de MRSA detecta cepas recién descubiertas de superbacterias resistentes a los medicamentos -- Ensayo BD MAX™ MRSA XT con tecnología de detección e XT ended recibe la marca CE BALTIMORE , Nov. 12, 2013 /PRNewswire/ -- BD Diagnostic
Read more →BDXBD Announces Results for 2013 Fourth Fiscal Quarter and Full Year; Provides Fiscal 2014 Guidance BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.1 billion for...
FRANKLIN LAKES, N.J. , Nov. 5, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.1 billion for the fourth fiscal quarter ended September 30, 2013 , representing an increase of
Read more →BDXBD Rx Announces FDA Approval of High-Demand Injectable for Pain Management BD Rx Inc., a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), announced today...
FRANKLIN LAKES, N.J. , Nov. 4, 2013 /PRNewswire/ -- BD Rx Inc. , a wholly-owned subsidiary of leading global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX ), announced today that the U.S. Food and Drug Administration (FDA) has approved Morphine Sulfate
Read more →BDXEl nuevo ensayo molecular para exploración pre-quirúrgica detecta cepas de MRSA recientemente descubiertas BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), ha anunciado hoy la disponibilidad del ensayo BD MAX™ StaphSR certificado CE con...
- El ensayo BD MAX ™ StaphSR con tecnología de detección e XT ended recibe la CE Mark BALTIMORE , 30 de octubre de 2013 /PRNewswire/ -- BD Diagnostics, un segmento de BD (Becton, Dickinson and Company), ha anunciado hoy la disponibilidad del ensayo BD MAX™ StaphSR certificado CE
Read more →BDXBD Launches BD Helping Build Healthy Communities with Direct Relief and the National Association of Community Health Centers BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, together with Direct Relief and the National Association...
FRANKLIN LAKES, N.J. , Oct. 28, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, together with Direct Relief and the National Association of Community Health Centers (NACHC), today launched BD Helping Build Healthy
Read more →BDXWorld Health Organization and BD Announce New Commitment to Address Maternal and Newborn Mortality BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and the World Health Organization (WHO), together with...
FRANKLIN LAKES, N.J. , Sept. 27, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and the World Health Organization (WHO), together with Saving Lives at Birth: A Grand Challenge for Development partners, today anno
Read more →BDXJury Returns Verdict in RTI vs. BD Lawsuit BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that a jury has returned a mixed verdict in the lawsuit filed against the Company by...
FRANKLIN LAKES, N.J. , Sept. 20, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that a jury has returned a mixed verdict in the lawsuit filed against the Company by Retractable Technologies, Inc. (RTI) in the United States Court for the Easte
Read more →BDXBD Announces Results For 2013 Third Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for...
FRANKLIN LAKES, N.J. , Aug. 1, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.053 billion for the third fiscal quarter ended June 30, 2013 , representing an increase of 3.6
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 49.5 cents per common share, payable on...
FRANKLIN LAKES, N.J. , July 23, 2013 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 49.5 cents per common share, payable on September 30, 2013 to holders of record on September 9, 2013 . The indicated
Read more →BDXBD Appoints Christopher Reidy as Chief Financial Officer BD (Becton, Dickinson and Company) (NYSE:BDX) , a leading global technology company, today announced the appointment of Christopher Reidy as Chief...
FRANKLIN LAKES, N.J. , July 8, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) , a leading global technology company, today announced the appointment of Christopher Reidy as Chief Financial Officer and Executive Vice President of Administration, effective Jul
Read more →BDXBD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2013 earnings...
FRANKLIN LAKES, N.J. , July 3, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2013 earnings conference call on Thursday, August 1, 2013 , at 8:00 a.m. (ET) . BD will issue a pres
Read more →BDXBD to Present at the Goldman Sachs 34th Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman...
FRANKLIN LAKES, N.J. , June 6, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Goldman Sachs 34 th Annual Global Healthcare Conference on Wednesday, June 12, 2013 , at 5
Read more →BDXBD and Heart to Heart International Continue Ongoing Collaboration to Help Improve Healthcare in Haiti with Third Volunteer Service Trip BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and Heart to Heart International, a nonprofit...
FRANKLIN LAKES, N.J. and OLATHE, Kan. , June 4, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Heart to Heart International, a nonprofit humanitarian medical aid organization, are collaborating on their third
Read more →BDXBD to Present at the Deutsche Bank 38th Annual Health Care Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Deutsche...
FRANKLIN LAKES, N.J. , May 24, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Deutsche Bank 38 th Annual Health Care Conference on Thursday, May 30, 2013 , at 10:40 a.m
Read more →BDXBD Issues 2012 Sustainability Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the publication of its 2012...
FRANKLIN LAKES, N.J. , May 22, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the publication of its 2012 Sustainability Report . This is BD's fifth Sustainability Report and it continues to focus
Read more →BDXBD Announces Results For 2013 Second Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for...
FRANKLIN LAKES, N.J. , May 2, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.0 billion for the second fiscal quarter ended March 31, 2013 , representing an increase of 3.7
Read more →BDXBD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2013 earnings...
FRANKLIN LAKES, N.J. , April 8, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2013 earnings conference call on Thursday, May 2, 2013 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD Enters Pharmaceutical Industry with New Line of Generic Prefilled Injectable Products BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that the U.S. Food and Drug...
FRANKLIN LAKES, N.J. , March 27, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first drug to be offered in the just-launched BD S
Read more →BDXBD Announces Appointment of Dr. Ellen Strahlman as Chief Medical Officer and Senior Vice President, Research & Development BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Ellen Strahlman, M.D., ...
FRANKLIN LAKES, N.J. , March 13, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the appointment of Ellen Strahlman , M.D., M.H.Sc., to the newly created position of Chief Medical Officer and Senio
Read more →BDXBD Acquires Cato Software Solutions BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Cato Software...
FRANKLIN LAKES, N.J. , March 12, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has acquired Cato Software Solutions, the manufacturer of cato® and chemocato® software, a suite of comprehe
Read more →BDXBD Announces Results for 2013 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.90 billion for...
FRANKLIN LAKES, N.J. , Feb. 5, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.90 billion for the first fiscal quarter ended December 31, 2012 , representing an increase of
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 49.5 cents per common share, payable on ...
FRANKLIN LAKES, N.J. , Jan. 29, 2013 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 49.5 cents per common share, payable on March 29, 2013 to holders of record on March 8, 2013 . The indicated annual
Read more →BDXCatherine M. Burzik Elected as BD Director BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced that Catherine M. Burzik has been elected to...
FRANKLIN LAKES, N.J. , Jan. 29, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced that Catherine M. Burzik has been elected to its Board of Directors. Ms. Burzik, 62, is a seasoned healthcare executive wi
Read more →BDXBD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2013 earnings...
FRANKLIN LAKES, N.J. , Jan. 8, 2013 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2013 earnings conference call on Tuesday, February 5, 2013 , at 8:00 a.m. (ET) . BD will issue a pre
Read more →BDXBD Completes Acquisition of Safety Syringes, Inc. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has completed its acquisition of ...
FRANKLIN LAKES, N.J. , Dec. 26, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has completed its acquisition of Safety Syringes, Inc., a privately held California -based company that speci
Read more →BDXBD to Present at the 24th Annual Piper Jaffray Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a global medical technology company, announced today that it will present at the 24th Annual Piper...
FRANKLIN LAKES, N.J. , Nov. 21, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will present at the 24 th Annual Piper Jaffray Healthcare Conference Wednesday, November 28, 2012 , at 9:30 a.m. EST
Read more →BDXBD Board Increases Dividend by 10 Percent The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 49.5 cents per common share, an...
FRANKLIN LAKES, N.J. , Nov. 20, 2012 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 49.5 cents per common share, an increase of 10 percent from the previous quarter. The dividend will be payable on De
Read more →BDXBD Announces Results For 2012 Fourth Fiscal Quarter And Full Year BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.967 billion for...
FRANKLIN LAKES, N.J. , Nov. 7, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.967 billion for the fourth fiscal quarter ended September 30, 2012 , representing a decrease o
Read more →BDXBD Announces Funding and Product Support for Hurricane Sandy Relief Efforts BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it is pledging up to $500,000,...
FRANKLIN LAKES, N.J. , Nov. 6, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it is pledging up to $500,000 , including $250,000 in cash and up to $250,000 in product donations, to support Hu
Read more →BDXBD Announces Appointment of William A. Kozy as Chief Operating Officer BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of William A. Kozy as...
FRANKLIN LAKES, N.J. , Nov. 6, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the appointment of William A. Kozy as Chief Operating Officer, effective today. Mr. Kozy adds this title to his curren
Read more →BDXBD Completes Sale of Majority of Discovery Labware Unit BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the completion of the sale of its BD...
FRANKLIN LAKES, N.J. , Nov. 1, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the completion of the sale of its BD Biosciences - Discovery Labware unit, excluding its Advanced Bioprocessing platfo
Read more →BDXBD is Awarded WindMade™ Certification; Ranks Among Top 40 U.S. Companies in Newsweek's 2012 Green Rankings BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it has received the WindMade™ label, ...
FRANKLIN LAKES, N.J. , Oct. 29, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has received the WindMade ™ label, a global consumer label for companies that use wind energy and other renew
Read more →BDXBD Announces Chief Financial Officer Transition BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that David V. Elkins, 44, Executive Vice...
FRANKLIN LAKES, N.J. , Oct. 10, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that David V. Elkins , 44, Executive Vice President and Chief Financial Officer, has informed the Company of his plan
Read more →BDXBD Acquires Sirigen Group Limited BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired Sirigen Group...
FRANKLIN LAKES, N.J. , Aug. 27, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has acquired Sirigen Group Limited, a developer of unique polymer dyes that are used in flow cytometry and ca
Read more →BDXBD Announces Results For 2012 Third Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.981 billion for...
FRANKLIN LAKES, N.J. , Aug. 2, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.981 billion for the third fiscal quarter ended June 30, 2012 , representing an increase of 1.5
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 45 cents per common share, payable on...
FRANKLIN LAKES, N.J. , July 24, 2012 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 45 cents per common share, payable on September 28, 2012 to holders of record on September 7, 2012 . The indicated a
Read more →BDXBD Board of Directors Elects Rebecca W. Rimel BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that it has elected Rebecca W. Rimel to its...
FRANKLIN LAKES, N.J. , July 23, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced that it has elected Rebecca W. Rimel to its Board of Directors, effective today. Ms. Rimel, 61, is President and Chief Exe
Read more →BDXBD Announces Agreement to Acquire Safety Syringes, Inc. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has entered into a definitive...
FRANKLIN LAKES, N.J. , July 11, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has entered into a definitive agreement to acquire Safety Syringes, Inc., a privately held California -based
Read more →BDXBD Announces Live Webcast Of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2012 earnings...
FRANKLIN LAKES, N.J. , June 28, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2012 earnings conference call on Thursday, August 2, 2012 , at 8:00 a.m. (ET) . BD will issue a pre
Read more →BDXBD to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Goldman Sachs ...
FRANKLIN LAKES, N.J. , May 30, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Goldman Sachs 33rd Annual Global Healthcare Conference on Wednesday, June 6, 2012 , at 1:0
Read more →BDXBD Appoints CEO Vincent A. Forlenza as Chairman of the Board BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that Chief Executive Officer and...
FRANKLIN LAKES, N.J. , May 22, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that Chief Executive Officer and President Vincent A. Forlenza will assume additional responsibility as Chairman of th
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 45 cents per common share, payable on...
FRANKLIN LAKES, N.J. , May 22, 2012 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 45 cents per common share, payable on June 29, 2012 to holders of record on June 8, 2012 . The indicated annual divid
Read more →BDXBD Announces Results for 2012 Second Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.991 billion for...
FRANKLIN LAKES, N.J. , May 1, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.991 billion for the second fiscal quarter ended March 31, 2012 , representing an increase of 3.
Read more →BDXBD Signs Agreement to Sell Majority of Discovery Labware Unit BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it has signed a definitive agreement ...
FRANKLIN LAKES, N.J. , April 10, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has signed a definitive agreement to sell its BD Biosciences - Discovery Labware unit, excluding its Advance
Read more →BDXBD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE:BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2012 earnings...
FRANKLIN LAKES, N.J. , April 2, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2012 earnings conference call on Tuesday, May 1, 2012 , at 8:00 a.m. (ET) . BD will issue a press
Read more →BDXBD to Present at the Barclays Capital Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, announced today that it will present at the Barclays...
FRANKLIN LAKES, N.J. , March 9, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Barclays Capital Global Healthcare Conference on Tuesday, March 13, 2012 , at 2:00 p.m. (
Read more →BDXBD Acquires KIESTRA Lab Automation BV BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it has acquired KIESTRA Lab...
FRANKLIN LAKES, N.J. , Feb. 13, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it has acquired KIESTRA Lab Automation BV, a Netherlands -based company that designs, develops, manufactures, ma
Read more →BDXMesenchymal Stem Cells Have New Cell Culture Environment BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Mosaic™ Mesenchymal Stem Cell...
BILLERICA, Mass. , Feb. 8, 2012 /PRNewswire/ -- BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the availability of the new BD Mosaic™ Mesenchymal Stem Cell Serum-Free (hMSC SF), a complete cell culture environment for human mesenchymal stem cells
Read more →BDXBD Announces Results for 2012 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.888 billion for...
FRANKLIN LAKES, N.J. , Feb. 7, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.888 billion for the first fiscal quarter ended December 31, 2011 , representing an increase of
Read more →BDXBD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2012 earnings...
FRANKLIN LAKES, N.J. , Jan. 11, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2012 earnings conference call on Tuesday, February 7, 2012 , at 8:00 a.m. (ET) . BD will issue a pr
Read more →BDXBD to Present at the 30th Annual J. P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 30th Annual...
FRANKLIN LAKES, N.J. , Jan. 4, 2012 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 30th Annual J. P. Morgan Healthcare Conference on Wednesday, January 11, 2012 , at 7:00 p.
Read more →BDXBD to Present at the 23rd Annual Piper Jaffray Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will present at the 23rd Annual Piper...
FRANKLIN LAKES, N.J. , Nov. 22, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will present at the 23 rd Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2011 , at 10:00 a.m. ES
Read more →BDXBD Board Increases Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 45 cents per common share, an increase...
FRANKLIN LAKES, N.J. , Nov. 22, 2011 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 45 cents per common share, an increase of 4 cents per share, or about 10 percent, from the previous quarter. The div
Read more →BDXBD Announces Results for 2011 Fourth Fiscal Quarter and Full Year BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for...
FRANKLIN LAKES, N.J. , Nov. 2, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.051 billion for the fourth fiscal quarter ended September 30, 2011 , representing an increase
Read more →BDXBD Announces 2011 Analyst Day and Webcast BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will host an institutional investor and analyst meeting on Wednesday, November ...
FRANKLIN LAKES, N.J. , Oct. 28, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will host an institutional investor and analyst meeting on Wednesday, November 9, 2011 , in New York City from 7:45 a.m. – 12:45 p.m. (ET) . The meeting wi
Read more →BDXBD Launches a New Generation Short Peripheral IV Catheter to Reduce Risk of Blood Exposure to Healthcare Workers A new generation of safety short peripheral IV catheter (SPIVC) technology designed to keep healthcare workers safe from needlestick injuries and...
SANDY, Utah , Sept. 21, 2011 /PRNewswire/ -- A new generation of safety short peripheral IV catheter (SPIVC) technology designed to keep healthcare workers safe from needlestick injuries and blood exposure is now available from BD Medical, a segment of BD (Becton, Dickinson and C
Read more →BDXBD to Increase Access to Vital Cervical Cancer Screening in Resource-Limited Settings Through Commitment to Pink Ribbon Red Ribbon Initiative® BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a commitment to Pink Ribbon Red Ribbon®, ...
FRANKLIN LAKES, N.J. , Sept. 13, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced a commitment to Pink Ribbon Red Ribbon®, an innovative initiative to leverage public and private investments in glob
Read more →BDXBD to Present at the 2011 Morgan Stanley Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will present at the 2011 Morgan Stanley...
FRANKLIN LAKES, N.J. , Sept. 7, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will present at the 2011 Morgan Stanley Global Healthcare Conference on Tuesday, September 13 , at 9:45 a.m. EDT A l
Read more →BDXBD Completes Acquisition of Carmel Pharma BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of its acquisition of...
FRANKLIN LAKES, N.J. , Aug. 16, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced the completion of its acquisition of Carmel Pharma, AB, a Swedish company that manufactures the PhaSeal® System, the
Read more →BDXBD Announces Results For 2011 Third Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $2.014 billion for...
FRANKLIN LAKES, N.J. , Aug. 2, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $2.014 billion for the third fiscal quarter ended June 30, 2011 , representing an increase of 10.
Read more →BDXBD Announces Agreement to Acquire Carmel Pharma, Inc. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it signed a definitive agreement to ...
FRANKLIN LAKES, N.J. , July 27, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it signed a definitive agreement to acquire Carmel Pharma, Inc., a Swedish company that manufactures the PhaSeal
Read more →BDXBD Board of Directors Elects Vincent A. Forlenza as Next Chief Executive Officer, Effective October 1, 2011 The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that, in...
FRANKLIN LAKES, N.J. , July 26, 2011 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that, in accordance with its long-term succession planning, it has elected Vincent A. Forle
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 41 cents per common share, payable on...
FRANKLIN LAKES, N.J. , July 26, 2011 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 41 cents per common share, payable on September 30, 2011 to holders of record on September 9, 2011 . The indicated a
Read more →BDXBD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its third fiscal quarter 2011 earnings...
FRANKLIN LAKES, N.J. , July 8, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its third fiscal quarter 2011 earnings conference call on Tuesday, August 2, 2011 , 8:00 – 9:00 a.m. (ET) . BD will issue a p
Read more →BDXBD and Heart to Heart International Launch Volunteer Service Trip to Help Build Back Better in Haiti BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Heart to Heart International, a humanitarian medical ...
FRANKLIN LAKES, N.J. and OLATHE, Kan. , June 9, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Heart to Heart International, a humanitarian medical aid nonprofit organization, announced a joint volunteer init
Read more →BDXBD to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the Goldman...
FRANKLIN LAKES, N.J. , June 3, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the Goldman Sachs 32nd Annual Global Healthcare Conference on Thursday, June 9, 2011 , at 11:0
Read more →BDXBD Board Declares Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX) has declared a quarterly dividend of 41 cents per common share, payable on...
FRANKLIN LAKES, N.J. , May 24, 2011 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 41 cents per common share, payable on June 30, 2011 to holders of record on June 9, 2011 . The indicated annual divid
Read more →BDXBD Issues 2010 Sustainability Report BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the publication of its 2010...
FRANKLIN LAKES, N.J. , May 19, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today the publication of its 2010 Sustainability Report . The report reaffirms the commitment of BD's 29,000 dedicated assoc
Read more →BDXResource Now Available to Help Clinicians Reduce Risk of Blood Exposure from Short Peripheral IV Catheter Insertion Healthcare workers now have the ability to better identify risks for exposure to bloodborne pathogens, take precautions to better protect themselves, ...
SANDY, Utah , May 3, 2011 /PRNewswire/ -- Healthcare workers now have the ability to better identify risks for exposure to bloodborne pathogens, take precautions to better protect themselves, and share information and experiences as a result of a new program developed by BD Medic
Read more →BDXBD Announces Results for 2011 Second Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.922 billion for...
FRANKLIN LAKES, N.J. , April 26, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.922 billion for the second fiscal quarter ended March 31, 2011 , representing an increase of
Read more →BDXBD Announces Live Webcast of Second Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its second fiscal quarter 2011 earnings...
FRANKLIN LAKES, N.J. , April 13, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its second fiscal quarter 2011 earnings conference call on Wednesday, April 27, 2011 , 10:00 – 11:00 a.m. (ET) . BD will is
Read more →BDXBD Completes Acquisition of Accuri Cytometers, Inc. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global technology company, today announced the completion of its acquisition of Accuri...
FRANKLIN LAKES, N.J. , March 18, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global technology company, today announced the completion of its acquisition of Accuri Cytometers, Inc., an Ann Arbor, Michigan -based company that develops and manufa
Read more →BDXBD Statement Regarding Impact of Japan Earthquake BD (Becton, Dickinson and Company) (NYSE: BDX) has operations in Japan led by its Nippon Becton Dickinson headquarters office in Tokyo, and a...
FRANKLIN LAKES, N.J. , March 15, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) has operations in Japan led by its Nippon Becton Dickinson headquarters office in Tokyo , and a manufacturing facility and distribution center in Fukushima prefecture. The Compan
Read more →BDXBD Donates $325,000 for Japan Earthquake and Tsunami Relief Efforts BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it is donating $325,000 to assist...
FRANKLIN LAKES, N.J. , March 15, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it is donating $325,000 to assist in relief efforts for victims of the earthquake and tsunami in Japan . BD wil
Read more →BDXBD Announces Agreement to Acquire Accuri Cytometers, Inc. BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it signed a definitive agreement to ...
FRANKLIN LAKES, N.J. , Feb. 7, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it signed a definitive agreement to acquire Accuri Cytometers, Inc., an Ann Arbor, Michigan -based company that d
Read more →BDXBD Announces Results For 2011 First Fiscal Quarter BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.842 billion for...
FRANKLIN LAKES, N.J. , Feb. 7, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.842 billion for the first fiscal quarter ended December 31, 2010 , representing a decrease of
Read more →BDXBD Announces Results of Shareholder Votes at Annual Meeting BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced that at the Company's Annual Meeting of...
FRANKLIN LAKES, N.J. , Feb. 1, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced that at the Company's Annual Meeting of Shareholders today, its shareholders approved management's "say-on-pay" proposal reg
Read more →BDXBD and Rady Children's Hospital-San Diego Announce Innovative Pilot Project to Reduce Environmental Impact of Sharps Disposal BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Rady Children's Hospital-San Diego today announced...
FRANKLIN LAKES, N.J. and SAN DIEGO , Jan. 24, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, and Rady Children's Hospital-San Diego today announced that they have implemented an innovative pilot program at the Ho
Read more →BDXBD Announces Live Webcast of First Fiscal Quarter Earnings Conference Call BD (Becton, Dickinson and Company) (NYSE: BDX) announced today that it will conduct a live webcast of its first fiscal quarter 2011 earnings...
FRANKLIN LAKES, N.J. , Jan. 11, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ) announced today that it will conduct a live webcast of its first fiscal quarter 2011 earnings conference call on Tuesday, February 8, 2011 , 10:00 – 11:00 a.m. (ET) . BD will issu
Read more →BDXBD to Present at the 29th Annual J. P. Morgan Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 29th Annual...
FRANKLIN LAKES, N.J. , Jan. 4, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 29th Annual J. P. Morgan Healthcare Conference on Monday, January 10, 2011 , at 6:00 p.m.
Read more →BDXBD to Present at the 22nd Annual Piper Jaffray Health Care Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it will present at the 22nd Annual...
FRANKLIN LAKES, N.J. , Nov. 24, 2010 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, announced today that it will present at the 22nd Annual Piper Jaffray Health Care Conference on Wednesday, December 1, 2010
Read more →BDXBD Board Increases Dividend The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) has declared a quarterly dividend of 41 cents per common share, an increase...
FRANKLIN LAKES, N.J. , Nov. 23, 2010 /PRNewswire-FirstCall/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX ) has declared a quarterly dividend of 41 cents per common share, an increase of 4 cents per share, or 10.8%, from the previous quarter. The divi
Read more →BDXBD Announces Results for 2010 Fourth Fiscal Quarter and Full Year BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly revenues of $1.873 billion for...
FRANKLIN LAKES, N.J. , Nov. 3, 2010 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today reported quarterly revenues of $1.873 billion for the fourth fiscal quarter ended September 30, 2010 , representing an
Read more →BDXBD Ranks Among Top 25 U.S. Companies in Newsweek's 2010 Green Rankings; Receives EPA Green Power Leadership Award; Named to Dow Jones Sustainability World Index for Fifth Consecutive Year BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has ranked among the top 25...
FRANKLIN LAKES, N.J. , Oct. 25 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a leading global medical technology company, today announced that it has ranked among the top 25 companies in Newsweek's second annual "Green Rankings" of the 500 largest U.S. corporat
Read more →BDXBD to Present at the 2010 Morgan Stanley Global Healthcare Conference BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, announced today that it will present at the 2010 Morgan Stanley...
FRANKLIN LAKES, N.J. , Sept. 8 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, announced today that it will present at the 2010 Morgan Stanley Global Healthcare Conference on Tuesday, September 14 , at 1:35 p.m. EDT . A live
Read more →Competitive Position
How BDX ranks across every disease it competes inCompetitive Position is a premium feature
See how BDX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial